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Cough is a common complaint that results in significant morbidity and impairment 
in quality of life. The assessment of cough severity is central to the diagnosis and 
clinical management of cough. The aim of this thesis was to evaluate objective 
measures of cough frequency and cough intensity in patients with acute and chronic 
cough. 
24-hour cough frequency was investigated in a longitudinal observational study of 
33 healthy subjects with acute cough. At baseline, 24-hour cough frequency was 
elevated and was associated with impaired health related quality of life. Cough 
frequency improved significantly over the 8-day study period. The minimal clinically 
important difference in cough frequency was determined as a 54% change from 
baseline. The sample sizes required for clinical trials to use cough frequency as a 
primary endpoint were calculated using this data. A second study of cough 
frequency was undertaken in 100 patients with chronic cough to investigate 
whether short duration recordings (1-6 hours) were comparable to 24-hours. Cough 
frequency obtained from short recordings were strongly correlated with 24-hour 
cough frequency (ρ=0.77 to 0.93), but those less than 4 hours were limited by weak 
relationships with subjective measures of cough. 4-hour cough frequency was found 
to be responsive to improvements in cough severity following trials of therapy, 
supporting its feasibility as a tool for assessing outcomes in chronic cough. 
The intensity of cough is an important determinant of global cough severity, but few 
studies have assessed cough intensity objectively in patients with chronic cough. 
The intensity of voluntary, induced and spontaneous cough was investigated in 28 
patients with chronic cough and 21 healthy controls. Oesophageal pressure (Poes), 
gastric pressure (Pga) and peak cough flow rate (PCFR) during maximum voluntary 
cough were significantly greater in patients with chronic cough compared with 
controls when taking into account the preceding inspired volume. There was no 
difference in expiratory muscle strength or degree of abdominal muscle activation 
between patients and controls but the compression phase duration (CPD) was 
increased in female patients with cough compared to controls (mean ± SD CPD 0.50 
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± 0.22 vs. 0.28 ± 0.17 seconds; p=0.007). Cough intensity during spontaneous cough 
was comparable to induced cough, but less than maximum voluntary cough 
intensity. Poes, Pga and PCFR were closely correlated with cough intensity visual 
analogue score (ρ=0.86 to 0.90), suggesting that these indices are important to 
subjective perception of cough intensity. Cough sound is a potential measure of 
cough intensity, but it has not been validated against physiological measures of 
cough intensity. The relationship between a range of cough sound parameters and 
PCFR and Poes were investigated in 17 patients with chronic cough and 15 healthy 
controls. Cough sound power and energy were found to correlate most strongly 
with PCFR (ρ=0.82 to 0.88) and Poes (ρ=0.85 to 0.89). The relationships between 
sound and PCFR or Poes were similar for sound analysed from a fixed 0.5-second 
time-window and from time-windows that were manually marked by cough phase, 
supporting the potential for future automated analysis. Sound power and energy 
were highly repeatable measures (ICC 0.93 to 0.94). Cough sound measurement has 
the advantage of being non-invasive and suitable for ambulatory monitoring and 
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1.1 Cough: the clinical problem 
Cough is a natural defence mechanism that clears secretions from the airways and 
protects against aspiration of inhaled foreign bodies. An impaired cough reflex is 
seen in patients with conditions such as neuromuscular disease, stroke and 
Parkinson's disease and can lead to an increased risk of aspiration and pulmonary 
infections [1-4]. At the other end of the spectrum are patients with heightened 
cough reflex sensitivity who are troubled by excessive coughing. Cough can be acute 
and transient when due to upper respiratory tract infection but in some cases it can 
be chronic and without apparent physiological advantage for its persistence [5]. The 
symptom of cough is often perceived as a trivial problem, but it may be associated 
with significant physical and psychological morbidity. Syncope, urinary 
incontinence, chest pain, sleep disturbance, relationship difficulties, social 
embarrassment and depression are just some of the adverse consequences of 
chronic cough [6-10]. The assessment of the severity of cough is important since the 
clinical response to trials of therapy is central to establishing a diagnosis for chronic 
cough and evaluating the efficacy of antitussive therapy. A number of subjective 
tools have been developed and validated, particularly those that measure health 
status, but there is a relative paucity of studies for objective measures [11, 12]. A 
greater understanding of objective cough measures would facilitate better clinical 
assessment of patients and research in future.  
1.1.1 Epidemiology 
Cough is a common complaint. The prevalence of cough is estimated between 9-
33% in the community and the economic cost to society is substantial; 
approximately £100 million is spent on antitussive drugs every year in the UK [13-
15]. Most of this burden relates to acute cough due to viral upper respiratory tract 
infection (URTI), of which there are an estimated 48 million episodes per year in the 
UK [16]. On average, it is estimated that each adult is affected by URTI 2-5 times a 
year [17]. Chronic cough is also common, with a reported prevalence of 12% of the 
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general population in the UK, and accounts for 10% of all respiratory outpatient 
clinic referrals [16, 18].  
1.1.2 Classification of cough 
Cough is thought to be a manifesting symptom of a range of conditions. It is usually 
classified according to duration of presence. Acute cough is defined as a cough 
which lasts less than 3 weeks in duration, sub-acute cough as that lasting between 3 
and 8 weeks, and chronic cough as that lasting greater than 8 weeks in duration 
[19]. Despite some degree of overlap, the potential aetiology of cough is often 
discernible from whether the cough is acute, sub-acute or chronic in nature. 
1.1.3 Acute cough 
Acute cough is a major problem and leads to disturbed sleep, time off work and 
significantly impaired quality of life [12, 20]. The cost to the UK economy is 
estimated at £979 million when considering healthcare costs, loss of productivity 
and costs of over-the-counter medications [16]. The economic impact in the USA 
approaches $40 billion [21]. 
Acute cough is most often due to viral upper respiratory tract infection [16, 22]. The 
mechanism for cough in URTI may be related to a transient increase in cough reflex 
sensitivity [5]. A recent study has demonstrated that cough receptor expression is 
up-regulated in neuronal cells infected with human rhinovirus [23].  
Despite the fact that acute cough is usually self-limiting, patients still spend around 
£100 million on antitussive medications every year in the UK, and up to $3 billion in 
the USA [14, 24]. However, a recent Cochrane review failed to establish the efficacy 
of currently available over-the-counter antitussive remedies [25]. It was reported 
that the studies were limited by a lack of validated outcomes measures and 
objective tools, resulting in unclear clinical significance of the results [25]. There is a 
need for greater understanding of the course and degree of natural recovery of 
acute cough using validated outcome measures in order to advance knowledge of 




1.1.4 Sub-acute cough 
Sub-acute cough is usually attributed to post-infectious cough. Suggested definition 
criteria, other than a duration lasting between three and eight weeks, includes the 
absence of pneumonia, a normal chest radiograph and the eventual resolution of 
the cough [27]. If the clinical picture is not suggestive of post-infectious cough, then 
workup for chronic cough is recommended. 
It is speculated the mechanism responsible for post-infectious cough is of transient 
inflammation of the lower airways with possible further aggravation by either 
bronchial hyper-responsiveness, mucus hyper-secretion, precipitation of pre-
existing gastro-oesophageal reflux or a combination of these [27]. 
Treatment may not be required since post-infectious cough is self-limiting. Inhaled 
ipratropium or a short course of inhaled or oral corticosteroids are often considered 
when the cough is troublesome but the evidence base is weak [28]. Antibiotics are 
not usually recommended unless Bordatella pertussis, the prevalence of which has 
risen to its highest level in the last decade, is suspected as the cause [27, 29].  
1.1.5 Chronic cough 
Chronic cough can be a manifestation of, or be associated with, many conditions. 
The list is long and varied but some of the recognised associations are given in Table 
1-1. Most of these conditions are evident following initial clinical assessment, 
spirometry and chest radiography. The remainder of cases are often referred to 
respiratory physicians and specialist cough clinics for further investigation. These 
patients tend to be non-smokers with unremarkable clinical examination and 
normal lung function. This cohort is generally the population of interest in chronic 
cough studies. Several specialist cough centres have conducted prevalence studies 
on the associated causes of chronic cough (Table 1-2). The conditions most 
commonly associated with cough are asthma, gastro-oesophageal reflux disease 
and rhinitis. In 1981, Irwin et al proposed an "anatomical diagnostic protocol" for 
investigating patients based on the evaluation for these common associations, and 
has been the basis for clinical guidelines for the past 30 years - this is described in 
more detail in section 1.1.6 [30]. 
22 
 







Ace-inhibitor drug therapy  
Obstructive sleep apnoea 
Tonsillar enlargement 
Snoring 
Premature ventricular complexes 
Organ-specific auto-immune disease 
Ear wax (Arnold's reflex) 
 
Table 1-2 Causes of cough in specialist respiratory and cough clinics 
 Number Diagnosis 
 
(women) Asthma/CVA/EB/AC GORD PNDS Idiopathic 
USA 
Irwin [31] 102 (59) 24% 21% 41% 1% 
Poe  [32] 139 (84) 33% (mostly CVA) 5% 27% 12% 
Smyrnios  [33] 71 (32) 24% 15% 40% 3% 
Mello  [34] 88 (64) 14% 40% 38% 2% 
French  [9] 39 (32) 15% 36% 40% 3% 
UK 
McGarvey  [35] 43 (29) 35% (CVA) 19% 35% 19% 
Brightling [36] 91 (NR) 31% (EB 13%) 8% 24% 7% 
Birring [37] 236 (NR) 24% 15% 12% 26% 
Niimi [38] 50 (39) 30% 11% 13% 40% 
Kastelik  [39] 131 (86) 24% 22% 6% 7% 
Japan 
Fujimura  [40] 176 (NR) 79% 4% 26% 6% 
Shirahata  [41] 55 (NR) 42% (CVA) 0 7% 13% 
Brazil 
Palombini  [42] 78 (51) 59% 41% 58% 0% 
CVA: cough variant asthma; EB: eosinophilic bronchitis; AC: atopic cough; GORD: 




Cough Variant Asthma 
Cough can be the sole clinical manifestation of asthma and this is often referred to 
as cough variant asthma (CVA). CVA is a common cause of cough, accounting for 
around 30% of cases of cough referred to specialist clinics (Table 1-2). Originally 
described by Glauser in 1972 and more clearly defined 7 years later by Corrao, CVA 
is typified by the presence of dry cough and demonstrable airway hyper-
responsiveness but without airflow obstruction on spirometry [43, 44].  
The mechanism of cough is likely to be one or more of eosinophilic airway 
inflammation, airway hyper-responsiveness and cough reflex hypersensitivity [45]. 
Indeed, the airway inflammation seen in CVA is similar to that of classic asthma, 
with similar eosinophilia levels in bronchial biopsies and bronchoalveolar lavage 
[46]. Airway remodelling occurs in CVA, but to a lesser extent than in classic asthma 
[47]. Unlike classic asthma however, patients with CVA have a more heightened 
cough reflex when assessed by cough challenge tests [48]. 
The characteristics of the cough and presence of nocturnal cough are not helpful in 
distinguishing CVA from other causes of cough. Routine tests for asthma such as 
peak flow monitoring, bronchodilator reversibility and bronchoprovocation tests 
have a limited role in the assessment of CVA since they lack sensitivity and 
specificity for the diagnosis and are poor at predicting the response to treatment 
[49, 50]. Measures of airway inflammation such as induced sputum eosinophil 
differential cell count (>3%) or fraction of exhaled nitric oxide (FeNO) are better 
tests but are seldom available to physicians in current clinical practice [49, 51]. 
Diagnosis by trial of therapy is therefore widely employed. Inhaled corticosteroids 
are effective for CVA and are often used for this purpose [52-54]. In cases where 
concerns exist regarding inhaler technique and compliance, a trial of oral 
corticosteroid is recommended [16, 52].  
Treatment with inhaled bronchodilator therapy has been shown to reduce 
subjective cough severity but not objective cough counts, leading to opinion that its 
efficacy needs to be re-evaluated in larger randomised controlled trials [52, 55]. 
Leukotriene receptor antagonists have been shown to improve subjective cough 
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scores and cough reflex sensitivity and are a further option [56]. In most patients 
with CVA, the cough returns following cessation of therapy and follow-up studies 




Eosinophilic bronchitis (EB) was first described by Gibson et al in 1989 when they 
identified a group of patients with corticosteroid responsive cough who all had 
eosinophilic sputum infiltration but without reversible airflow obstruction or the 
symptoms associated with asthma [58]. These patients were non-smokers and were 
distinguishable from patients with chronic bronchitis [59]. Like CVA and classic 
asthma, EB is characterised by eosinophilic airway inflammation. In contrast to CVA 
and asthma however, airway hyper-responsiveness is absent [58, 60].  The lack of 
disordered airway function in EB is thought to be due to the absence of mast cell 
inflammation in airway smooth muscle that is usually seen in asthma [61]. 
EB accounts for up to 10-13% of chronic cough referrals to respiratory clinics and 
may co-exist with other airway diseases such as COPD [36, 62]. The diagnosis may 
be established by the demonstration of eosinophilic airway inflammation in induced 
sputum or exhaled nitric oxide measurement in the absence of airway hyper-
responsiveness [36]. Inhaled corticosteroids are effective at reducing cough reflex 
hypersensitivity and cough severity [60]. EB is seldom diagnosed outside of 
specialist clinics, probably due to the combination of lack of access to the diagnostic 
tests and mistaken diagnosis of classic asthma following successful response to 
corticosteroids [36, 52].  
Atopic cough is a condition that has been reported almost exclusively in Japan. It is 
characterised by chronic cough in the presence of atopy but without airway hyper-
responsiveness and bronchodilator reversibility. Atopy is confirmed by positive 
sputum eosinophilic airway inflammation, elevated total IgE level, positive allergen 
skin prick testing or elevated specific IgE [57]. Atopic cough differs from EB in that 
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there is no bronchoalveolar lavage eosinophilia but in most other regards, it is 
analogous to EB [63].  
 
Gastro-oesophageal reflux related cough 
In 1977, a systematic review of patients with chronic cough by Irwin and colleagues 
reported a high prevalence of symptoms of gastro-oesophageal reflux (GOR) in 
patients with chronic cough and led to the widespread practice of evaluating for 
and treating extra-pulmonary symptoms [64]. Since then, GOR has been found to 
account for up to 41% of chronic cough in patients referred to specialist clinics 
(Table 1-2). 
Suggested mechanisms for cough in GOR include the microaspiration of refluxate 
into the trachea-bronchial tree (the reflux theory) or vagal stimulation of the 
oesophageal-bronchial reflex (the reflex theory) [65, 66]. The latter is supported by 
the fact that cough can be induced by infusing acid into the distal oesophagus [67]. 
Recent randomised controlled trials have failed to confirm the positive findings of 
earlier uncontrolled studies on the efficacy of proton-pump inhibitors (PPI) for 
improving cough in patients with GOR related cough [68-70]. Subjective cough 
scores were used to define response in those trials and the inconsistency between 
results could be due to lack of objective outcome measures. Furthermore, the early 
trials were uncontrolled or small in number. As a result, the role of acid GOR in 
chronic cough has been questioned [52]. Only a minority of reflux events reach the 
proximal oesophagus in GOR related cough, which suggests that a central neuronal 
process may be the more likely mechanism for the sensitisation of the oesophageal-
bronchial reflex than peripheral microaspiration [71, 72].  
The symptom association probability (SAP) index can be used to define whether 
cough events and reflux events are temporally related more than that which would 
occur by chance. In a study of patients with chronic cough by Blondeau et al, where 
asthma and rhinitis had been excluded, only 1-9% of subjects had a positive SAP 
score for acid reflux and cough [71]. Cough events were recorded both subjectively 
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on a data logger and objectively by analysis of manometric changes in the 
oesophageal impedance pH recording. The lower SAP rate (1%) was found when 
relating reflux events to subjectively recorded coughs and the higher rate (9%) was 
found with manometric labelled cough. The poor correlation between subjective 
cough scores and objective cough frequency is well documented and the use of 
manometric cough labelling alone could lead to inaccuracies since actions such as 
gag or sneezes can mimic cough on manometry [73]. The study was recently 
repeated by Smith et al using a sound based objective cough frequency monitor to 
detect cough events [72]. A higher positive SAP rate (31%) was found in their study, 
which highlights the potential differences with use of objective cough detection 
tools. 
Non-acid GOR has been postulated to be more important than acid GOR in reflux 
related cough [74]. In the study by Blondeau et al, a positive SAP for non-acid reflux 
was found in 9-23% of patients compared with 1-9% for acid-related reflux [71]. In 
the study by Smith et al, the SAP positive rate for non-acid reflux was identical to 
that for acid reflux (31%) [72]. Non-acid reflux events have not been shown to occur 
any more frequently in chronic cough when compared with healthy controls [75].  
Pharmacological therapy for non-acid GOR associated cough includes alginates and 
motility agents, such as metoclopramide and domperidone, but evidence from 
controlled trials to support their use is currently lacking [52]. 
There is also uncertainty in the role of investigations for GOR related cough. 
Oesophageal pH monitoring may detect reflux events but are poor at predicting 
response to anti-reflux therapy [76]. At present, there is no evidence that tests for 
non-acid GOR, such as oesophageal impedance monitoring, are able to predict the 
response to treatment. 
The current evidence for surgical therapy for cough associated with GOR, Nissen 
fundoplication, is also weak and this procedure is associated with significant 
adverse symptoms and complications [52, 77]. The need for controlled studies using 





Rhinosinusitis, also referred to as post-nasal drip syndrome or upper airways cough 
syndrome (UACS), has been reported in up to 58% of patients with chronic cough 
[42]. As with GOR, there is a paucity of evidence to support a causal role of rhinitis 
in cough. Ear, nose and throat specialist evaluation and laryngoscopy is worthwhile 
particularly when upper airway symptoms are prominent but X-ray and CT scan of 
the sinuses are poorly predictive of the response to treatment and are not 
recommended for routine use [78]. Empirical treatment is recommended before 
diagnostic workup since the response to treatment is key to establishing the 
diagnosis. Anti-histamines, decongestants and topical nasal corticosteroids are 





1.1.6 Evaluation and treatment of the patient with cough 
Current guidelines on the assessment of the patient with cough are based on the 
anatomical diagnostic protocol approach proposed by Irwin et al [16, 30, 78, 79]. 
This approach involves targeting likely causes of cough by identifying symptoms or 
signs that pinpoint the likely anatomical origin of the associated condition (i.e. 
heartburn suggesting gastro-oesophageal reflux disease as the cause of cough). 
Therapeutic trials are endorsed, in addition to careful history, examination, 
spirometry and a chest x-ray. The required specific treatment may be apparent 
from the initial assessment, but empirical therapy may also be necessary. An 
example of a diagnostic and management protocol is presented in Figure 1-1. 
Treatment of cough is often integrated into the evaluation process since trials of 
therapy are often employed to establish the diagnosis. The specific treatments for 
cough have been briefly outlined in the earlier sections on cough aetiology. 
Resolution of cough with specific therapy confirms the diagnosis. On the other 
hand, lack of response to therapy can cause uncertainty since it may result from a 
genuine lack of treatment efficacy or incorrect diagnosis. 
Many cases of chronic cough remain unexplained despite detailed investigation. 
This is reported to account for up to 42% of patients referred for investigation [80]. 
A number of terms are used in the literature to describe the cough in this cohort: 
idiopathic, refractory, sensory neuropathic, laryngeal sensory neuropathy, airway 
sensory hyper-reactivity and vagal neuropathy-associated cough. These patients are 
predominantly female and middle aged [80]. An onset following viral illness and an 
association with organ specific autoimmune disease has been described in some 
patients [80-82]. This group have demonstrable heightened cough reflex sensitivity, 
and this has led some investigators to propose a greater focus on that key 
underlying mechanism and the use of a new name "Cough Hypersensitivity 
Syndrome" (CHS) to type these patients [45, 52, 83]. An approach for the evaluation 
of cough based on features of cough hypersensitivity rather than the traditional 
anatomical protocol has been suggested [45, 84]. 
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In cases of refractory cough, a limited number of non-specific treatments are 
available. Pharmacological agents include Morphine, which has been shown to 
suppress cough in a randomised double-blind placebo-controlled trial, but is 
associated with side effects [85]. Amitriptyline has been shown to be superior to 
other cough suppressants in a small open label study and gabapentin has also 
recently been reported to be efficacious in case reports and a recent randomised 
controlled trial [86-88]. Cough suppression therapy is a promising non-
pharmacological treatment provided by speech therapists and physiotherapists 
which involves education, avoidance of triggers, vocal hygiene, correction of 
breathing patterns and cough control [89, 90]. Improvements in cough specific 
quality of life as well as voice, breathing and cough scores were demonstrated 
although randomised placebo-controlled trials are required to confirm the findings 




Figure 1-1 Example of a diagnostic and management protocol 
 
Reproduced from the American College of Chest Physicians cough guidelines [78] 
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1.2 The cough reflex 
Cough is a vagally mediated physiological reflex that is designed to protect the lungs 
by preventing aspiration and clearing secretions or foreign material from the 
airways [91, 92]. It is a complex manoeuvre that requires intact sensory pathways 
from airway cough receptors, cortical processing and a functional efferent system 
from the brain to the appropriate muscles (Figure 1-2).  
In this chapter, the physiology of cough will be described by reviewing the 
understanding of the afferent and efferent pathways. Most evidence has originated 
from animal models since it is difficult to conduct in vivo human studies for obvious 
reasons. Animal models are also necessary for the development of antitussive 
therapies [93]. The guinea pig cough model is felt to be the most representative of 
the induced cough response in humans, but it is acknowledged that differences in 
experimental settings and protocols can influence the relevance of these models to 
humans [93, 94]. The major limitation of animal models is the inability to study 
cough analogous to human spontaneous cough. 
1.2.1 The afferent pathway 
As a reflex defence mechanism, cough is initiated in response to peripheral 
stimulation of cough receptors. The brainstem coordinates inputs from peripheral 
afferent nerves and from central regulatory cortical fibres and then activates the 
motor pathway of the cough reflex (Figure 1-2) [13].  
Cough receptors are most concentrated in the upper airways but are also found 
throughout the lower airways and lung parenchyma. A wide range of triggers can 
activate these receptors including cigarette smoke, capsaicin, acid and alkaline 
solutions, hypertonic saline and mechanical stimulation [13, 95]. In some patients 
however, no exogenous tussogenic trigger is identified, suggesting exaggerated 
sensation [96]. Indeed, patients with chronic cough often report coughing in 




Figure 1-2 Overview of cough pathophysiology 
 
TRPV1: transient receptor potential vanilloid cation channel subtype 1; TRPA1: 
transient receptor potential ankyrin cation channel subtype 1; RAR rapidly adapting 
receptor; SAR: slowly adapting receptor. Reproduced from Lee et al (2012) [84]. 
The receptors that mediate cough have not been conclusively identified, but they 
include Rapidly Adapting Receptors (RARs) and non-myelinated C-fibre receptors 
[97]. They differ with respect to conduction velocity and in their sensitivities to 
varied stimuli but both transmit their signals via the afferent vagus nerves [97]. 
RARs respond to excess mucus secretion and oedema, whereas C-fibres are 
sensitive to chemical stimuli such as capsaicin. Capsaicin binds to, and stimulates, 
TRPV1 receptors (transient receptor potential vanilloid subtype 1 ion channel). 
TRPV1 is the best known member of the TRP family and the subtype most 
implicated in cough [98]. Other subtypes include TRPA1 and TRPM8. TRPV1 
receptors are located throughout the respiratory tract but have also been identified 
within the central nervous system, skin, gastrointestinal tract and nasal mucosa in 
animal models [99-102]. TRPV1 is also activated by acids, heat, and endogenous 
mediators such as bradykinin, substance P and prostaglandins [98]. TRPV1 receptor 
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activation leads to increased permeability to Na+ and Ca2+ ions and the resulting 
influx causes neuronal depolarisation [103].  
The vagal afferents from both C-fibres and RARs converge at the Nucleus Tractus 
Solitarius (NTS), which sends out impulses to the other relevant areas in the 
brainstem and then subsequent signalling via sympathetic nerves to stimulate the 
respiratory muscles to contract and produce a cough (Figure 1-2) [13]. During 
chronic cough, airway inflammation may cause neuroplastic changes, such as the 
up-regulation the TRPV1 receptors. This may increase the patient’s susceptibility to 
coughing in response to trivial stimuli [13, 104]. 
Many patients with chronic cough report laryngeal paraesthesia, suggesting 
afferent nerve hypersensitisation as the underlying pathophysiological mechanism 
[96]. This cough reflex hypersensitivity is transient or reversible when associated 
with infection, eosinophilic airway inflammation and angiotensin-converting 
enzyme (ACE) inhibitor drug therapy, but in most patients with unexplained chronic 
cough it is persistent [52]. An enhanced cough reflex has been demonstrated in a 
number of conditions typically associated with cough [48]. The mechanism by which 
this sensitisation occurs remains poorly understood. 
It is possible to assess or identify cough reflex hypersensitivity with cough challenge 
tests using tussive agents such as capsaicin but they are of limited value for clinical 
use since they cannot reliably discriminate subjects with cough from healthy 
subjects [48]. A better understanding of these cough mechanisms however has led 
to a shift away from historical anatomically based diagnostic ‘causal’ approach and 
towards one based on the pathophysiology mechanisms. Some have suggested that 
those conditions classically felt to be causing the cough are in fact acting as 
aggravating factors on underlying cough reflex hypersensitivity [45, 83]. Indeed, 
several of the current antitussive treatments in development are targeted against 
these over-sensitised cough receptors [105, 106]. There is still some uncertainty 
around cough hypersensitivity syndrome, due to the lack of an accepted definition, 
and it therefore remains to be seen how well this view will be received.  
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1.2.2 The cough motor system 
In physiological terms, cough is described as an inspiration followed by a forced 
expiratory effort against a transiently closed glottis resulting in a rapid expulsion of 
air [107]. 
The inspiratory phase of the cough sequence has more importance than simply 
providing a volume of air that can be expelled to assist clearance of the airways. The 
expansion of the thorax also results in lengthening of the expiratory muscles, 
thereby optimising force generation due to the length-tension relationship of 
muscle fibres [108]. The result of inhalation to high lung volumes is that higher 
pressures can be generated by the muscles for any given degree of neural activation 
[109].  
At the end of inspiration, the glottis closes, preventing escape of air and permitting 
retention of intra-thoracic pressure. While the glottis is closed, an active expiratory 
effort follows, raising the intra-abdominal and intra-thoracic pressures during this 
"compression phase" (Figure 1-3). Additionally, glottis closure also minimises 
shortening of the expiratory muscle fibres, which in turn encourages isometric 
contraction. This isometric state maximises efficiency of the contraction with a 
more optimal force-length relationship [110]. The glottis then opens while 
expiratory effort continues, leading to transmission of intra-thoracic pressure into 
thoracic airflow, which is labelled the cough expiratory phase. Airflow rate can vary 
throughout the expiratory phase but peak airflow usually occurs soon after glottic 
opening during an initial burst which lasts approximately 30-50 ms [109]. Peak 
airflow during these bursts can exceed maximal flow generated during voluntary 
expiratory flow manoeuvres [111, 112]. Supramaximal flows are possible due to the 
added effect of dynamic airway compression during cough [113]. Airstream velocity 
is inversely proportional to the cross-sectional area in which the flow is traversing 
and, therefore, dynamic compression will increase velocity [109]. The ability to 
generate supramaximal flow has been linked with expiratory muscle strength in 
patients with neuromuscular weakness [111, 114]. The importance of supramaximal 
flow on airway clearance is not clear [112]. Nevertheless, cough peak flow rate 
remains a widely used tool for quantifying cough function. 
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Figure 1-3  Glottis activity during cough 
 
Reproduced from Korpas et al (1996) [115]. 
1.2.3 Supramedullary control of cough 
The cough motor pathway is regulated by higher cortical control and is the subject 
of much interest. It is known that humans are able to both voluntarily produce and 
inhibit a cough manoeuvre [116, 117]. Reflex coughs can be inhibited by simply 
instructing subjects to consciously suppress their cough [116]. Similarly, subjects 
undergoing tussogenic cough challenge testing can perceive an urge to cough 
without an actual motor cough response, suggesting that subjects can voluntarily 
ignore the urge [118]. Finally, diurnal variation in cough frequency has been 
consistently demonstrated with significantly lower numbers of coughs occurring at 
night, implying an inhibitory effect of sleep on spontaneous cough, and reflex cough 
thresholds have been shown to be higher at night [119-121]. The exact level of the 
control in unclear, but is most likely to be cortical. This is supported by the 




1.2.4 The expiratory reflex 
The expiratory reflex (ER) is another respiratory reflex that is similar to cough but 
with one important difference. Although the efferent sequence also includes glottis 
closure and a forced expiratory effort like a cough reflex, there is no preceding 
inspiratory phase in ERs (Figure 1-4) [123]. Stimulation of the larynx by injection of 
distilled water or mechanical stimulation induces both expiratory reflexes and 
coughs [124].  
The distinction between the two reflexes has been compared by Widdicombe and 
Fontana [107]. They note differences in brainstem neural pathways, modulatory 
actions, and pharmacological inhibitions between the two reflexes. The afferent 
pathways from the peripheral cough receptors to the cough centre for the two 
reflexes must be different, as one does not trigger an inspiration.  
The lack of a preparatory inspiration during the ER could have major implications 
when considering the efficiency of the reflex as a defence mechanism. The volume 
of inspired air prior to coughing has been shown to correlate with peak cough flow 
rate, and hence a lack of inspiration could be detrimental to cough efficiency [125]. 
On the other hand, however, a lack of inspiratory action could be advantageous in 
the event of inhalation of foreign material from the larynx in order to prevent 
further propagation into the tracheobronchial tree. Other differences also exist 
between the ER and cough. In animal models, duration and intensity of abdominal 
muscle electromyographic activity (EMG) were reduced in ER compared with cough 
[126]. In the same study, laryngeal muscle EMG burst duration was also reduced in 




Figure 1-4  Pressure and flow changes during cough and expiratory reflex 
 
Trace showing 3 expiratory reflexes (without preceding inspiration) followed by a 
cough and 2 further ERs during capsaicin cough challenge testing in a female 
healthy subject. Upper trace represents gastric pressure and lower trace represents 
airflow. 
There is differing opinion on the classification of the ER as a separate entity. Whilst 
some would define the ER as a distinct reflex, others consider it merely a result of 
the stimulus to cough occurring at different phases of the respiratory cycle [127]. 
The ER has been studied in the laboratory using experimentally induced cough, 
either chemically or mechanically. To my knowledge, the ER has not been studied in 
patients with chronic cough or during spontaneous pathological cough. 
Most cough studies have not defined which cough reflex was being assessed (true 
cough or ER, or more likely due to the lack of distinction, both). It is therefore 
unknown how much ER and cough contribute to spontaneous coughing in patients 




1.2.5 The muscles which contribute to cough  
Early electromyographic studies confirmed upper and lower abdominal muscle 
activity during the expulsive phase of cough [128]. These muscles include the rectus 
abdominis, transversus abdominis, internal oblique and external oblique muscles 
[129, 130]. In addition, activity from the pectoralis major and latissimus dorsi has 
been demonstrated in tetraplegic and healthy subjects, suggesting that they can act 
as accessory expiratory muscles [131, 132]. If the initial inspiration phase of cough is 
included, then the diaphragm and other inspiratory muscles are also of importance. 
The patterns of activation of the main and accessory expiratory muscles during 
voluntary and reflex cough were studied in healthy subjects by Lasserson et al [133]. 
During voluntary cough, predominantly the main expiratory muscles were activated 
at lower cough flow rates with sequential and increasing recruitment of accessory 
expiratory muscles at higher cough intensities. In induced cough, there was rapid 
and diffuse activation of both muscle groups, but with shorter EMG burst duration.  
The laryngeal muscles are important for the compression phase of cough. Rapid 
vocal cord closure is required to allow build up of sub-glottic pressure [134]. Poletto 
et al demonstrated that thyroarytenoid and lateral cricoarytenoid EMG activity was 
related to vocal cord closure during voluntary cough in healthy subjects [134]. 
Posterior cricoarytenoid EMG activity correlated with opening of the vocal cords in 
cough but its activity was not specific to cough manoeuvres.  Poliacek et al studied 
the relationship between laryngeal and respiratory muscle activity during cough in 
cats [126]. They found that thyroarytenoid and diaphragmatic activity was 
prolonged in response to laryngeal stimulation compared to tracheobronchial 
stimulation, but that abdominal muscle activity was no different between the two 
stimuli. A similar study has not been performed in humans. 
1.2.6 Voluntary, induced and spontaneous cough 
Spontaneous or pathological cough is of most significance since it is relevant to 
patients. However, the unpredictable timing of spontaneous cough in patients and 
the lack of it in healthy subjects has necessitated the study of experimental cough 
models such as voluntary cough or induced cough. Physiological differences 
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between induced and voluntary cough have been demonstrated [133, 135]. For 
example, as described earlier, voluntary cough is associated with sequential 
activation of the main expiratory muscles followed by activation of accessory 
muscles, whereas induced cough is associated with simultaneous activation of both 
muscle groups [133]. Addington et al found that intra-abdominal pressure remained 
elevated above baseline throughout induced coughs bouts, suggesting sustained 
expiratory effort [135]. Diaphragmatic movement during induced cough may also be 
greater than in voluntary cough [136]. Induced cough often results in bouts of 
coughing, which may be similar to spontaneous cough since patients with 
spontaneous cough often report coughing fits (Figure 1-5) [137, 138]. Coughs within 
bouts tend to be of shorter duration than single voluntary coughs, suggesting some 
modification to the motor pattern [125]. The experimental model that most closely 
represents spontaneous cough is unknown. 
Figure 1-5  A series of cough bouts  
 
3 bouts of coughing represented as numerous efforts occurring in close succession. 
Trace obtained during capsaicin cough challenge testing in a male patient with 
chronic cough. Poes: oesophageal pressure; Pga: gastric pressure; Flow: respiratory 
flow rate.  
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1.3 Subjective assessments of cough 
Assessment of treatment efficacy depends on demonstration of a partial or 
complete response. The way in which this response is measured is therefore of 
paramount importance since it is the cornerstone by which physicians determine 
whether to maintain the patient on treatment or change to another trial of therapy. 
A valid measure of cough could therefore quantify cough severity, determine 
treatment efficacy and indirectly yield diagnostic information [16].  
Currently available subjective and objective tools assess different aspects of cough 
and its impact on quality of life. No standard measure is universally accepted. 
Vernon et al recently conducted a qualitative focus group study and identified 3 
domains which chronic cough patients perceive as important determinants of 
overall cough severity: cough frequency, cough intensity and degree of disruption 
(Figure 1-6) [137]. The authors recommend high precision tools for assessing cough 
severity, but emphasise that these measures ought to be concordant with the 
features important to patients. Indeed, it is postulated that a single severe bout of 
coughing causing incontinence may be of more importance to some patients than 
the hundreds of barely noticeable coughs [139]. 
The subjective assessment of cough has been better studied than objective 
assessments, but recent technological advances have brought about several new 
tools. The available cough severity measures and their advantages and limitations 
are reviewed here. 
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Figure 1-6  Dimensions of cough severity 
 
Adapted from Vernon et al (2009) [140] 
1.3.1 Cough symptom scores 
Cough symptom scores or diaries utilise self-reported estimations of cough 
frequency and severity. Most cough symptom scores are simple tools that allow a 
limited number of possible responses. They have been extensively used in studies 
on cough but good evidence to support their validity is lacking. The repeatability of 
cough symptoms scores has not been reported, and the reproducibility of symptom 
questions relating to cough is questionable. One study demonstrated kappa 
coefficients ranging only from 0.27 -0.58 [141].  
Much of the studies on the accuracy of subjective cough frequency scores have 
been conducted in paediatric subjects. Hamuctu et al found no relationship 
between cough symptom score and objective daytime or nighttime cough 
frequency in children with cystic fibrosis [142]. Chang et al also compared subjective 
scoring of cough against objective cough frequency, using both parent and child-
reported visual analogue scales and Verbal Category Descriptive scores (VCD) [143]. 
The VCD comprised a 5-point scale rating the frequency of cough. The best 
relationship was found between the daytime cough frequency and daytime VCD 
(r=0.63 to 0.65). Nighttime relationships were poor. Falconer et al evaluated 
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subjective assessment of nocturnal cough in asthmatic children against objective 
cough recordings [144]. The subjective score was a simple binary assessment 
(whether nocturnal cough was present or not) but poor agreement was found 
between subjective and objective measures (Kappa 0.30). Hsu et al reported a 
statistically significant correlation between cough symptom score and cough 
frequency, but the magnitude of that correlation was not given [119]. The 
relationship was only applicable to daytime cough, presumably because subjects are 
cannot accurately quantify coughs occurring in and around sleep periods.  
The poor relationship between cough symptom scores and objective cough 
frequency may be due to the wording of questions within the scores, which do not 
always specifically refer to frequency of cough. Non-specific wording may allow 
other aspects of cough severity to influence scoring.  
1.3.2 Cough severity visual analogue scales 
Cough visual analogue scales (VAS) are 100 mm linear scales on which patients can 
demarcate self-perceived cough severity. The scale is anchored at each end by a 
phrase to denominate extremes of possible cough severity range: for example, no 
cough and worst cough.  
The cough VAS has been shown to be repeatable in patients with chronic 
obstructive pulmonary disease, yielding a within-subject standard deviation of 7.75 
mm and intra-class correlation coefficient 0.87 [145]. The cough VAS is also highly 
repeatable and responsive in chronic cough, with an intra-class correlation 
coefficient 0.84 and an effect size of 3.2 [11]. However, it does not relate well with 
cough frequency in children (r=0.47 to 0.55) or adults (r=0.38) [143, 146]. This may 
not be surprising since cough VAS is usually worded to assess subjective perception 
of global cough severity, and cough frequency is only one component of overall 
cough severity. It is unknown how well cough VAS relates to objective measures of 
cough intensity. 
In a study of 104 patients with chronic cough, the mean cough VAS was found to be 
48 mm [11]. In another study of 62 patients, mean daytime and night-time VAS was 
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40 mm and 18 mm respectively [147]. Cough VAS has also recently been reported in 
30 otherwise healthy subjects with acute viral cough [148]. In this study, the mean 
cough VAS was 39 mm and the minimal important clinical difference (MICD) was 13 
mm [148].  
1.3.3 Health status questionnaires 
A number of health related quality of life questionnaires have been developed to 
specifically address cough-related health status. Whilst they assess the impact of 
cough rather than cough severity per se, they have become standard outcome 
measures in studies investigating chronic cough. 
The Leicester Cough Questionnaire (LCQ) comprises 19 items within 3 domains: 
physical, psychological and social [11]. It has been widely validated in chronic cough, 
and an adapted version has been validated in acute cough [11, 148, 149]. The LCQ is 
repeatable and responsive in acute and chronic cough, with a minimal important 
clinical difference of 2.5 and 1.3 respectively [11, 148, 149]. It has been used as an 
outcome measure in randomised clinical trials of gabapentin and erythromycin for 
chronic cough [88, 148]. The LCQ is also validated for use in patients with COPD and 
has been found to be reproducible in patients with idiopathic pulmonary fibrosis 
[150, 151]. Its use has also been reported in patients with cystic fibrosis, 
bronchiectasis and asthma [152-154]. 
The Cough Specific Quality of Life Questionnaire (CQLQ) comprises 28 items which 
are divided into 6 domains: physical complaints, psychosocial issues, functional 
abilities, emotional well-being, extreme physical complaints and personal safety 
fears [12]. Good construct validity and internal consistency were shown in both 
acute cough and chronic cough, and repeatability and responsiveness was 
demonstrated in the chronic cough cohort [12]. The minimal clinical important 
difference of the CQLQ has not yet been reported. Nevertheless, the CQLQ has been 
used to assess cough in a number of respiratory disorders including COPD, asthma 
and bronchiectasis and has been used as an outcome measure in a randomised 
controlled trial of acid suppression therapy in chronic cough [69, 155].  
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The Chronic Cough Impact Questionnaire (CCIQ) comprises 21 items divided into 4 
domains: sleep/concentration, social relationship, impact on daily life and mood 
[156]. Its development was derived from 166 patients with chronic cough and the 
construct validity, internal consistency and repeatability met required standards. 
Concurrent validity was poor when assessed against the Short Form 36 (SF36) 
generic health status questionnaire, with only one of the CCIQ domains (impact on 
daily life) showing a weak correlation with 4 of the SF36 domains (r=-0.008 to 0.367) 
[156]. The tool was deemed responsive after a significant difference in 16 of the 21 
items was recorded following treatment [156]. The effect sizes or minimal 
important clinical differences were not reported. Scores have only been reported 
for the individual item and domains scores, and no mean overall composite score 
was reported in the development studies [156, 157]. The responsiveness of the 
overall tool is also unknown. At the time of writing, there were no published clinical 




1.4 Objective assessment of cough frequency 
Objective cough frequency assessment is recommended by the European 
Respiratory Society task force as part of the assessment of cough severity to 
improve clinical practice, research and assess new therapies [79]. 
The gold standard method in cough frequency monitoring was previously held to be 
that obtained from video recordings [158]. However, the impracticality of confining 
subjects to an observation room for several hours prompted the study of digital 
audio recordings, which could allow ambulatory measurements in the subject's 
home environment. Coughs produce a characteristic sound that can be counted 
from playback of sound recordings. Excellent agreement has been demonstrated 
between cough frequency counted from audio recordings and that from video 
recordings, with an error of only 0.1 to 0.3 coughs per hour [159]. This has led to 
the proposition of audio manual cough counting as the new gold standard.  
1.4.1 Early methods of objective cough frequency assessment 
Early examples of objective cough frequency assessment date back to 1954, when 
Gravenstein et al recognised the limitations of subjective estimations of cough 
frequency for assessing the effect of antitussive agents [160]. They described a 
technique using an instrument developed by Albert Grass of the Grass Instrument 
Company, which consisted of an inkwriting apparatus that recorded coughs by 
depicting the cough sounds on moving paper as spikes [160]. The investigators 
analysed the number of cough spikes (cough frequency), spike duration and 
amplitude, and the duration of cough bouts in response to tussive challenge tests. 
The interest in recording sound for the purpose cough monitoring continued and 
subsequent developments led to use of tape recorders instead of inkwriters [161] 
[162]. In the 1960's, Woolf et al adopted a system in which a free-field microphone 
was fixed in place above the head of a bed and connected in series to a tape 
recorder [161]. The tape recorder was triggered to record if the microphone 
detected any sound, and would then continue recording for 5 seconds after the end 
of the sound activity. This trigger-activated recording method allowed 24 hours of 
monitoring to be captured on a 2-hour tape. The setup necessitated subjects to be 
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confined to a hospital room which was isolated as much as possible from ambient 
noise.  
Alternative devices to free-field microphones for recording cough sounds were later 
employed. In the late 1970's and early 1980's, Rühle et al and in Matthys et al used 
contact microphones attached to the throat [163, 164]. The contact microphones 
were essentially pressure transducers that were fixed over the larynx which some 
subjects reported as uncomfortable. The sound signals were relayed to a recorder, 
which was activated by coughs but not other sounds such as speech, and was 
capable of 8 hours of monitoring [163, 165] 
By the late 1980's, the addition of on-line processing techniques was incorporated 
into cough monitoring systems in order to filter cough detection from other sounds 
or manoeuvres. Salmi et al developed a system that comprised of simultaneous 
sound and body movement detection [166]. Body movements were sensed using a 
kinesthetic transducer paired with a static charge-sensitive bed mattress whilst 
subjects were observed lying or sitting on the bed. Coughs were only labelled if pre-
set thresholds of noise and movement levels were detected by both the 
microphone and the movement sensor. They were one of the first investigators to 
provide validation data of the performance of their cough detection system, against 
a reference of manually triggered recording of coughs by a trained observer. 
Performance was good, with a sensitivity and specificity of 99% and 98% 
respectively, but the major limitations included restriction of the subject to the bed 
and the need for subjects to refrain from making any high frequency noise or 
sudden movements. 
1.4.2 Modern cough frequency monitoring systems 
The ideal objective cough monitoring system requires excellent accuracy of course, 
but other desirable features are portability and automation - to make the system 
practical for clinical use and reduce the time-consuming nature of manual cough 
counting. A number of systems have recently been reported. Most are still based on 
the detection of the cough sound, which is reasonable since it is our recognition of 
the characteristic sound that we use to identify cough. Some systems use 
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accelerometers to measure vibration in place of sound, and others have combined 
the use of sound with electromyography [167, 168]. Each system has its own 
advantages and disadvantages and these are described below. In general, whilst 
cough sounds are simple to record and interpret in a controlled environment, their 
analysis is challenged by ambient noise when monitoring systems are made 
ambulatory. Speech, throat clearing, laughter and sneezing are some of the non-
cough sounds that can lead to false positives [169]. Complex computer algorithms 
are often used to differentiate cough sounds from ambient noises in order to 
facilitate automated analysis. The technical aspects of these detection algorithms 
are not within the remit of this thesis. The main cough monitoring systems are 
described below and their validation studies summarised in Table 1-3. At the time 
of submission of this thesis, only 2 of the cough monitoring systems were available 
and in use, the Leicester Cough Monitor and VitaloJak.  
 
Leicester Cough Monitor 
The Leicester Cough Monitor (LCM) is a sound-based system that allows ambulatory 
24-hour monitoring. One key advantage of the LCM system above some of the 
other cough monitoring systems lies in the automated aspect of the analysis 
method and minimal user input requirement, allowing a final report to be 
generated after approximately one hour of analysis [170]. The system works by 
automated analysis and detection of candidate cough sounds using custom 
software based on Hidden Markov Models speech recognition algorithms [171]. 
Following an initial automatic analysis of the recording, a selection of the detected 
candidate sounds are validated by an operator and the results from the validation 
process are then incorporated back into the programme in order to refine the 
detection algorithm (Figure 1-7) [172]. The operator input improves sensitivity and 
acts as a real-time calibration method to account for individual cough sound 
differences. The LCM was originally validated in patients with chronic cough and in 
healthy controls. Initial validation was performed against manual cough counting of 
6-hour recordings, with further subset analysis of two single hour-long epochs 
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extracted from 18-hour recordings [172]. The 6-hour validation study showed that 
95% of manually marked coughs were labelled by the programme as candidate 
cough events, although presumably with significant false positive rates. Following 
user refinement, overall cough detection sensitivity and specificity were reported as 
86% and 99% respectively. Data from the longer recording validation study showed 
that the user refinement process improved the sensitivity and specificity to 98%, 
compared with manual analysis of all the pre-user refinement candidate events. The 
overall performance of the LCM in the longer subset analysis was better than that 
of the 6-hour group, with a sensitivity 91%, specificity 99% and false positive rate of 
2.5 coughs per hour [172, 173]. The agreement between the LCM counted cough 
rates and manually counted cough rates was 0.87. LCM counts were also repeatable 
over 6 hours, with an intra-subject SD of 11 coughs/pt/hr and an intra-class 
correlation coefficient of 0.9. The short duration of these validation studies for a 24-
hour cough monitoring system led to some criticism, but later external validation 
studies performed over a 24 hour period reaffirmed the good correlation (r=0.97) 
and agreement (r=0.98) between LCM counts and manual cough counts [169, 172, 
174]. A further recent 24-hour validation study in patients with chronic cough and 
healthy controls found the LCM to have a sensitivity and specificity of 82-84% and 
99.9% respectively [175]. The LCM has been used as an outcome measure in 
randomised controlled trials of gabapentin and erythromycin [88, 176].  
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Figure 1-7 Leicester Cough Monitor set up and analysis 
 




The Vitalojak is a custom-built cough recording device paired with a lapel 
microphone which is capable of ambulatory 24-hour monitoring [177]. The 
recording, once uploaded onto a computer, is compressed (by removing periods 
without any sound) and then manually analysed via an audiovisual display. During 
its evolution, the developers have used different recording devices to capture the 
data, but the analysis technique is well established. Early validation studies of this 
technique during overnight monitoring in 8 patients with chronic cough showed 
excellent agreement with cough counts from video recordings and a mean 
difference of 0.3 coughs/hr, which was within one standard deviation [178]. The 
excellent results are not surprising since the Vitalojak uses manual cough counting 
from audio recordings, which was previously shown to be as good as video 
recordings [159, 178]. The major limitations of this technique are the laborious 
manual counting method due to the lack of automation and the need for operator 
experience and training. Nevertheless, the system has been used as a cough 
monitoring tool in a number of clinical studies of patients with chronic cough, COPD 
and pulmonary fibrosis [72, 151, 159]. 
 
Hull Automatic Cough Counter 
The Hull Automatic Cough Counter (HACC) is another sound based cough 
monitoring system which operates by compressing the sound recording and then 
identifies coughs using a neural network algorithm which is trained to recognise 
specific features based on reference "coughs" and "non-coughs" [179]. 33 subjects 
were recruited for the original development study, of which 23 were studied for the 
purpose of defining the reference cough features, leaving 10 subjects for the 
validation phase [179]. The monitoring period of the validation phase was limited to 
one hour in duration. At the time of publication, the HACC was not fully automated 
and required manually verification and counting of the detected coughs. The 
average sensitivity and specificity of the Hull Automatic Cough Counter for cough 
detection, using manual audio cough counting as the reference, was 80% and 96% 
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respectively. There was a 20% false positive rate attributed to ambient sounds that 
included coughs from sources other than the subject undergoing monitoring. This 
limitation arose because the recordings for the study took place within a clinic 
where other coughing patients were present. Faruqi et al used a newer version of 
the HACC to investigate cough frequency in patients with chronic cough [146]. 
Cough monitoring was performed over a 24-hour period, and validation of the 
system was performed against manual cough counts in 10 patients with chronic 
cough. Although there was good agreement between the HACC version ii and 
manual cough counts (r=0.87), the HACC consistently underestimated cough counts 
(HACC vs. manual 24-hour cough counts 237 vs. 546 coughs, p<0.001). This may be 
due to the algorithm applied to the recordings, developed to wean out periods 
without sound and reduce analysis time but perhaps at the expense of losing low 
intensity cough sounds.  
 
RBC-7  
Munyard et al developed the RBC-7 cough monitoring system, a multi-parametric 
system incorporating sound, electromyography and electrocardiography data in 
unison [180]. The RBC-7 can record for a continuous period of 6 hours, or 
intermittently for 48 hours if set to trigger upon EMG activity reaching a set 
threshold. Recorded coughs were counted manually. The bulk of the study by 
Munyard et al focussed on the identification of optimal chest wall positions for the 
EMG surface electrodes, to aid cough detection and differentiate from other 
manoeuvres such as speech, throat clearing and sneezing. The validation study was 
performed in daytime recordings from 10 subjects (4 adults and 6 children) and 
overnight inpatient recordings of 1-8 hours duration from a further 10 children with 
cystic fibrosis [180]. The reference was an additional separate audio recording, 
which was analysed manually. Coughs counts identified with the RBC-7 system 
correlated strongly with manual cough counts (r=0.99), with equally good 
performance for both day and nighttime analyses. The authors admitted limitations 
of such a system including the need for EMG expertise, cost and lack of automation, 
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although Hsu et al also used this technology within their Brompton Cough 
Recording system in a study of cough frequency in healthy subjects, stable 
asthmatics with cough and patients with chronic cough [119].  
 
Logan Sinclair LR 100 
A later modification of the RBC-7 system led to the development of the LR 100 
system [142]. In the validation study by Hamutcu et al, the investigators used an 
algorithm to remove periods within recordings which were void of any sound 
signals, shortening the analysis time by several hours, but the identification and 
counting of coughs remained manual [142]. In this study, 14 children with cystic 
fibrosis underwent simultaneous monitoring with the LR 100 and a separate 
conventional tape recorder during chest physiotherapy sessions. There was good 
agreement between the two methods and the mean difference was within two 
standard deviations (Table 1-3). The LR 100 has also been validated in pre-school 
infants, with a resulting sensitivity of 81% and positive predictive value of 0.8 [181].  
 
Adapted Holter monitor cough meter 
Chang et al also combined cough sound and EMG for cough monitoring with their 
adaptation of a Holter monitor [167]. A contact microphone was attached to the 
skin just inferior to the substernal notch and EMG surface electrodes placed at the 
xiphisternum and both costal margins. The cough meter was capable of continuous 
monitoring for 24 hours. Data analysis, cough identification and counting were 
performed manually by visual playback on a display monitor. Validation of the 
cough meter was performed in a group of children with recurrent cough and 
healthy children, and compared against a separate sound recording from a static 
bedside microphone, which was also scored manually. The agreement was good, 
although the cough meter tended to capture more coughs than the standard tape 
recorder, possibly due to the limitations of the older stationary system, which 
would fail to capture cough sound if the child moved away from the bed or the 
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sound was, muffled (Table 1-3). Although inexpensive, the main disadvantage of the 
system is the lack of automation, necessitating time-intensive analysis [167]. This 
system has been used by the same group in further studies comparing modalities of 
cough assessment in children with recurrent cough [143, 182]. 
 
Lifeshirt® 
The Lifeshirt® system incorporates respiratory inductance plethysmography 
together with a contact microphone, an accelerometer and ECG monitoring [158]. 
The multiparameter system is capable of recording 24 hours of data and can yield 
information on cardiorespiratory indices, body position and sound profiles. Analysis 
is performed once the data is uploaded into a central computer, and a software 
algorithm identifies cough events. Validation of the system was performed for 24 
hours of monitoring in 8 patients with COPD under laboratory conditions [158]. 
Cough counts detected by the Lifeshirt® system were compared with manually 
counted coughs from video and audio recordings. Although results were promising, 
there have been no larger scale validation studies in other patient groups and the 
system has not yet been used in clinical studies. The performance of the system for 
cough detection is given in Table 1-3.  
 
Other systems 
Subburaj et al developed a computerised cough acquisition and analysis system, 
using cough sound data acquired from a microphone which was then recorded 
using a digital audio tape [183]. Analysis is performed by playing back 30-minute 
segments of data and manual labelling of coughs. The system is able to measure 
cough sound energy, proposed by the authors as a measure of cough effort. 
Accuracy was reported as 100% although the validation methodology and reference 
used to assess accuracy are unclear. Furthermore, sample size was limited to eight 
30-minute files obtained from one subject. The system was later made portable and 
used as an outcome measure in six clinical studies assessing the antitussive efficacy 
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of dextromethorphan in acute cough [184]. All six studies were similar in design, 
although two studies used an accelerometer to acquire the cough signal instead of a 
microphone. The meta-analysis by Pavesi et al reported that the consistent findings 
across the studies confirmed the validity of the system [184]. No comparison was 
made between the performance of this system and other standard cough counting 
techniques. 
Paul et al developed a portable self-contained system using an accelerometer 
positioned at the suprasternal notch to measure vibration [185]. Validation was 
performed in 15 subjects of varied ages against manual counting from video 
recordings as a reference. The recordings were performed within hospital and at 
home but for a short duration, ranging from 15 to 60 minutes. Excellent agreement 
between the two methods was found (Table 1-3). At the time of writing, there were 
no further studies validating the system over longer periods.  
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Table 1-3 Studies of cough frequency monitoring systems 
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10 smokers with chronic 
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1 hour Sens 80%; spec 96% 
Munyard, 1994 [180] RBC-7 Sound, EMG & 
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10 subjects for daytime; 
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night time 
1-8 hours r=0.99 
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modified 
analysis 









Corrigan, 2003 [181] LR 100 Sound & EMG Manual Manual from 
audiovisual 
recordings 
9 infants with cough; 17 
healthy infants; total of 
38 recordings 
Up to 18 
hours 
Sens 81%; spec not 
reported. PPV 80% 
Matos, 2006 [171] 
Birring, 2008 [173] 
LCM Sound Semi-
automated 
Manual 18 chronic cough; 8 
healthy subjects 
6 hours and 
two single 
hour 
Sens 86%; spec 99%; 
ICC 0.87 
Yousaf, 2013 [175] LCM Sound Semi-
automated 
Manual 12 patients (asthma, 
eosinophilic bronchitis, 
chronic cough, COPD); 8 
healthy subjects 
24 hours Sens 82-84%; spec 
99.9%; ICC 0.85-0.98 
Faruqi, 2011 [146] HACC version ii Sound Automated Manual 10 chronic cough 24 hours Manual vs. HACC 546 
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8 COPD 24 hours Sens 78%; spec 
99.6%; PPV 84.6%; 
NPV 99.4%; Accuracy 
99%; kappa 81% 
Smith, 2006 [178] Vitalojak Sound Manual Manual from 
video recording 
9 chronic cough Overnight Mean difference -0.3 
c/hr 
Subburaj, 1996 [183] 
 
 Sound  Manual n/a 1 subject 4 hours Accuracy 100% 
HACC: Hull Automatic Cough Counter; LCM: Leicester Cough Monitor; Sens: sensitivity; Spec: specificity; EMG: electromyography; CF: cystic 




1.4.3 Cough sounds 
In the classic form, cough produces a double sound, as shown in Figure 1-8. This 
sound signal can be divided into three component phases: the explosive, the 
intermediate and the voiced phases (or phases 1, 2 and 3 respectively), and the first 
and last phases are responsible for the typical double sound. Whilst all coughs 
contain the first phase, only some contain a voiced phase [187, 188]. Reports 
suggest that the voiced phase may be absent in approximately one third of coughs 
from healthy subjects and possibly more frequently in disease states [115, 187, 
189]. There is, however, no relationship between the number of cough sound 
components and aetiology of cough [190]. 
Figure 1-8 Cough sound signal 
 
Sound signal of a cough showing 2 peaks in sound amplitude corresponding to the 
characteristic double cough sound. Trace is of a voluntary cough in a female patient 
with chronic cough. 
The generation of cough sound is dependent on laryngeal and nasopharyngeal 
structures and airflow from the thorax [191]. It is unknown how much each of those 
contributes to the nature of the sound. In normal cough, the glottis is fully open 
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during the inspiratory phase and closes transiently during the compression phase 
whilst an expiratory effort ensues, allowing sub-glottic pressure to rise. The glottis 
then opens for the explosive phase of the cough manoeuvre and the turbulent flow 
of air produces the first characteristic cough sound (Figure 1-9). The quieter 
intermediate cough sound phase relates to steady state flow through the open 
glottis, and the voiced phase occurs secondary to glottis narrowing at the end of the 
expulsive phase [115].  
Figure 1-9 Temporal relationship between sub-glottic pressure, flow and cough 
sound generation 
 
Reproduced from McCool (2006) [109] 
Although variation is noted, some characteristics of the cough sound have been 
described. The duration of the cough sound in normal subjects is approximately 410 
ms, although in asthma and chronic bronchitis the duration may be as long as to 
600 ms [192, 193]. Murata et al reported a shorter mean cough sound duration, less 
than 355 ms for healthy subjects or patients with chronic bronchitis [188]. Piirila et 
al reported ranges for the frequency spectrum profile of cough sounds [194]. They 
reported a fundamental frequency (also known as maximum frequency) of 436 Hz ± 
544 Hz across a range of respiratory conditions and the lowest upper frequency 
limit of 5,400 Hz, in asthmatics. Korpas et al found the upper frequency limit to be 
at 3,000 Hz [195].  
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A host of cough sound parameters have been assessed with varying aims including 
the distinction between cough and speech, detection of abnormal lung function or 
as a proposed measure of cough effort [184, 187, 196]. Smith et al investigated the 
ability of healthcare professionals to identify respiratory disease aetiology by 
listening to cough sounds [197]. The observers were able to differentiate wet from 
dry cough but they were unable to discriminate between idiopathic pulmonary 
fibrosis, asthma, COPD, bronchiectasis or laryngitis  [197]. 
Cough sound detection and analysis forms the basis for most cough frequency 
monitoring systems. These are discussed in more detail in section 1.4.2. Few studies 
however, have validated cough sound as a measure of cough intensity or strength. 
1.4.4 Relationship between cough frequency and subjective cough 
severity 
Cough frequency may be an outcome measure in its own right, but its importance 
to overall subjective cough severity can be implied by their relationship. A number 
of studies have confirmed, at best, a moderate relationship between objective 24-
hour cough frequency and subjective cough-specific quality of life, with reported 
correlation coefficients ranging from 0.36 to 0.71 [120, 147, 153, 159, 198]. The 
modest relationship highlights that the number of coughs is not the only factor 
important to patients' perception of cough severity. Intensity of cough and the 
degree of disruption caused by cough are also important [137].  
Coughs can occur in isolation or within bouts or peals (Figure 1-10). Cough counts 
differ depending on whether the individual events within a cough bout are 
considered separate. Kelsall and colleagues investigated the importance and 
relevance of these methodological differences by comparing the relationship 
between the different methods of counting cough and subjective cough severity 
and cough-related quality of life [120]. They examined three methods of counting 
coughs - cough explosive phases (number of individual characteristic cough sounds), 
cough seconds (number of seconds containing at least one cough) and cough 
epochs (number of periods of continued coughing separated by at least 2 seconds) - 
and compared these with cough severity VAS and LCQ score. Cough explosive 
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phases and cough seconds were in good agreement with each other and correlated 
equally well with VAS and LCQ, but cough epochs performed less well [120].  
Figure 1-10 Airflow and sound waveforms for a bout of coughs  
 
14 explosive phases are organised within 3 cough bouts. Upper trace is flow rate and 
lower trace is cough sound signal. Trace obtained during capsaicin challenge testing 
in a male patient with chronic cough. 
1.4.5 Cough frequency in health and disease                                                                                                                                                        
Estimates for expected cough frequency in health and disease can be deduced from 
many of the cough monitoring validation studies listed in Table 1-3. 
In healthy subjects, cough frequency rates of 2 ± 1 coughs per hour are reported, 
although this study was limited to 6-hour monitoring periods in only eight male 
subjects [173]. A more recent study in a larger cohort of 44 male and female healthy 
subjects, using the same technology, demonstrated 24-hour total cough counts of 
18.6 coughs (equivalent to cough frequency of 0.8 coughs per hour) [175]. Sumner 
et al also demonstrated similar findings in healthy non-smokers (median cough 
61 
 
frequency 0.7 coughs per hour), although smokers had higher cough frequency, 5.3 
coughs per hour [199]. 
Objective cough frequency rates in patients with chronic cough have been well 
documented in several studies, with reported 24-hour cough frequency rates 
ranging from 16 to 33 coughs per hour [119, 120, 173, 175]. Cough frequency has 
also been reported for a number of other conditions. In a group of 8 patients with 
COPD undergoing video monitoring, the mean cough frequency was 33 coughs per 
hour [158]. The median 24-hour cough frequency in asthmatic patients was found 
to be 11.8 coughs per hour [119]. Two studies have described cough frequency in 
patients with cystic fibrosis during inpatient admissions for pulmonary 
exacerbations, with one study including 14 children and the other including 19 
adults [142, 200]. Cough frequency in the paediatric study was counted in cough 
epochs or bouts and not as individual events; cough frequency rates were 
unchanged between admission and at discharge (baseline daytime cough frequency 
18.2 ± 8.4 cough epochs per hour and night-time cough frequency 5.8 ± 2.9 cough 
epochs per hour) [142]. The adult study reported cough frequency as time spent 
coughing, and did demonstrate a fall in both daytime and night-time cough 
frequency between admission and discharge (median (IQR) admission vs. discharge 
daytime cough frequency 21.2 (14.0-34.9) vs. 9.0 (5.8-12.8) cough seconds per hour 
and night-time cough frequency 4.8 (1.0-6.8) vs. 1.5 (0.8-5.0) cough seconds per 
hour) [200]. The same investigators also investigated cough frequency in idiopathic 
pulmonary fibrosis, showing overall 24-hour cough frequency rates of 9.4 coughs 
per hour, although the range was wide (1.5 to 39.4 coughs per hour) [151]. 
In contrast to chronic cough, there is relatively little data for cough frequency in 
acute cough. Two community-based studies reported on the duration of acute 
cough and other related symptoms, but the assessments of cough were subjective 
and, furthermore, up to 50% of subjects in those studies had used antitussive 
treatments [201, 202]. In the meta-analysis of dextromethorphan efficacy in acute 
cough by Pavesi et al, objective cough frequency was measured [184]. Similarly, Lee 
et al used objective measures to examine the placebo effect on cough frequency 
[203]. In both studies however, cough monitoring periods were short (between 15 
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minutes and 3 hours). The former study included a placebo group, which is 
susceptible to significant placebo effect, as established by the latter study. The 
latter study included a no-treatment group, but the extremely short nature of the 
observation period (15 minutes) restricts its use for characterising the natural 
changes in cough frequency in acute cough. 
Sunger et al recently reported objective cough frequency in an observational study 
of acute cough in 54 otherwise healthy subjects [204]. Over-the-counter cough 
treatments were not permitted, and so the study yielded valuable information on 
cough frequency rates and repeatability of cough frequency. 24-hour cough 
frequency was measured on two consecutive days. Geometric mean cough 
frequency was 12.1 coughs per hour at baseline and reduced significantly to 2.9 
coughs per hour on the following day. The minimal important clinical difference in 
cough frequency was not assessed. The study period was 2 days in duration and the 
median duration of cough at baseline was 4 days, but other studies have shown that 
half of subjects with acute cough report ongoing symptoms 10 days after onset 




1.5 Objective assessment of cough intensity 
Most studies involving measures of the intensity of coughs have been conducted in 
the context of assessing cough as a function (Table 1-4). This is most relevant in 
cases where the efficiency of cough as a defence mechanism is in question, that is, 
in possible cases of weak cough. This includes neuromuscular diseases, stroke, 
Parkinson’s disease and laryngectomised patients [4, 205-207]. Therefore, the 
measure by which cough intensity is defined in these studies has generally been 
with relevance to the ability of cough to perform its underlying physiological 
purpose – to protect the lungs from aspiration of foreign bodies and clear 
secretions and debris from the airways. Some of these studies were conducted in 
healthy subjects but there are few studies assessing cough intensity in patients with 
chronic cough.  
There is no widely accepted gold standard measure of cough intensity [123]. As 
previously described, the physiological sequence of the efferent cough pathway 
begins with neurological signalling from the cerebral cortex and cough centre down 
to the muscles responsible for generating force to elevate intra-abdominal 
pressure, which is then transmitted to intra-thoracic pressure and leads to rapid 
respiratory airflow as an output. Based on this sequence, a number of potential 
methods are available for measuring cough function, including electromyography, 
cough airflow rates, pressure and sound (Figure 1-11). These are reviewed in detail 
in the subsequent chapters. 
Few studies have examined the intensity of spontaneous cough, presumably due to 
its unpredictable nature and timing. This has led to the use of experimental models 
such as voluntary or induced cough using tussive stimuli such as capsaicin. The 
availability of experimentally induced cough permits evaluation of the efficacy of 
antitussive agents on cough reflex sensitivity [208]. As shown in studies with 
codeine however, demonstration of antitussive effect in experimentally induced 
cough does not necessarily translate into efficacy in pathological cough [209, 210]. 




Table 1-4 Selected studies assessing cough intensity or function 
Author Population Sample size Cough type 
studied 
Cox, 1984 [211] Healthy 10 VC/RC 
Chaudri, 2002 [1] Motor neurone disease 53 VC 
Chellini 2011 [212] Laryngectomy 10 VC 
Davenport, 2007 [213] Healthy NR RC 
Ebihara, 2003 [4] Parkinson's disease/Healthy 15/15 VC 
Fontana, 1997 [214] Healthy 30 VC/RC 
Fontana, 1999 [206] Laryngectomy/Healthy 10/10 VC/RC 
Fontana, 1999 [215] Healthy 30 RC 
Kim, 2009 [216] Elderly healthy 18 RC 
Kyroussis, 1997 [217] Healthy 6 VC 
Lasserson, 2006 [133] Healthy 10 VC/RC 
Lavietes, 1998 [218] Healthy 5 VC/RC 
Lavorini, 2007 [219] Healthy 19 VC/RC 
Lavorini, 2007 [220] CCHS/healthy children 7/7 VC/RC 
Man, 2005 [221] COPD/Healthy 43/25 VC 
Murty, 1991 [222] Laryngectomy/healthy 10/10 VC 
Pitts, 2008 [223] Parkinson's disease 20 VC 
Pitts, 2009 [224] Parkinson's disease 10 VC 
Polkey, 1998 [111] Amyotrophic lateral sclerosis 16 VC 
Reilly, 2012 [225] Cystic fibrosis/Healthy 10/10 VC 
Smith, 2012 [125] Healthy 16 VC/RC 
Smith Hammond, 2001 [2] Stroke/Healthy 43/18 VC 
Steier, 2007 [226] Suspected respiratory muscle 
weakness 
>500 VC 
Ward, 2010 [205] Stroke/Healthy 18/20 VC/RC 




Figure 1-11  Opportunities for measurement of cough function  
 
Reproduced from Smith & Woodcock (2008) [227] 
1.5.1 Electromyography of the abdominal muscles 
Electromyography (EMG) is a method of recording electrical activity from the 
muscles. The electrical signals arise from action potentials as they propagate along 
the muscle fibre. The level of EMG activity can therefore be used as a measure of 
the recruitment of motor units within the muscle of interest. The rate of rise of 
integrated EMG activity is representative of the rate of recruitment of motor units, 
while the peak of the integrated EMG activity reflects the total number of units 
recruited and of their maximum firing frequency [228]. 
EMG activity can be recorded using needle or fine wire electrodes inserted directly 
into the muscle [129]. Alternatively, EMG activity can be recorded non-invasively 
using surface electrodes placed onto the skin overlying the muscle [128, 133]. 
Surface EMG is easily applied but the signal quality and total activity level can vary 
with individual differences in body habitus due to interference with signals from 
skin resistance and subcutaneous fat. The filtering effect from the skin can be 
improved by preparing the skin to remove dead skin cells and natural oils [229]. 
Surface EMG is less precise than needle or fine wire EMG, but larger surface area 
covered by the electrode also means that it can capture signals from a greater 




A limitation of EMG measurements is the inability to compare values between 
subjects and indeed between experimental sessions. This is because of the 
numerous variable factors that can affect the EMG signals including skin resistance, 
electrode position, distance between electrodes and contact between the electrode 
and the skin [230]. Raw EMG values can only therefore be compared within subjects 
and within the same experimental session. Data processing can allow relative 
comparisons between subjects if the error is eliminated. Normalisation is a method 
by which values are expressed as a fraction or percentage of another value, often 
the maximum value observed, and permits comparisons of EMG measurements 
between subjects [133, 214]. Since both the numerator and denominator (observed 
value and maximum observed value) for each subject study are measured during 
the same experimental session and with identical recording settings, any error from 
the aforementioned factors will affect both values and are hence nullified. 
Normalised results are expressed in relative units.  
EMG of the expiratory muscles has previously been used to quantify cough intensity 
as early as 1984 and correlates well with cough flow rate [3, 206, 211, 214]. The 
pattern of motor activation in voluntary and reflex cough has been reported [133]. 
Abdominal muscle EMG activity has been shown to be repeatable during induced 
cough challenges performed 30 minutes apart [214].  
1.5.2 Gastric pressure 
Gastric pressure (Pga) is a reflection of intra-abdominal pressure and can be 
measured during cough to assess expiratory muscle function [231]. In healthy 
subjects, cough Pga can exceed 300 cmH2O during maximal voluntary cough [207]. 
Reference ranges for cough Pga have been described: 214 ± 42 cmH2O for males and 
165 ± 35 cmH2O for females [207]. 
Cough Pga has been advocated as a measure of expiratory muscle strength since 
coughing is a more natural manoeuvre than that used to measure maximal static 
expiratory mouth pressure (PE,max) and therefore may be an easier technique for 
patients [207]. There is a linear relationship between cough Pga and PE,max but there 
is a difference in their ability to identify subjects with respiratory muscle weakness: 
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Man et al found that 42% of subjects with low PE,max had normal cough Pga whereas 
only 6% of subjects with low Pga had normal PE,max [207]. In another similar study, 
both PE,max and cough Pga in isolation were subject to false positives but the use of 
both tests together resulted in a reduction in the number of cases labelled with 
weakness from 38% to 27% [232]. The addition of non-volitional respiratory muscle 
testing using gastric pressure in response to lower thoracic nerve root magnetic 
stimulation resulted in further reduction in subjects labelled with weakness to 17% 
[232]. Man et al suggest that these differences may be due to technical limitations 
related to the manoeuvres including understanding, cooperation and motivation 
but they also recognise that different manoeuvres do not recruit exactly the same 
muscle groups [207]. 
It is important to note that the above studies were of expiratory muscle function, 
and not specifically cough function. Furthermore, these studies were conducted in 
patients with suspected expiratory muscle weakness and in healthy subjects. At the 
time of writing this thesis, no studies have quantified cough Pga in patients with 
chronic excessive cough or assessed the relationship between cough Pga and 
subjective cough intensity as perceived by patients.  
A major limitation of gastric pressure measurement is the invasive nature, since it 
requires a balloon catheter to be inserted intra-nasally. This can be done readily in 
the laboratory, but is associated with some practical inconvenience. The existence 
of tools such as ambulatory oesophageal manometry supports the feasibility for 
longitudinal studies using gastric catheters to measure spontaneous cough since 
both techniques are similar. However, a number of factors may affect baseline Pga, 
including body position, state of rest of the abdominal muscles or external 
compression from tight-fitting belts, which may be difficult to account for during 
ambulatory studies [233, 234]. 
1.5.3 Oesophageal pressure 
Oesophageal pressure (Poes) is a gauge of intra-thoracic pressure and can be 
measured using a balloon catheter within the oesophagus [235]. Peak Poes during 
cough is considered to be an important driving force for cough flow but the 
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relationship between the measures can be variable and both are recommended for 
physiological studies of cough [236].  
Poes increases during the compression and expulsion phases of cough and can reach 
pressures as high as 250-300 mmHg in healthy subjects [109, 237]. It is not known 
what pressures can be reached in patients with chronic cough and the importance 
of cough Poes to subjective perception of cough intensity has not been studied. 
Oesophageal manometer devices are available and in clinical use. Similar to gastric 
pressure measurement, a limitation is the invasive nature since it requires a 
catheter to be sited within the oesophagus. Another potential disadvantage is that 
the presence of the oesophageal catheter itself can have an inhibitory effect of 
cough frequency, and it is therefore possible that cough intensity is also attenuated 
[238]. Indeed, subjects report lower daytime cough severity VAS when an 
oesophageal catheter is in-situ [238]. Body position and other actions such as 
swallowing are also known to influence oesophageal pressure measurement [125, 
239].  
1.5.4 Cough flow 
Many studies have used flow rate as a measure of cough (Table 1-4). Like gastric 
and oesophageal pressure however, most of these studies assessed cough flow in 
relation to efficacy of cough as a defence mechanism.  
Cough flow rate is easily measured using a pneumotachograph and is non-invasive. 
In healthy subjects, the maximal voluntary cough flow rates in healthy subjects 
reported in the literature varies between 276 to 497 L/min, although some have 
reported upper limits over 800 L/min [125, 205, 214]. Cough flow rates during 
induced cough can be more challenging to measure due to technical limitations, but 
Ward et al demonstrated a mean peak cough flow rate of 379 L/min in response to 
tartaric acid [125, 214]. 
Cough flow rates are subject to interference from laryngeal activity, since partial or 
complete closure of the glottis can result in interruption of airflow. Glottis function 
is integral to the cough manoeuvre, but cough is still possible even without a 
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functional larynx [222, 240]. Fontana et al found no difference in maximal voluntary 
cough flow rates between laryngectomised patients and healthy controls, similar to 
a previous study, although both study sample sizes were small (n=10 for each 
group) [206, 222]. Time to cough peak flow was longer in laryngectomised patients 
due to the absence of the compression phase, which is dependent on glottis closure 
[206]. Chellini et al also reported the absence of compression phase in patients 
undergoing partial laryngectomy but they found that cough flow was reduced 
compared to controls [212].  
 In a recent study by Smith et al, measures of cough flow, oesophageal pressure and 
gastric pressure were measured during voluntary and induced cough in healthy 
subjects [125]. They found that the lung capacity prior to coughing (operating 
volume) affected cough flow rates but not oesophageal or gastric pressures. They 
were unable to assess cough flow rates during induced cough due to 
methodological difficulties and since the study was limited to healthy subjects, they 
did not assess spontaneous cough. 
1.5.5 The optimal physiological measure of cough intensity 
The optimal physiological measure of cough intensity is not known. There is no 
recommended gold standard measure or accepted definition of cough intensity. The 
currently available measures have been described but which of the measures is best 
remains uncertain. As Fontana states, “you pays your money and you takes your 
choice” [123]. It seems reasonable that, by virtue of being the furthest downstream, 
cough flow may be the ideal measure of cough function, but its use as a measure of 
intensity of cough is seen by some as a disadvantage because flow is a  secondary 
index of cough [123]. Lavietes et al recommended that physiological studies of 
cough use both measures of flow and oesophageal pressure [218]. It is suggested 
that objective measure used to assess cough intensity should be relevant to 
patients’ perception of intensity, but it is currently not known which measure of 
cough intensity relates best to the patients' perspective [137].  
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1.5.6 Cough sound: a potential measure of cough intensity 
Use of cough sound analysis in clinical practice has most commonly been used for 
the purposes of cough detection in cough counting monitors. Some investigators 
have explored the potential for using cough sound to identify cough aetiology or 
differentiate between productive and non-productive cough [191].  
The use of cough sound as a measure of cough intensity has been suggested [184]. 
Pavesi et al conducted a meta-analysis of 6 studies evaluating the efficacy of the 
anti-tussive dextromethorphan in acute cough due to upper respiratory tract 
infection using identical cough sound recording technology and protocols [183, 
184]. The outcome measures were derived from the cough sound analysis and 
included cough counts, cough effort (cough sound power spectral area), and cough 
intensity (average cough effort per cough). They did not validate their sound 
parameter against other measures of cough intensity however, so whilst their 
parameter can be accepted as a measure of intensity of cough sound, there is no 
data to support it as a measure of subjective or objective physiological cough 
intensity. 
Thorpe et al analysed cough sounds from 12 asthmatic and 5 non-asthmatic 
subjects [187]. Cough flow dynamics were also assessed and the authors assessed 
the relationship between cough sound and flow. They reported a correlation 
between sound power and peak cough flow (r=0.42) and between sound duration 
and average cough flow (r=0.38) for the first phase of cough sound. Additionally, 
they found an association between standard deviation of distribution of sound 
energy and peak cough flow for the intermediate phase (r=0.46). The weak 
relationships may due to the analysis method, which combined coughs from a 
heterogeneous group of asthmatic and healthy children of mixed ages. It is not 
known how this could influence cough sounds. Furthermore, only 117 coughs were 
analysed and the coughs were recorded before and after exercise, which could have 
altered flow dynamics and hence the relationship between flow and sound. 
Goldsmith et al devised a unique system that allowed simultaneous measurement 
of cough sound and cough airflow [241]. Using this technology, Abaza et al applied 
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complex principle component analysis on several sound parameters for an 
algorithm to detect abnormal lung function [196]. The investigators examined over 
100 candidate sound parameters including total energy, total power, peak power 
and dominant frequency (maximum frequency) and they achieved a sensitivity and 
specificity of 98% for detecting abnormal lung function, but they did not specify 
which parameters were found to be most important [196]. They also did not assess 
the algorithm's ability to predict airflow rate quantitatively. 
1.6 Unanswered questions on objective measures of cough 
1.6.1 Cough frequency 
The standard duration for cough frequency monitoring is over a 24-hour period 
[79]. 24-hour monitoring may be inconvenient for patients however, and can be 
time-consuming to analyse [146]. The validity of shorter periods of cough 
monitoring has not been studied, particularly with respect to responsiveness of 
such a measure. Most coughs occur during the daytime, giving the potential for 
using shorter daytime cough counts as a surrogate measure for 24-hour cough 
frequency or as an outcome measure in its own right [119, 173].  
Cough frequency in healthy subjects and in chronic cough is well documented, but 
cough frequency in acute cough is not well described, with few studies having used 
objective measures. This lack of a consistent and well defined outcome measure is 
considered partly responsible for the variable efficacy results of antitussive 
medications in acute cough [25]. The study by Sunger et al provides important 
objective data on cough frequency rates in acute cough but one of its limitations is 
its short duration [204]. It is not known how quickly acute cough resolves over a 
longer period. Furthermore, the minimal important clinical differences in cough 
frequency remain unknown. Understanding of the pattern of natural recovery in 
acute cough would allow definition of clinically important differences in cough 
frequency and inform sample size calculations to power future antitussive efficacy 
trials [26].  
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1.6.2 Cough intensity 
Objective physiological methods for the measurement of cough intensity are 
available but the focus in the majority of studies has been on the efficacy of cough 
function in patients with potentially weak cough or in healthy subjects. Few studies 
have assessed cough intensity in patients with excessive or chronic cough. 
Furthermore, much of the current literature on cough intensity originates from the 
study of voluntary or induced cough and, there is far less data on the study of 
spontaneous cough. Differences in cough intensity may exist between experimental 
and spontaneous cough, particularly in patients with pathological cough. A better 
understanding of these potential differences in cough intensity may help clarify if 
experimentally induced cough is an appropriate model for testing antitussive 
agents.  
The expiratory reflex sound is similar to the cough sound but physiological 
differences between the reflexes are recognised, yet most cough studies have not 
defined which reflex was assessed [107]. It is unknown if measures of cough 
intensity are different between cough and ER. 
Objective measures of cough intensity may be useful to guide clinical practice and 
assess antitussive drugs in clinical trials. The current methods for the assessment of 
cough intensity have limitations including their invasive nature or impracticality for 
ambulatory monitoring. Cough sound analysis has been proposed as a potential 
method for assessing cough intensity non-invasively but few studies have validated 




2 Aims and hypotheses 
 
The aims of this thesis are to develop and evaluate objective measures of cough: 
Cough frequency 
1. to evaluate cough frequency as an objective outcome measure of acute 
cough and determine the minimal important difference; 
2. to assess the validity of short duration cough frequency monitoring. 
Cough intensity 
3. to compare physiological cough intensity during voluntary, reflex and 
spontaneous cough in patients with chronic cough and explore the 
relationship between physiological and subjective measures of cough 
intensity; 
4. to determine the relationship between cough sound and measures of cough 
intensity. 
 
My hypotheses are:  
1. objective 24-hour cough frequency measurement in acute cough is feasible 
and the minimal important difference can be quantified; 
2. short duration daytime cough frequency accurately reflects 24-hour cough 
frequency and is a responsive measure in chronic cough; 
3. cough intensity differs between patients with chronic cough and healthy 
controls and between voluntary, induced and spontaneous cough; 
4. cough sound measures correlate with physiological measures of cough 




3 Materials and methods 
3.1 Ethical approval 
The studies reported within this thesis were approved by The East London and The 
City Research Ethics Committee 1, London (REC reference number: 10/H0703/6). All 
subjects gave their informed written consent to participate. 
3.2 Subjects 
Patients with chronic cough were recruited from specialist cough clinics at King's 
College Hospital, London. Healthy volunteers involved in the studies were recruited 
from staff and students at King's College Hospital and King's College London. 
Subjects with acute cough were recruited from healthy staff and students at King’s 
College Hospital and King’s College London, and from The Corner Surgery General 
Practice, London. 
3.3 Pulmonary function tests 
Standard spirometry was measured in all subjects in accordance with international 
guidelines [242, 243]. Measurements were performed using true volume 
displacement (Spiro Air®, Medisoft, Sironnes, Belgium), calibrated daily using a 3L 
syringe (Hans Rudolph Inc, Kansas City, USA). Forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) were measured with subjects in the 
seated position and wearing a nose-clip [242]. Subjects were asked to breathe in as 
deeply as possible (to maximal inspiration), place their lips around the mouthpiece 
while ensuring an airtight seal, and then to exhale rapidly with maximal force. A 
minimum of three technically acceptable efforts were performed until results 
returned within a 5% error of each other, and the largest value was taken for each 
given measure. Reference values for predicted FEV1 and FVC were derived from the 




3.4 Assessment of subjective cough severity 
3.4.1 Cough specific quality of life 
Cough specific health status was assessed using the Leicester Cough Questionnaire 
(LCQ) [11]. The LCQ is a 19-item self-completed quality of life questionnaire that 
was developed for patients with chronic cough (Error! Reference source not 
ound.). The questionnaire uses a 7-point Likert response scale per item and groups 
the component questions into 3 domains:  physical, psychological and social. Each 
LCQ domain score ranges from 1 to 7, and the overall LCQ score ranges from 3 to 
21, with a higher score reflecting better health status [11].  
3.4.2 Subjective cough severity 
A 100 mm visual analogue scale was used to assess subjective daytime, nighttime 
and overall cough severity (Figure 3-2). The phrases “no cough” and “worst cough 
ever” were labelled at opposite ends of the scale to provide anchors by which 
subjects could rate the severity of their cough. 
3.4.3 Change in cough severity 
Temporal changes in cough severity were assessed using a Global Rate of Change 
Questionnaire (GRCQ) which was completed at follow up visits [245]. The GRCQ 
comprises of a 15-point Likert response scale ranging from -7 to 7 and can be used 
to establish minimal important differences in outcome measures. (Figure 3-3). 
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Figure 3-1 Leicester Cough Questionnaire 
LEICESTER COUGH QUESTIONNAIRE 
This questionnaire is designed to assess the impact of cough on various aspects of your life. Read each question carefully and answer by CIRCLING the number of the 
response that best applies to you.  Please answer ALL questions, as honestly as you can. 
 
1. In the last 2 weeks, have you had 
chest or stomach pains as a result 
of your cough? 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
2. In the last 2 weeks, have you 
been bothered by sputum (phlegm) 
production when you cough? 
 
 
1. Every time 
2. Most times 
3. Several times 
4. Some times 
5. Occasionally 
6. Rarely  
7. Never 
 
3. In the last 2 weeks, have you 
been tired because of your cough? 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
4. In the last 2 weeks, have you felt 
in control of your cough? 
 
 
1. None of the time 
2. Hardly any of the time 
3. A little of the time 
4. Some of the time 
5. A good bit of the time 
6. Most of the time 
7. All of the time 
 
5. How often during the last 2 
weeks have you felt embarrassed 
by your coughing? 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
6. In the last 2 weeks, my cough has 
made me feel anxious 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
7. In the last 2 weeks, my cough has 
interfered with my job, or other 
daily tasks 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
8. In the last 2 weeks, I felt that my 
cough interfered with the overall 
enjoyment of my life 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
9. In the last 2 weeks, exposure to 
paints or fumes has made me 
cough: 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
10. In the last 2 weeks, has your 
cough disturbed your sleep? 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
11. In the last 2 weeks how many 




1. All the time (continuously) 
2. Most times of during the day 
3. Several times during the day 
4. Some times during the day 




12. In the last 2 weeks, my cough 
has made me feel frustrated 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
13. In the last 2 weeks, my cough 
has made me feel fed up 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
14. In the last 2 weeks, have you 
suffered from a hoarse voice as a 
result of your cough? 
 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
15. In the last 2 weeks, have you 
had a lot of energy? 
 
 
1. None of the time 
2. Hardly any of the time 
3. A little of the time 
4. Some of the time 
5. A good bit of the time 
6. Most of the time 
7. All of the time 
16. In the last 2 weeks, have you 
worried that your cough may 
indicate a serious illness? 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
17. In the last 2 weeks, have you 
been concerned that other people 
think something is wrong with you, 
because of your cough? 
 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 
18. In the last 2 weeks, my cough 
has interrupted conversation or 
telephone calls 
 
1. Every time 
2. Most times 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
19. In the last 2 weeks, I feel that 
my cough has annoyed my partner, 
family or friends 
 
1. Every time I cough 
2. Most times when I cough 
3. Several times when I cough 
4. Some times when I cough 

























 2001. University of Leicester 
NHS Trust, Glenfield Hospital, UK. 
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Figure 3-2 Example of visual analogue scale 
Visual analogue scale  
 
(please put a cross on the line to indicate how severe your cough has 
been in the last day) 
 
      WORST COUGH EVER 
















Figure 3-3 Global Rate of Change Questionnaire 
Q1. Since your first cough questionnaire, has there been any change in the severity 
of your cough? 
 
-7 A very great deal worse 
-6 A great deal worse 
-5 A good deal worse 
-4 Moderately worse 
-3 Somewhat worse 
-2 A little worse 
-1 Almost the same, hardly any worse at all 
 0 No change 
 1 Almost the same, hardly any better 
 2 A little better 
 3 Somewhat better 
 4 Moderately better 
 5 A good deal better 
 6 A great deal better 





3.5 Measurement of pressures  
3.5.1 Measurement of mouth pressure  
Mouth pressure (Pmo) was measured relative to atmospheric pressure using a 
flanged mouthpiece (Hans Rudolph Inc, Kansas City, USA) attached to a manually 
operated shutter valve. Mouth pressure was measured using a differential pressure 
transducer (MP45, Validyne, Northridge, CA, USA) attached to the valve via a fine 
bore catheter. The pressure signal was amplified before acquisition (CD280, 
Validyne, Northridge, CA, USA). The shutter valve contained an exit port of 2 mm 
internal diameter, located proximally to the valve. This port introduced a small air 
leak, thereby preventing glottic closure and reducing the contribution of the buccal 
muscles during maximum expiratory manoeuvres [231]. 2-point calibration of the 
mouth pressure transducer system was performed daily against a known applied 
pressure determined by a digital manometer (C9953, Comark Ltd®, Hertfordshire, 
UK). The accuracy of the digital manometer was validated against a mercury 
manometer over the range 0-300 mmHg in a laboratory experiment (Figure 3-4). 
Figure 3-4 The linearity and accuracy of the digital manometer 
 
Laboratory experiment showing accuracy and linear relationship between applied 
pressure as measured by a mercury manometer and observed pressure as measured 




3.5.2 Measurement of oesophageal and gastric pressure 
Oesophageal pressure (Poes) and gastric pressure (Pga) was measured separately 
using two closed-ended catheters, each 86 cm in length and with a 9.5 cm flexible 
polytetrafluoroethylene balloon at one end (Cooper Surgical, Berlin, Germany). The 
balloon catheters were each attached to differential pressure transducers (MP45, 
Validyne, Northridge, CA, USA). The pressure signals were amplified before 
acquisition (CD280, Validyne, Northridge, CA, USA). 2-point calibration of the 
oesophageal and gastric pressure transducer system was performed daily against a 
known applied pressure determined by the digital manometer. 
Topical anaesthetic with 10% lidocaine spray (Xylocaine, AstraZeneca, Luton, UK) 
was applied to the subject’s nostril and oropharynx prior to insertion of the balloon 
catheters to reduce discomfort [246]. Lubricant gel (K-Y™, Johnson and Johnson, 
New Jersey, USA) was applied to both catheter tips to facilitate smooth insertion. 
With the head in a relaxed and neutral position, both the oesophageal and gastric 
balloon catheters were inserted simultaneously via one nostril and advanced past 
the hypopharynx and into the oesophagus and stomach whilst the subject 
swallowed sips of water through a straw. The catheters were inserted to a distance 
of 70 cm from the catheter tips to the level of the nostril, using the scale marked on 
the catheters as a guide. Verification of the position of both catheters within the 
stomach was verified by demonstrating a positive deflection in both Poes and Pga 
traces during a sniff manoeuvre. One catheter was then repositioned into the 
oesophagus by withdrawing the catheter to a distance of 40 cm. Verification of the 
position within the oesophagus was established by observing a change in sniff-
related Poes from positive to negative. The correct position of the oesophageal 
balloon was also confirmed by comparing Poes and mouth pressure during an 
inspiratory effort against an occluded airway. Poes and Pmo values within 10% of each 
other were considered indicative of accurate positioning [247]. The catheters were 
then securely taped to the subject's nose to ensure that their position was kept 
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constant and the pressure balloons inflated with air (0.5 ml into the oesophageal 
and 2 ml into the gastric balloon catheter) [231]. 
3.5.3 Pressure volume characteristics of the balloon catheter 
The pressure-volume characteristics of the balloon catheter were tested to assess 
the elastic properties of the balloon and its contribution to measured Poes and Pga 
values [248]. This was determined by initially submerging the catheter under 5 cm 
of water to empty the balloon [249]. A 3-way tap at the proximal end of the balloon 
catheter was closed to the atmosphere to keep the system airtight and the catheter 
attached to a differential pressure transducer. The observed pressure within the 
balloon was then recorded whilst 0.1 ml aliquots of air were incrementally added 
via the 3-way tap to gradually fill the balloon [249]. As demonstrated in Figure 3-5, 
there was minimal change in observed pressure within the balloon between the 
operating ranges of inflation volumes used in this thesis (0.5 ml to 2.0 ml).  
Figure 3-5 Pressure volume characteristics of the balloon catheter 
 
Laboratory experiment showing stable pressure measurements within the operating 




3.5.4 Linearity of the mouth pressure transducer system 
The linearity of the mouth pressure transducer system was tested by applying 
known pressures using the digital manometer and plotting these against the Pmo 
system output. The mouth pressure transducer system had a linear response across 
a range of -250 to 250 cmH2O (Figure 3-6). 
Figure 3-6 Linearity of mouth pressure transducer system 
 
Laboratory experiment showing the linearity of the mouth pressure transducer 
system across a range of applied pressures. Data provided in Appendix 2. 
3.5.5 Linearity of the oesophageal and gastric pressure transducer 
systems 
The linearity of the oesophageal and gastric balloon catheter-pressure transducer-
amplifier systems were tested by applying known pressures using the digital 
manometer to an airtight container in which the balloon catheter had been placed. 
The observed system output from the amplifier was plotted against the applied 
pressures. The oesophageal balloon catheter was inflated with 0.5 ml of air and the 




















Applied pressure (cmH2O) 
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The oesophageal and gastric balloon catheters and their associated pressure 
transducers and amplifier were linear across the range of pressures recorded in this 
thesis. The oesophageal balloon catheter system was linear across the range -200 to 
250 cmH2O (Figure 3-7). As expected, the gastric balloon catheter system was linear 
across the desired operating positive pressure range, only becoming alinear at 
negative pressures in excess of 100 cmH2O (Error! Reference source not found.). 
ince pressures within the abdominal compartment are always positive, this 
limitation did not affect results.  
Figure 3-7 Linearity of oesophageal balloon catheter system 
  
Laboratory experiment showing the linearity of the oesophageal balloon catheter 
system across a range of applied pressures between -250 cmH2O and 200 cmH2O. 
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Figure 3-8 Linearity of gastric balloon catheter system 
 
Laboratory experiment showing the linearity of the gastric balloon catheter system 
output across a range of applied pressure between -100 cmH2O and 250 cmH2O, but 
a non-linear response to negative applied pressures in excess of -100 cmH2O. Data 
provided in Appendix 4. 
3.5.6 Frequency response of the balloon catheter pressure transducer 
system 
The ability of a measuring system to accurately detect and represent changes in the 
signal is known as its frequency response [250]. The “time constant” of the 
measuring system gives a measure of its dynamic response to an input step change 
and is related to the frequency response.   
The frequency response of the mouth pressure transducer amplifier system was 
assessed by introducing a catheter (of the same length and diameter as that used to 
measure the mouth pressure) into a pressurised inflatable balloon and then 
measuring the response to a quasi-instantaneous change by bursting the balloon 
with a needle [250, 251]. As shown in Figure 3-9, the response time for the pressure 
signal to fall from 90% to 10% of baseline was 13 ms. Using the Fourier 
transformation equation, the frequency response (Fr) of the balloon catheter-
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Fr = (3*0.013)-1 = 25.6 Hz.  
This frequency response was sufficiently high to measure respiratory pressure 
waves [231, 236, 252]. 
Figure 3-9 Frequency response of balloon catheter system 
 
Laboratory 'balloon pop test' experiment showing a response time of 13 ms for the 
observed pressure by the balloon catheter pressure transducer system to fall from 
90% to 10% of baseline in response to a quasi-instantaneous change.  
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3.6 Measurement of flow 
3.6.1 Measurement of cough flow rate and volumes  
Respiratory flow was measured at the mouth using a Fleisch type 
pneumotachograph (Size 5, P.K. Morgan ltd, Kent, UK) attached to a full-face mask 
(Hans Rudolph Inc, Kansas City, USA). The pressure differential across the 
pneumotachograph was measured using a differential pressure transducer (DP45, 
Validyne, Northridge, CA, USA) and amplifier (CD280, Validyne, Northridge, CA, 
USA). The pneumotachograph was calibrated prior to each study by employing 2-
point calibration using a rotameter (KDG Mobrev®, England).  
Peak cough flow rate (PCFR), inspired volume (IV) and compression phase duration 
were calculated from the flow signal (Figure 3-10). PCFR was defined as the peak 
expiratory flow rate during a cough manoeuvre. IV was defined as the volume of air 
inspired prior to a cough expulsion, and was measured by integration of the 
respiratory flow signal between the onset and end of inspiration [211]. CPD was 
defined as the time between termination of inspiration (return to zero flow) and 
onset of expiration (departure from zero flow) [223]. To ensure standardisation, a 
custom software script was used to automatically place cursors at the onset and 
end of the inspiratory and compression phases. The accuracy of all cursor positions 
were verified manually prior to calculation of flow measures. 
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Figure 3-10 Respiratory flow trace during a cough manouevre 
 
Flow signal during a voluntary cough manoeuvre in a healthy female subject. 
3.6.2 Linearity of the pneumotachograph system 
The linearity of the pneumotachograph-transducer-amplifier system was tested by 
applying a range of known flow rates using a rotameter (± 1000 L/min) and plotting 
these against the observed system output. The pneumotachograph-transducer-
amplifier system was linear across the flow range ± 800 L/min (Figure 3-11). 
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Figure 3-11 Linearity of the pneumotachograph system 
  
Laboratory experiment showing the linearity of the pneumotachograph system 
output across a range of applied flow rates between -800 L/min and 800 L/min. 
Data provided in Appendix 5. 
3.6.3 Frequency response of the pneumotachograph system 
The frequency response of the pneumotachograph system was tested by using a 
pressurised inflatable balloon to deliver a constant flow rate through the 
pneumotachograph and then causing quasi-instantaneous cessation of flow by 
bursting the balloon with a needle. The response time for the fall in the flow signal 
from 90% to 10% of baseline was 8 ms (Figure 3-12). Using the Fourier 
transformation equation described in section 3.5.6, the frequency response of the 
pneumotachograph system was: 
Fr = (3*0.008)-1 = 41.7 Hz. 
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Figure 3-12 Frequency response of pneumotachograph system 
 
Laboratory 'balloon pop test' experiment showing a response time of 8 ms for the 
observed flow rate by the pneumotachograph system to fall from 90% to 10% of 
baseline in response to a quasi-instantaneous change. 
3.6.4 Linearity of the pneumotachograph system after nebulisation of 
capsaicin  
The linearity of the pneumotachograph-transducer-amplifier system was tested 
following ultrasonic nebulisation of capsaicin (see section 3.10) to assess the effect 
of nebulised particle deposition on the pneumotachograph. As shown in Figure 
3-13, the pneumotachograph-transducer-amplifier system remained linear across 
the flow range ± 700 L/min after nebulisation of capsaicin. 
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Figure 3-13 Linearity of pneumotachograph system following capsaicin 
nebulisation 
 
Laboratory experiment showing the maintained linearity of the pneumotachograph 
system following nebulisation of capsaicin during induced cough challenges. Data 
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3.7 Measurement of abdominal electromyography 
3.7.1 Equipment and placement of EMG electrodes 
Surface EMG was recorded from the right rectus abdominis muscle using 55 mm 
diameter Ag-AgCl electrodes (Kendall liquid gel electrodes, Tyco healthcare, 
Hampshire, UK). Prior to electrode attachment, the skin was thoroughly cleaned 
and lightly prepared using an abrasion gel (Nuprep abrasive skin gel, Weaver & Co, 
USA)[229]. The active electrode was placed 5 cm from the midline, just below the 
level of the umbilicus, and the reference electrode was placed 5 cm laterally [133]. 
The earth electrode was placed over the anterior superior iliac spine (Figure 3-14).  
Figure 3-14 Placement of electrodes for abdominal electromyography  
 
 
3.7.2 EMG signal processing 
EMG signals were amplified and digitally filtered between 10 Hz and 2,000 Hz (1902 
signal conditioner, Cambridge Electronic Design, Cambridge, UK). An additional 50 
Hz notch filter was also applied to eliminate mains voltage background noise. Data 
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was sampled at a frequency of 5,000 Hz (Micro 1401 analogue to digital converter, 
Cambridge Electronic Design, Cambridge, UK), and displayed on a computer using 
Spike 2 software (Cambridge Electronic Design, Cambridge, UK). 
3.7.3 EMG data analysis 
The EMG signals from the abdomen were rectified by applying post-acquisition 
processing using Spike 2 software. The root mean square of the EMG signal was 
calculated with a 50 ms time window to give a moving average of the EMG activity 
[211, 214]. This resulted in 250 data points per 50 ms window, giving a smoother 
envelope of EMG activity for analysis [254]. Abdominal muscle EMG activity 
(EMGabdo) was taken as the peak value of the root mean squared EMG trace for any 
given cough.  
To allow collective group analyses, EMG data was normalised by expressing EMGabdo 
for each cough as a fraction of the largest EMGabdo observed during the maximum 
voluntary cough (MVC) protocol for that subject.  
For comparisons of EMGabdo during MVC between subjects, it was not possible to 
normalise to MVC since all values would be 1.0. In this case, EMGabdo was 
normalised to that achieved during non-volitional lower thoracic nerve root 
magnetic stimulation at 100% stimulator output (EMGabdo:Tw). Details of this 
manoeuvre are described in section 3.8.2. The resulting EMG activity seen from 




3.8 Assessment of expiratory muscle function 
3.8.1 Volitional assessment of expiratory muscle strength  
The maximum expiratory mouth pressure (PE,max) was measured as a volitional 
assessment of expiratory muscle strength [231]. Mouth pressure (Pmo) was recorded 
as described in section 3.5.1. Subjects were seated comfortably and instructed to 
insert the flanged mouthpiece attached to the metal tube into the mouth and form 
an airtight seal around the mouthpiece. With the shutter valve open, subjects were 
instructed to inhale to total lung capacity (TLC), at which point the shutter valve was 
closed, and then to exhale with maximum sustained force against the closed valve. 
The procedure was repeated until at least three PE,max measures were recorded and 
at least two were of consistent magnitude (within 10% error).  
3.8.2 Non-volitional assessment of expiratory muscle strength  
Gastric pressure was measured during lower thoracic nerve root magnetic 
stimulation as a non-volitional assessment of expiratory muscle contractility [111, 
226, 255]. Stimulations were delivered using a double energy stimulator (Magstim 
Co Ltd, Dyfed, Wales) and a 90 mm circular coil.  
Since the prior contractile history of a muscle can significantly affect the amplitude 
of the twitch response (twitch potentiation),  subjects were rested for 20 minutes 
whilst refraining from talking or coughing prior to undertaking magnetic stimulation 
studies [217, 256]. Subjects were placed in the seated position and leant slightly 
forwards [255, 257]. All stimulations were performed with the subject relaxed and 
at end-expiration [111]. The level of the 9th (T9), 10th (T10) and 11th (T11) thoracic 
vertebrae were marked on the skin with a pen. The optimal position of the coil for 
delivering stimulations was determined by delivering stimulations at T9, T10 and 
T11. The level which evoked the largest Pga response to magnetic stimulation was 
defined as the optimal position [258]. This position was marked with indelible ink 
and used for all subsequent stimulations.  
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Gastric pressure elicited by magnetic stimulation (twitch gastric pressure, Twitch T10 
Pga) was measured from trough-to-peak of the Pga trace and was determined from 
the average response to five stimulations [226]. 
Supramaximality of the magnetic stimulation procedure was assessed in subjects by 
measuring Twitch T10 Pga and CMAP amplitude at stimulations of different power. 
Stimulator output was altered by 10% increments and delivered in a random order. 
Subjects were blinded to the stimulator power level. Supramaximality was defined 
as the absence of a significant difference in CMAP or Twitch T10 Pga between 100% 
and 90% stimulator output [217, 259].  
   
95 
 
3.9 Measurement of cough sound 
3.9.1 Equipment and acquisition of sound data 
Cough sound was recorded using a free-field microphone (MKE 2-5-C, Sennheiser, 
Wedemark, Germany) and a contact microphone (3017, Philips Respironics, Surrey, 
UK). It was beyond the scope of this thesis to validate the frequency range of the 
microphones, but the free-field microphone has a reported frequency range of 20-
20,000 Hz. The contact microphone was positioned anterolaterally over the larynx 
and fixated with a purpose made adhesive pad. The free-field microphone was fixed  
15 cm inferiorly to the contact microphone in the midline.  
3.9.2 Sound signal processing 
Signals from both microphones were acquired through a signal conditioner (1902, 
Cambridge Electronic Design, Cambridge, UK) and time-synchronised with 
physiological data via an analogue to digital converter (micro 1401 mk II, Cambridge 
Electronic Design, Cambridge, UK). Signals were sampled at a frequency of 8,000 Hz, 
amplified (free field microphone gain x10, contact microphone gain x3) and digitally 
filtered with a high pass filter of 10 Hz and a low pass filter of 4,000 Hz. A 50 Hz 
notch filter was applied to eliminate background mains voltage noise.  
3.9.3 Cough sound data analysis 
Each cough sound signal was divided into its component phases: the explosive 
phase (phase 1), the intermediate phase (phase 2) and, if present, the voiced phase 
(phase 3) (Figure 3-15). All cough sounds contain a phase 1 segment, but not all 
sounds contain a voiced phase. In order to maximise consistency, the start and end 
of the each phase was identified by a custom automated script using Spike 2 
software (Cambridge Electronic Design, Cambridge, UK) before manual 
confirmation. A further labelling cursor was placed precisely 0.5 seconds after the 
onset of phase 1. From preliminary analysis, reliable demarcation of the end of 
phase 2 can be difficult for coughs without a phase 3 segment due to the gradual 
dissipation of the sound signal towards baseline. Therefore, cough sound 
parameters were calculated for the following time-windows: from onset to end of 
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phase 1 (P1), from onset of phase 1 to end of phase 3 (the whole cough sound, P1-3) 
and a 0.5-second duration from onset of phase 1 (P0.5). 
Figure 3-15 A typical 3-phase cough sound signal 
 
Phases of a 3-phase cough sound signal and time-windows chosen for analysis. 
Trace is of a voluntary cough manoeuvre in a female patient with chronic cough. P1: 
phase 1 time window; P1-3: phases 1-3 time window; P0.5: 0.5 second time window. 
Each time window was analysed using a custom script for MATLAB® software (The 
MathWorks Inc, Massachusetts, USA) to calculate the following parameters: total 
power (PW), peak energy (Ep), mean energy (Em), rise time (RT), duration (D), 
bandwidth (BW), peak frequency (Fp) and centroid frequency (Fc).  
The time domain parameters (Ep, Em, RT and D) were calculated from the root 
mean square (RMS) of the sound signal and the frequency domain parameters (PW, 
BW, Fp and Fc) were derived from the frequency spectrum profile [194, 260]. The 
RMS envelope was calculated using 32-point (4 ms) windows with 50% overlap and 
the frequency spectrum, or power spectral density (PSD), was calculated using 
8,000-point Fast Fourier Transformation (FFT) of the sound signal [187, 194]. A 
graphical presentation of a sample sound signal presented in the frequency 
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spectrum is shown in Figure 3-16. The definitions of the sound parameters are 
described in detail in section 7.4.3. 
Figure 3-16 Cough sound signal displayed in the frequency spectrum 
 
Cough sound signal displayed in the frequency spectrum following Fast Fourier 
Transformation. The trace above is the transformed signal of the cough shown in 




3.10 Induced cough challenges  
Induced coughs were evoked by using capsaicin cough challenges [79]. Capsaicin 
induces cough in a dose-dependent manner and the challenge tests are safe and 
reproducible [261-263]. The capsaicin solution concentrations required ranges from 
0.49 µM to 10,000 µM [208]. 
3.10.1 Capsaicin preparation and storage 
Capsaicin (8-Methyl-N-Vanillyl-6-Nonenamide) has a molecular mass of 305 Daltons 
and therefore 305 g of capsaicin in 1 litre of fluid yields a solution concentration of 1 
M or 1,000,000 µM. A ‘stock solution’ containing 10 ml of 10,000 µM capsaicin was 
prepared by dissolving 0.03054 g (30.5 mg) of capsaicin (Sigma-Aldrich, Missouri, 
USA) in 1 ml of 100% ethanol (Absolute alcohol 100, Hayman Ltd, Witham, Essex, 
UK), 1 ml of Tween® 80 (Sigma-Aldrich, Missouri, USA) and 8 ml of physiological 
saline [264]. A high sensitivity scale (SBA32, Scaltec instruments, Heiligenstadt, 
Germany) was used to measure the capsaicin. 1 ml of stock solution was then 
diluted with 9 ml saline to produce a solution with a concentration of 1,000 µM. 
Further serial doubling dilutions with saline produced solutions with capsaicin 
concentrations ranging from 0.49 µM to 1,000 µM (Table 3-1) [79, 264].  
Capsaicin stock solution was kept for a maximum of 4 weeks at 4⁰C and shielded 




 Table 3-1 Serial dilution of capsaicin stock solution for induction of reflex coughs 
Initial 
concentration 
Volume of capsaicin 
solution 




10,000 µM (stock) 1 ml 9 ml 1,000 µM 
1,000 µM 5 ml 5 ml 500 µM 
500 µM 5 ml 5 ml 250 µM 
250 µM 5 ml 5 ml 125 µM 
125 µM 5 ml 5 ml 62.5 µM 
62.5 µM 5 ml 5 ml 31.25 µM 
31.25 µM 5 ml 5 ml 15.6 µM 
15.6 µM 5 ml 5 ml 7.8 µM 
7.8 µM 5 ml 5 ml 3.9 µM 
3.9 µM 5 ml 5 ml 1.95 µM 
1.95 µM 5 ml 5 ml 0.98 µM 
0.98 µM 5 ml 5 ml 0.49 µM 
 
3.10.2 Equipment and administration of capsaicin 
Capsaicin was administered in aerosolised form using an ultrasonic nebuliser 
(U3000, DeVilbiss Healthcare, Wollaston, UK). Subjects inhaled the nebulised 
capsaicin through a facemask attached to a valve box (Hans Rudolph Inc, Kansas 
City, USA). The nebuliser efferent tubing was connected to the inflow port of the 
valve box and a particle filter was attached to the outflow port to prevent 
dispersion of nebulised capsaicin into the open atmosphere (Figure 3-17). The valve 
box permitted uni-directional flow from the ultrasonic nebuliser to the subject on 
inspiration and uni-directional flow from the subject to the atmosphere on 




Figure 3-17 Capsaicin nebulisation circuit valve box 
 
A valve box was used during capsaicin cough challenges to allow uni-directional flow 
of nebulised capsaicin from the ultrasonic nebuliser whilst permitting bi-directional 
measurement of airflow at the mouth with a pneumotachograph. 
3.10.3 Protocol 
The tidal breathing method over a 1-minute period was employed rather than the 
single breath method, as this allowed continuous measurement of cough flow rates 
with a pneumotachograph during induced coughs [4, 266]. Subjects underwent 
nebulisation with saline control solution prior to administration of capsaicin 
solutions. Increasing incremental concentrations of aerosolised capsaicin were then 
administered, beginning with the lowest concentration, 0.49 µM. Subjects were 
blinded to the protocol order. Placebo nebulisations with physiological saline were 
randomly interspersed with capsaicin nebulisations [208]. Each nebulisation was 
delivered for 1 minute, with 2-minute intervals between concentrations [219]. 
Subjects were instructed to maintain resting tidal breathing and to refrain from 
suppressing coughs [208]. The number of coughs induced by each capsaicin 
concentration nebulisation was counted. The lowest concentration inducing 5 or 
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more coughs was defined as C5, and the supra-C5 threshold was defined as the next 
concentration increment that reproduced at least 5 coughs. Supra-threshold 
challenges were performed since reproducibility of some cough measures such as 
cough frequency and time to cough have been shown to be superior with higher 
stimuli [215]. Capsaicin challenges continued until supra-threshold concentration 
was established. If the subject was unable to tolerate the threshold concentration, 




3.11 Measurement of cough frequency 
3.11.1 Objective cough frequency monitoring 
Cough frequency was measured using the Leicester Cough Monitor (LCM) [173]. It 
consists of an MP3 sound recording device (662 Digital Voice Tracer, Philips, UK) 
that records and stores sound data obtained from a lapel microphone (Figure 3-18). 
Details on the performance of the LCM have been described in section 1.4.2. 
Subjects were set up with the LCM system in the laboratory and then instructed to 
return to their usual daily activities within their own environment. The LCM was 
returned for analysis after 24 hours of monitoring. 
Figure 3-18 Leicester Cough Monitor system recorder 
 
The Leicester Cough Monitor recording system comprises of an MP3 recording 
device and a free-field microphone. 
3.11.2 Cough frequency data analysis 
The cough monitoring data was analysed on a computer using semi-automated 
custom LCM software, based on Hidden Markov Model speech recognition 








isolation or within bouts of coughs. Candidate cough events are automatically 
detected by the software and a sample of 50-100 candidate cough events are 
verified by an operator in order to refine the cough detection algorithm (see section 
1.4.2 for further details). The LCM cough frequency report presents data as the 
number of coughs detected in each hour of the 24-hour monitoring period (Figure 
3-19).  
Figure 3-19 Leicester Cough Monitor system report  
 
Example of a 24-hour cough frequency report from the Leicester Cough Monitor 
system. The above example was acquired in a female patient with chronic cough.  
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3.12 Acquisition, analysis and storage of data 
All acquired physiological and sound data were time synchronised and converted 
from analogue to digital format (Micro 1401 mk II, Cambridge Electronic Design, 
Cambridge, UK) and then recorded, stored and analysed on a computer (Dell 
Corporation Ltd, Berkshire, UK) using Spike 2 software version 6.14 (Cambridge 
Electronic Design, Cambridge, UK). Cough frequency data was transferred from the 
LCM to a computer (Dell Corporation Ltd, Berkshire, UK) for storage and analysis 
using custom software as described above.  
3.13 Statistical analysis 
Statistical analysis of the data was performed using Prism® v5.0 for Windows 
(GraphPad) and SPSS 19.0 for Windows (IBM). All data was tested for normality 
distribution using the D'Agostino and Pearson omnibus normality test prior to 
performing statistical analyses. A p-value of less than 0.05 was considered as 
indicative of statistical significance. A variety of statistical tests is used in this thesis 





4 A longitudinal assessment of acute cough  
This chapter was submitted in manuscript form and accepted for publication. 
Reference: 
Lee KK, Matos S, Evans DH, White P, Pavord ID, Birring SS. A longitudinal 
assessment of acute cough. American Journal of Respiratory and Critical Care 
Medicine 2013;187(9):991-997 
4.1 Abstract 
Rationale: Cough can be assessed with visual analogue scales (VAS), health status 
measures, and 24-hour cough frequency monitors (CF24). Evidence for their 
measurement properties in acute cough caused by upper respiratory tract infection 
(URTI) and longitudinal data is limited. 
Objectives: To assess cough longitudinally in URTI with subjective and objective 
outcome measures and determine sample size for future studies. 
Methods: Thirty-three previously healthy subjects with URTI completed cough VAS, 
Leicester Cough Questionnaire (LCQ-acute), and CF24 monitoring (Leicester Cough 
Monitor) on three occasions, 4 days apart. Changes in subjects’ condition were 
assessed with a global rating of change questionnaire. The potential for baseline 
first-hour cough frequency (CF1), VAS, and LCQ to identify low CF24 was assessed. 
Measurements and Main Results: Mean ± SD duration of cough at visit 1 was 4.1 ± 
2.5 days. Geometric mean ± log SD baseline CF24 and median (interquartile range) 
cough bouts were high (14.9 ± 0.4 coughs/h and 85 (39–195) bouts/24 h). Health 
status was severely impaired. There was a significant reduction in CF24 and VAS, and 
improvement in LCQ, from visits 1–3. At visit 3, CF24 remained above normal limits 
in 52% of subjects. The minimal important differences in CF24, LCQ, and VAS were 
54%, 2.0 and 17 mm changes from baseline, respectively. The sample sizes required 
for parallel group studies to detect these changes are 27, 51, and 25 subjects per 
group, respectively. CF1 (<20.5 coughs/h) was predictive of low CF24. 
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Conclusions: CF24, VAS, and LCQ are responsive outcome tools for the assessment of 
acute cough. The minimal important difference in cough frequency is 54%. The 
sample sizes required for future studies are modest and achievable. 
4.2 Introduction 
Acute cough due to upper respiratory tract infection (URTI) is the most common 
reason why patients seek medical attention [267]. It can be disruptive to the 
individual and is often associated with absence from work and lost productivity [6, 
12, 20]. More than $3 billion dollars are spent on over the counter cough and cold 
remedies each year in the USA [24]. The efficacy of antitussive medications has 
recently been questioned by the American College of Chest Physicians cough 
guidelines and the findings of a meta-analysis [25, 268]. There is a pressing clinical 
need to develop effective antitussive drugs.  
The severity of cough is thought to be determined by the frequency of coughs, their 
intensity and the impact on health status [137]. Assessment of cough severity can 
be performed using global measures such as visual analogue scales (VAS) or with 
tools measuring the individual components such as recently developed cough 
frequency monitors [52, 269]. The impact of cough on health related quality of life 
can be assessed with health status questionnaires. Little is known about the severity 
of cough in URTI particularly that assessed with objective tools such as cough 
frequency monitors. Furthermore, there is a paucity of longitudinal studies 
investigating cough severity and the natural history of URTI. A better understanding 
of the severity of cough in URTI will facilitate clinical interpretation of studies 
evaluating antitussive therapy.  
4.3 Aims 
The aim of this study was to investigate longitudinal cough frequency and other 
measures of cough severity in URTI, evaluate the magnitude of change important to 
patients and determine sample sizes necessary for future clinical studies. Some of 






Healthy volunteers with cough due to URTI of less than 10 days duration were 
recruited using advertisement posters or referred by their general practitioner 
during a 15-month period spanning two cold seasons (January 2010 to April 2011). 
Subjects with chronic cough, lung disease, current smoking history, symptoms 
suggestive of bacterial infection, or those taking angiotensin converting enzyme 
inhibitor, anti-histamine or antitussive medications were excluded. All subjects gave 
informed consent and the study was given ethical approval (East London and the 
City Research Ethics Committee 10/H0703/6). 
4.4.2 Cough frequency monitoring 
Objective 24-hour cough frequency (CF24) was recorded using the Leicester Cough 
Monitor (LCM), a validated ambulatory cough monitoring system which has been 
used in randomised controlled trials of therapy for patients with chronic cough [88, 
170, 173, 176]. Briefly, the LCM consists of a MP3 sound recording device (Philips 
LFH0662/LFH0865), external microphone (Philips LFH9173/Olympus ME-15) and 
automated cough detection software that requires minor operator input for 
calibration. Cough frequency was determined by counting all cough events 
individually, whether occurring in isolation or within coughing bouts. Cough bouts 
were defined as periods of continuous coughing, with pauses of <2 seconds [120]. 
Subjects were instructed to resume normal daily activities in their own environment 
during cough monitoring. Further details of the LCM and the cough detection 
algorithm have been described elsewhere [172, 173]. CF24 was expressed as the 
average number of coughs/hour over a 24-hour period. Cough bouts were 
expressed for 24-hour periods. 
4.4.3 Questionnaires 
Cough-specific, health related quality of life was assessed with the Leicester Cough 
Questionnaire (LCQ-acute), a 19-item questionnaire that has been validated in 
acute and chronic cough [11, 148]. The overall score ranges from 3 to 21 with a 
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higher score indicating a better quality of life. Subjective cough severity was 
assessed with a 100 mm cough visual analogue scale. Change in cough between 
visits was assessed with the Global Rate of Change Questionnaire (GRCQ) which was 
used to estimate clinically important changes in cough outcome parameters at visit 
2 [245]. The response scale ranged from -7 (a great deal worse) to +7 (a great deal 
better) and the scores were categorised as no change (-1,0,+1), small change (-2,-
3,+2,+3), moderate change (-4,-5,+4,+5) or large change (-7,-6,+7,+6) accordingly.  
4.4.4 Protocol 
Subject characteristics and symptoms at baseline were recorded. Subjects 
underwent objective 24-hour cough frequency monitoring at 3 time points during 
their illness: Visit 1 (recruitment), Visit 2 (visit 1 + 4 days) and Visit 3 (visit 1 + 8 
days). Subjects also completed LCQ and cough VAS at each visit and the GRCQ at 
visit 2. Cough frequency monitoring was commenced at a similar time of day for 
each visit. Subjects were instructed to refrain from taking antitussive drugs 
throughout the study period. 
4.4.5 Analysis 
SPSS version 19 (IBM) and Prism version 5 (GraphPad) were used for statistical 
analysis. Appropriate parametric or non-parametric tests were applied depending 
on data distribution. Cough frequency data were log-transformed to achieve normal 
distribution if appropriate. The upper limits of normal cough frequency in females 
and males were determined from a previous study, 5 and 2 coughs/hour 
respectively [175]. GRCQ scores were converted to absolute numbers, i.e. when the 
change was negative, the sign was reversed as was the sign of the corresponding 
change in VAS, LCQ and CF24 between visits [245]. Minimal important differences 
were calculated at visit 2 and were defined as the changes in CF24, LCQ and VAS in 
subjects reporting a small change in GRCQ score. The determinants of 24-hour 
frequency at baseline (visit 1) and change in cough frequency (visits 1-2) were 
evaluated by univariate analysis of gender, duration of cough, VAS and LCQ. A 
longitudinal measure of cough frequency, LCQ and VAS from visits 1 to 3 was 
determined by calculating the area under the curve (AUC) for each subject and 
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dividing by the duration of the study. Sample sizes were calculated using G*Power 
version 3.1.2 (Faul) to detect the smallest clinically important change (between 
visits 1 and 2) for both linear and AUC outcome parameters. Sample size 
calculations based on AUC data will account for change in cough severity in addition 
to natural recovery. Sample sizes were also determined by a responder analysis 
between visits 1 and 2 using Fisher's exact test. A responder was defined as a 
subject whose cough improved greater than the smallest clinically important 
change. The predictive value of baseline LCQ, cough VAS and CF1 for identifying 
subjects with low CF24 rates (≤10 coughs/hr) was assessed by plotting receiver 
operating characteristic (ROC) curves and calculating the AUC, sensitivity, 
specificity, negative predictive value and positive predictive value for each 
screening tool. A high sensitivity for identifying low frequency coughers was 
considered desirable.  
4.5 Results 
33 subjects (21 female) were included in the final analysis. The reasons for 
excluding subjects at screening are given in Figure 4-1. Baseline subject 
characteristics are given in Table 4-1. 




Table 4-1 Baseline characteristics 
Characteristic Value 
Age (years)  31 (23-37) 
Male:Female (n) 12:21 
Smokers (%) 0 
Cough duration to presentation (days)  4.1 ± 2.5 
 
 
Rhinorrhoea (%) 82 
Sneezing (%) 82 
Headache (%) 69 
Sore throat (%) 67 
Coloured sputum (%) 50 
Clear sputum (%) 33 
Aches and pains (%) 31 
Tiredness (%) 31 
Fever (%) 27 
Facial pain (%) 15 
 
 
LCQ score  14.3 (11.0-18.1) 
Cough VAS (mm) 46.0 (32.5-58.0) 
CF24 (coughs/hr)
* 14.9 ± 0.4 
Cough bouts/24-hours 85 (39-195) 
Data presented as median (IQR), mean ± SD, n or %. *: geometric mean ± log SD. 
LCQ: Leicester Cough Questionnaire; VAS: visual analogue scale; CF24: 24-hour cough 
frequency. 
4.5.1 Natural course of acute cough 
The mean ± standard deviation (SD) time from onset of cough to visit 1 was 4.1 ± 
2.5 days. Geometric mean ± log SD 24-hour cough frequency at baseline was 14.9 ± 
0.4 coughs/hr. The median (IQR) number of cough bouts in 24 hours at baseline was 
85 (39-195) bouts. Cough specific quality of life was impaired at baseline; median 
(IQR) LCQ score was 14.3 (11.0-18.1). There was a significant reduction in cough 
frequency, cough bouts and VAS from visits 1 to 3, and improvement in health 
status (Figure 4-2). The geometric mean ± log SD 24-hour cough frequency at visit 2 
and 3 was 8.8 ± 0.5 (41% reduction from baseline) and 3.3 ± 0.7 coughs/hr (78% 
reduction from baseline) respectively. The median (IQR) coughs per bout at visits 1-
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3 were 2.7 (2.3-3.0), 2.7 (2.2-3.0) and 2.5 (2.1-2.9) coughs respectively (p=0.07, 
visits 1-3). Cough frequency decreased from visit 1 to visit 2 in 73% of patients and 
was unchanged or increased in the remainder. In subjects whose cough frequency 
decreased from visit 1 to visit 2, the magnitude of change in cough frequency was 
not associated with duration of cough (p=0.72), baseline LCQ (p=0.36), baseline 
cough VAS (p=0.10) or baseline cough frequency (p=0.80). There were no significant 
differences in baseline characteristics or cough severity between subjects whose 
cough improved and deteriorated between visits. At visit 3, 52% of subjects still had 
cough frequency above normal limits. The geometric mean ± log SD AUC/day for 
cough counts and median (IQR) AUC for LCQ and VAS were 248 ± 0.43 coughs, 16.6 




Figure 4-2 Longitudinal changes in quality of life, subjective cough severity and 
objective 24-hour cough frequency 
 
LCQ, cough VAS and cough bouts data presented as median (IQR); cough frequency 
data presented as geometric mean (SEM); LCQ: Leicester Cough Questionnaire; VAS: 
visual analogue scale. 
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4.5.2 Relationship between subjective and objective cough outcome 
measures in acute cough 
There was a significant relationship between objective cough frequency and LCQ 
and cough VAS at visits 2 and 3 but not at visit 1 (Table 4-2). There was also a 
significant correlation between change in cough frequency and change in LCQ and 
cough VAS (Table 4-2).  
Table 4-2 Relationship between subjective and objective measures of cough 
severity in acute cough 
 
Cough Frequency 
(CF24, cough bouts) 
 
Δ Cough Frequency 
(CF24, cough bouts) 
 
 Visit 1 Visit 2 Visit 3 Visit 1-2 Visit 2-3 
LCQ -0.23, -0.23 -0.48†, -0.46* -0.63‡, -0.62‡   
VAS 0.03, 0.09 0.42*, 0.59‡ 0.69‡, 0.75‡   
      
Δ LCQ    -0.55*, -0.56† -0.62‡, -0.57† 
Δ VAS    0.51*, 0.45* 0.66‡, 0.70‡ 
Data presented as correlation coefficients. *: p<0.05; †: p<0.01; ‡: p<0.001. CF24: 24-
hour cough frequency (efforts per hour); cough bouts: number of coughing bouts in 
24 hours; LCQ: Leicester Cough Questionnaire; VAS: visual analogue scale; Δ: 
change.  
4.5.3 Determinants of cough frequency 
Female subjects coughed more frequently than men (geometric mean cough 
frequency AUC 309 vs. 168 coughs; mean fold difference 1.8; 95% CI 0.3 to 3.4; 
p=0.022). AUC cough severity VAS and LCQ were similar in both genders (p=1.0 and 
0.9 respectively). The relationship between age and cough outcome measures was 
not assessed due to the narrow age range of subjects. There was no significant 
relationship between cough frequency and duration of cough (p=0.16), VAS 
(p=0.85), LCQ (p=0.28) or presence of other URTI symptoms at presentation such as 
fever and myalgia (p=0.16 - 0.95). There was no difference in LCQ or VAS in subjects 
with and without non-cough URTI symptoms (p=0.05 - 0.94). 33% of subjects had 
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baseline 24-hour cough frequency rates ≤10 coughs/hr. Both LCQ and cough VAS 
score at baseline were poor at identifying low frequency coughers; the AUC of the 
ROC curves for LCQ and VAS were 0.61 and 0.56 respectively. The geometric mean ± 
log SD CF1 was 23.8 ± 0.4 coughs/hr. The AUC of the ROC curve for cough frequency 
during the first hour (CF1) to detect low frequency coughers was 0.86. A threshold 
of CF1 < 20.5 coughs/hr had a sensitivity and specificity of 91% and 77% respectively 
for predicting low 24-hour cough frequency. The sensitivities and specificities for a 
range of CF1 thresholds are listed in Table 4-3.  
Table 4-3 Predictive value of first hour cough frequency for detection of low 











<16.5 64 86 70 83 
<19.0 82 82 69 90 
<20.5 91 77 67 94 
CF1: cough frequency in the first hour; PPV: positive predictive value; NPV: negative 
predictive value. 
4.5.4 Sample size calculations for future studies 
In patients reporting a small change in GRCQ at visit 2, the change in CF24, LCQ score 
and cough VAS were a 54%, 2.0 and 17 mm change from baseline respectively 
(Figure 4-3). The geometric mean ± log SD cough frequency for these patients at 
visits 1 and 2 were 24.2 ± 0.4 and 12.6 ± 0.4 coughs/hr respectively; mean fold 
difference 1.9; 95% CI 1.0 to 3.7; p=0.049. The number of subjects required for a 
parallel group study design to demonstrate a 54%, 2.0 and 17 mm change in CF24, 
LCQ and VAS from visit 1 to 2 (i.e. a change from baseline) with 80% power (alpha 
level (α) of 0.05) were 26, 50 and 22 per group respectively. The number of subjects 
required for a parallel group study design to demonstrate a 54%, 2.0 and 17 mm  
change in AUC (i.e. a change in addition to that with natural recovery) for CF24, LCQ 
and VAS with 80% power (α=0.05) were 27, 51 and 25 per group respectively. 
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Responders were defined as patients whose cough frequency, LCQ and VAS reduced 
by ≥ 54%, 2.0 and 17 mm respectively between visits 1 and 2. 42%, 52% and 55% of 
subjects responded between visits 1-2 (for cough frequency, LCQ and VAS 
respectively). The sample sizes required to detect an additional 20%, 30% and 40% 
responders are presented in Table 4-4. 
Figure 4-3 Minimal important differences in LCQ, cough visual analogue scale 
and 24-hour cough frequency in acute cough 
 
LCQ and cough VAS data presented as median (IQR); cough frequency data 
presented as geometric mean (SEM). LCQ: Leicester Cough Questionnaire; VAS: 
visual analogue scale. 
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Responder Analysis                          
(additional response rate) 
20% 30% 40% 
Cough frequency 26 27 102 48 28 
LCQ 50 51 101 43 22 
VAS 22 25 98 41 20 
Sample sizes are per group for a parallel study design. Sample sizes are calculated 
with 80% power and alpha level of 0.05 to demonstrate minimal important 
differences:  54%, 2.0 and 17 mm change in 24-hour cough frequency, Leicester 
Cough Questionnaire (LCQ) and visual analogue scale (VAS) respectively.  
4.6 Discussion 
In this study, longitudinal changes in cough frequency, health status and cough VAS 
in subjects with acute cough due to URTI were evaluated and the minimal 
important differences quantified for the first time. Cough frequency, assessed 
objectively with a 24-hour cough frequency monitor, was increased at baseline. 
Cough frequency was greater in female subjects than in males. A significant 
reduction in cough frequency was seen in all subjects in the second week after 
onset of cough. However, no clinical characteristic at baseline predicted the 
magnitude of change in cough frequency. There were also significant improvements 
in health status and cough VAS. The minimal important differences in cough 
frequency, LCQ and VAS in URTI were a 54%, 2.0 and 17 mm change from baseline. 
The natural history of cough associated with URTI was characterised by a reduction 
in both cough frequency and cough bouts in most patients, as expected. There was 
a 41% reduction in cough frequency between visits 1 and 2 in the overall group, 
consistent with a rapidly changing condition. In a subgroup (27%) of patients 
however, cough frequency at visit 2 was either increased or unchanged from 
baseline, before decreasing at visit 3. This observation could have important 
implications when interpreting antitussive clinical trial results since any accounted 
mismatch in the number of subjects with early phase worsening of cough between 
the placebo and intervention arms could lead to misleading results. There were no 
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clinical characteristics at baseline such as duration of cough that prospectively 
identified subjects whose cough worsened. The proportion of subjects whose cough 
worsens during initial assessment should be reported in trials of antitussive therapy 
to ensure that subject groups are well matched in this respect.  
Few studies have evaluated objective cough frequency in subjects with URTI. A 
recent study by Sunger et al investigated cough frequency over 2 consecutive days 
in subjects with URTI [204]. Coughs were recorded using the Vitalojak monitoring 
system and counted manually. They reported a similar baseline cough frequency 
(12.1 coughs/hour). An important difference between our studies is that I assessed 
cough frequency on three occasions over a 9-day period compared with Sunger et 
al, who took two measurements over a 2-day period. I also quantified the minimal 
important differences in cough frequency and other outcome parameters, allowing 
sample sizes to be calculated with greater confidence and facilitating clinically 
meaningful interpretation of results from other studies. Furthermore, longitudinal 
changes in cough bouts and health status were also assessed. The number of cough 
bouts reduced significantly between visits 1-2 but the reduction between visits 2-3 
failed to reach statistical significance, in contrast to cough frequency which reduced 
significantly for both intervals. The relationship between health status and cough 
frequency and bouts was comparable.  
Kuhn et al also assessed cough frequency in URTI in their study of the efficacy of the 
expectorant guaifenesin [271]. Duration of cough at study recruitment was earlier 
than in this study (2 days vs. 4 days). This is likely to explain the higher cough 
frequency reported at baseline by Kuhn et al; 34 coughs/hr in the placebo group. 
Cough frequency on the 4th day from onset of cough, which would be comparable 
to the baseline visit in this study, was similar (16 coughs/hr). There were also 
important differences in the cough detection methodology. A voice-activated tape 
recorder was used, in contrast to continuous MP3 sound recording in this study. 
Subjects were confined to a study room in the study by Kuhn et al whereas in this 
study the LCM allowed ambulatory cough monitoring. Similarly, in the study by 
Pavesi et al of dextromethorphan in URTI, cough monitoring was assessed using a 
system that required subjects to remain in a confined environment [184].  
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The minimal important difference in cough frequency over a 4 day period was found 
to be substantial, a 54% change from baseline. Such a magnitude of change in 
cough frequency is noteworthy because it relates to subjects reporting only a small 
degree of change in their cough. This change was observed with natural recovery 
alone. Clinical trials of antitussive therapy, particularly those conducted over several 
days, should therefore aim for greater than 54% reduction in cough frequency. This 
may be difficult to achieve as suggested by the findings of Pavesi et al (13% 
reduction in cough frequency with dextromethorphan over placebo) [184]. I did not 
investigate the placebo effect that is often seen in cough studies [203].Further 
studies should explore the potential to evaluate antitussive therapy over a shorter 
duration, such as single dose studies, where the change in cough frequency with 
natural recovery is likely to be less marked. The minimal important difference in 
VAS in acute cough has been quantified for the first time, a 17 mm change. The VAS 
is a widely used, simple and valid tool for the assessment of global cough severity. 
This finding should facilitate clinical interpretation of VAS data in future studies. The 
minimal important difference in LCQ important to patients was 2.0, similar to that 
reported in a previous study [148].  
The purpose of estimating the minimal important difference (MID) was to 
determine sample sizes for future studies  [245]. The methodology used to for 
determine the MIDs was similar to that used in other studies, but some caution is 
advised in interpreting the MID data since the cough parameters are rapidly 
changing with natural recovery alone. The MIDs were determined at visit 2 because 
it was envisaged that cough would have resolved or be near resolution in most 
subjects by visit 3, which would make the assessment of the MID difficult. Further 
studies should assess whether the magnitude of MIDs are influenced by the time 
course of illness. The sample sizes required in future parallel group studies to detect 
the MIDs in cough frequency, LCQ and VAS were calculated based on the MID data. 
The sample size was greatest for LCQ. This reflects the relatively smaller MID for the 
LCQ compared with that for cough frequency. The sample size for cough frequency 
is consistent with that suggested by Sunger et al [204]. A strength of my sample size 
calculation is that I used an anchor-based method to determine the MID, ensuring 
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that the estimate is clinically relevant. Sample size calculations were also calculated 
using AUC data. The AUC is a measure of the trajectory of the outcome parameter 
over a period of time and hence already includes the effect of natural recovery in 
this study, unlike the baseline cough frequency rate. Therefore, the advantage of 
using AUC data for sample size calculations is that it will power for detection of 
change in addition to that due to natural recovery. The samples sizes calculated by 
responder analysis were larger, consistent with previous studies using responder 
analysis methods [272]. The limitations of responder analysis are its reduced power 
relative to that of continuous outcome measure scales and the arbitrary nature of 
the definition of a response; both are thought to increase the sample size [272]. I 
investigated the factors that may influence the magnitude of change in cough 
frequency since this affects the sample size calculation. Although the study was 
underpowered to study this with confidence, none of the parameters assessed 
predicted the change in cough frequency. Sample sizes were calculated for a 
parallel group study design. I would not propose a cross-over design for future 
studies because URTI is a rapidly changing condition and the data from this study 
suggests that the sample size for parallel group studies is achievable, but others 
have suggested that cross-over studies may be possible [204]. 
Potential predictors of 24-hour cough frequency at baseline were evaluated. A 
simple, brief screening tool that identifies patients with low 24-hour cough 
frequency may be useful for research studies and clinical trials to facilitate 
recruitment of patients with a clinically significant cough frequency. Cough 
frequency in the first hour was the best predictor of 24-hour cough frequency, 
whereas subjective assessments of cough severity were poor predictors. Cough 
frequency in the first hour <20.5 coughs/hour had a 91% sensitivity to identify low 
cough frequency. A limitation of this threshold is that approximately one third of 
subjects will potentially be misclassified as having a low frequency cough and 
therefore be excluded from studies (67% positive predictive value). Further 
evaluation of first-hour cough frequency as a screening tool in clinical trials is 
warranted. At the end of the study, 52% of subjects still had cough frequency rates 
above normal, suggesting that cough frequency due to URTI may take some weeks 
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to return to within normal limits in a significant number of subjects. This has 
previously been reported by Jones et al who noted that cough (assessed 
subjectively) persisted 2 weeks after onset in a similar proportion of subjects (58%) 
[202].  
Health status was severely impaired in cough associated with URTI, affecting all 
domains of the LCQ. This is consistent with previous studies [148, 273]. The degree 
of health status impairment was comparable to patients with chronic cough [11]. In 
contrast to chronic cough, health status was only transiently impaired, returning to 
near normal levels by visit 3. The relationship between health status and VAS with 
cough frequency was best at visits 2 and 3. However, the correlation was moderate, 
suggesting that other factors, such as cough intensity, may be important 
determinants of cough severity in URTI [120, 146, 198]. The relationship between 
subjective and objective parameters was poor at visit 1. It is possible that symptoms 
such as rhinorrhea, headache, sleep disturbance and those causing disruption to 
daily activities had a significant impact on general health status in the early stages 
of the illness. The relationship between longitudinal changes in subjective and 
objective measures of cough was more consistent than that with cross-sectional 
assessments. At baseline, the relationship with cough frequency was better with the 
LCQ compared to VAS. However, the change in VAS was a better representative of 
GRCQ category, and particularly in subjects reporting a large change in cough 
severity. The reasons for this are unclear, and further studies with larger number of 
subjects are needed to investigate whether there are important differences in the 
performance of subjective outcome tools.  
There are limitations to this study. Although the cough frequency of the overall 
group reduced significantly over the duration of the study, a significant proportion 
of subjects still had abnormally raised cough frequency at visit 3. Ideally, further 
assessments would have been made until the resolution of cough or until a plateau 
in cough frequency was observed. Additional assessments during the early phase of 
illness would also have been desirable. The study population was young and did not 
have co-morbidity, it is therefore not known if cough frequency in older subjects 
differs; this needs further investigation. However, in chronic cough, there is no 
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significant relationship between cough frequency and age [170]. The duration of 
cough at recruitment was not identical for all subjects; this could have had an 
impact on the degree of change in cough severity between study visits. The study 
was underpowered to perform a sub-analysis of patients with identical duration 
from onset of cough. The recruitment of patients with an identical duration of 
cough in the early phase of illness is challenging because of the unpredictable 
incidence and rapidly changing nature of acute cough. However, the impact of this 
limitation may be less marked in this study, since no association was found between 
the duration of cough and change in cough frequency. The viral aetiology of acute 
cough was not investigated in this study. It is possible that differences in the type of 
virus will have an impact on the severity of cough. Studies using induced viral URTIs 
could address this. It is also possible that non-infectious causes may have been 
responsible for acute cough in some subjects. 
It is possible that inaccuracies in the LCM cough detection software have affected 
the findings since the LCM was validated in subjects with chronic cough. However, 
the cough recordings in the current study were ambulatory and performed in the 
subjects’ own environment, similar to the validation studies in chronic cough [198]. 
Furthermore, the cough frequency rates observed in this study were similar to 
those in another study of acute cough in which coughs were counted manually 
[204]. My definition of low cough frequency was based on an arbitrary threshold of 
<10 coughs/hr. This was chosen this because it was less than the average cough 
frequency for subjects with URTI but higher than that reported for healthy subjects 
[274]. Further thresholds should be evaluated in larger studies. I only investigated 
the potential for the first hour cough frequency to predict 24-hour cough frequency 
and both measurements were obtained from the same recording. These limitations 
should be addressed by investigating longer duration recordings conducted 
separately from the 24-hour recording. I did not evaluate cough intensity in this 
study since its measurement is not currently possible in an ambulatory setting. It is 
possible that the MIDs differed between those who improved and those who 
deteriorated; the study was underpowered to assess this. Lastly, it is possible that 
subjects may have associated the change in cough assessed with the GRCQ more 
122 
 
closely with their cough severity at the follow up visit compared to baseline [275]. 
The short interval between study visits, 4 days, should have minimised recall bias 
but this should be addressed in future studies by determining change prospectively.  
4.7 Conclusion 
In conclusion, a number of valid tools are available to assess cough severity in acute 
cough secondary to URTI. 24-hour cough frequency monitoring is a practical, 
objective and responsive outcome parameter. Cough frequency in patients with 
URTI was significantly raised. The MID in 24-hour cough frequency was 54%. Health 
status was significantly impaired due to cough in URTI and returned to near normal 
levels with recovery. The relationship between cough frequency and health status 
was weak to moderate, suggesting that both subjective and objective outcome tools 
should be used to assess cough comprehensively. The findings of this study will 
facilitate the design of future trials of therapy. The sample sizes required for parallel 






5 Four-hour cough frequency monitoring in chronic 
cough  
This chapter was submitted in manuscript form and accepted for publication. 
Reference: 
Lee KK, Savani A, Matos S, Evans DH, Pavord ID, Birring SS. Four-hour cough 
frequency monitoring in chronic cough. Chest 2012;142(5):1237-1243 
5.1 Abstract 
Background: The recent development of automated cough monitors has enabled 
objective assessment of cough frequency. A study was undertaken to determine 
whether short-duration recordings (<6 hrs) accurately reflect 24-hr cough frequency 
and to investigate their responsiveness. 
Methods: One hundred adults with chronic cough underwent 24-hr cough 
frequency monitoring with the Leicester Cough Monitor and completed cough 
visual analogue scales (VAS) and the Leicester Cough Questionnaire (LCQ). Cough 
recordings were analysed using customised software to derive cough frequencies 
from 1 to 6 hrs and 24-hr recordings. Responsiveness was assessed with repeat 
assessments following therapeutic trials. 
Results: The median (interquartile range) 24-hr cough frequency was 11.5 (5.8-26.6) 
coughs/hr. Four hours was considered the shortest recording duration that 
represented 24-hr cough frequency (ρ=0.9, p ≤0.001). Median 4-hr cough frequency 
was 16.6 (7.3-36.8) coughs/hr. Both 4-hr and 24-hr cough frequency correlated 
moderately with cough VAS (ρ=0.49, p≤0.01 and ρ=0.44, p≤0.01) and LCQ (ρ=-0.48, 
p≤0.01; ρ=-0.50, p≤0.01). Four-hour cough frequency was responsive to 
improvements in cough severity following trials of therapy. 
Conclusions: Four-hour cough frequency correlates highly with 24-hr cough 
frequency recordings and relates equally well with subjective measures in chronic 
cough. Short-duration cough monitoring could be a practical tool to validate the 




The assessment of cough severity is integral to the investigation of patients with 
chronic cough. The demonstration of a reduction in cough severity following a 
therapeutic trial is widely used to establish the aetiology [78, 276]. Cough severity 
can be assessed by a number of methods such as patient opinion, symptom scales, 
patient diaries and quality of life questionnaires [6]. The subjective nature of the 
assessment of cough severity has led to the development of objective tools [167, 
173, 185, 186, 200]. 24-hour objective cough monitoring is regarded as the gold 
standard for quantifying cough frequency [277]. It is not known if shorter duration 
cough recordings reflect cough rates obtained from 24-hour recordings. The 
advantages of short duration recordings are quicker analysis times and convenience 
for patients.  
5.3 Aims 
The aim of this study was to investigate the relationship between short and 24-hour 
duration cough frequency recordings, determine the optimal duration for short 
recordings and assess their responsiveness in patients undergoing therapeutic trials. 
5.4 Methods 
5.4.1 Subjects 
100 consecutive patients with chronic cough were recruited from a general 
respiratory clinic that receives greater than 80% of its referrals from primary care. 
All patients presented with an isolated chronic cough. Chronic cough was defined as 
a cough lasting greater than 8 weeks duration. The cause of cough in all patients 
was ascertained from case note review when investigation and treatment trials 
were complete. All patients were assessed using a standardised diagnostic protocol 
[16]. A diagnosis was established if patients had suggestive history and/or 
investigations and a clinical response to specific therapy. Patients with idiopathic 
chronic cough had negative investigations and treatment trials for asthma, upper 
airway cough syndrome and gastro-oesophageal reflux disease. Patients with a 
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recent upper respiratory tract infection in the preceding 4 weeks were excluded. All 
subjects gave informed consent to participate in the study. This study was approved 
by King's College Hospital Research Ethics Committee (ref: 07/Q0703/9). 
5.4.2 Subjective cough severity assessment 
Health related quality of life was assessed using the Leicester Cough Questionnaire 
(LCQ), a validated cough-specific health status questionnaire [11]. The LCQ is self-
completed, comprises of 19 items and has 3 domains: physical, psychological and 
social. Domain scores range from 1-7, and total score ranges from 3-21. A higher 
score reflects better health status. Cough symptom severity was recorded using a 
100 mm cough visual analogue scale (VAS), where 100 mm indicated most severe 
cough and 0 mm indicated no cough.  
5.4.3 Cough frequency assessment 
Cough frequency was recorded with the Leicester Cough Monitor (LCM). The LCM is 
a validated ambulatory, semi-automated, cough monitor that measures cough 
frequency and has a sensitivity and specificity of 91% and 99% respectively for 
detecting cough [173, 198]. The LCM has been independently validated against 
manually counted cough recordings [173, 174]. The LCM consists of a portable MP3 
sound recorder and free-field microphone that are worn for 24 hours in the 
patients' own environment. Short (1-6 hours) and long (24-hour) recording cough 
frequencies were determined from the same recording. The sound files were 
uploaded onto a computer for automated analysis using customised cough 
detection software [173]. The software is based on a keyword spotting approach 
widely used in speech recognition, also known as Hidden Markov Models [171, 
172]. This was followed by minimal operator input to refine cough analysis and 
generate a final report. Coughs were detected as single events whether occurring in 
isolation or clusters. Cough monitoring set-up took less than 5 minutes, automated 
cough detection analysis 60-90 minutes and operator refinement and report 
generation 10 minutes.  
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5.4.4 Determination of optimal short recording duration 
The shortest LCM recording duration that was representative of 24-hour cough 
frequency (CF24) was determined by assessing the relationship with CF24, health 
status (LCQ) and cough VAS. This was done sequentially for 1 to 6-hour recordings. 
The optimal short recording duration was determined if (1) there was good 
agreement between short duration cough frequency and awake cough counts; 
intra-class correlation coefficient >0.8, (2) the relationship of short recordings with 
subjective cough outcome parameters was consistent with those of CF24 and (3) the 
short recordings were responsive; effect size >0.4. The optimal time of day for 
conducting short recording studies was determined by assessing the relationship 
between short recording cough frequency commenced at different times of day and 
overall daytime cough frequency (CFday). Daytime and nighttime periods were 
established from self-reported awakening and bed times using patient diaries. 
5.4.5 Protocol 
Patient characteristics were recorded using a structured questionnaire during a 
clinic visit. Subjective cough severity and cough specific health related quality of life 
were recorded using the cough VAS and LCQ respectively. The LCM was attached to 
patients during the daytime and worn for 24 hours. Patients were encouraged to 
resume normal daily activity in their own environment during recordings. A 
subgroup of 20 patients undergoing trials of therapy (inhaled and nasal 
corticosteroids) underwent repeat LCM, LCQ and cough VAS assessments after 2 
months. The repeat assessment was performed at the same time of day as the first 
recording. Response was defined as "no response", "partial response" or "good 
response" by asking patients to rate the improvement in their cough severity at the 
second visit. The relationship between cough frequency during self-reported day-
time (CFday) and night-time hours (CFnight) was compared with day-time and night-
time cough frequency determined by arbitrary times (CF08-22 and CF22-08) to 
investigate the potential to do cough monitoring without using patient diaries to 
define day-time and night-time periods. The effect of meals (1 hour before vs. after) 
and awakening (first vs. second hour) on cough frequency were investigated to 
assess the potential for these situations to affect short duration recordings. 
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5.4.6 Statistical analysis 
Statistical analysis was performed with SPSS version 16 and GraphPad Prism 5 
software. Cough frequency is presented as 24-hour cough frequency (CF24), daytime 
cough frequency (CFday), nighttime cough frequency (CFnight) and as absolute cough 
counts. Cough frequency data was non-normally distributed and therefore Mann-
Whitney tests, Kruskal-Wallis tests and Spearman's ρ correlation coefficients were 
used for analysis. Effect sizes were calculated as the difference in mean cough 
frequency / standard deviation of baseline cough frequency. Confidence intervals 
for effect sizes were constructed using 'R' package (R Development Core Team) 
[278]. Sample size calculation was limited by the exploratory nature of this study in 
an unselected population with unexplained chronic cough. I therefore chose to 
recruit a large population similar to that used in the development of other cough 
severity tools [11].  
5.5 Results 
100 patients with chronic cough were recruited. The primary causes of cough were 
asthma (n=24), eosinophilic bronchitis (n=7), rhinitis (n=9), gastro-oesophageal 
reflux disease (GORD)  (n=3), idiopathic chronic cough (n=29), post-viral cough 
(n=7), sarcoidosis (n=6), interstitial lung disease (n=8), obstructive sleep apnoea 
(n=2), bronchiectasis (n=2), chronic bronchitis (n=1), ACE-inhibitor induced (n=1) 
and post-infective (n=1)). Baseline characteristics are shown in Table 5-1. There 
were no significant differences in age, lung function, quality of life or cough VAS 
between diagnostic groups. No patients reported adverse incidents with cough 




Table 5-1 Patient baseline characteristics 
Characteristic Value 
Number 100 
Male (%) 43 
Age (years) 54 (1) 
Cough duration (months) 40 (7) 
FEV1 (% predicted) 90 (2) 
FVC (% predicted) 97 (3) 
BMI (kg/m2) 32 (4) 






Data presented as mean (standard error of mean) or %. FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; BMI: body mass index. 
The median (interquartile range) total cough counts during awake-hours, sleep-
hours and 24-hours were 216 (124 to 606) coughs, 31 (8 to 62) coughs and 277 (139 
to 637) coughs respectively. The median (IQR) 24-hour cough frequency (CF24) was 
11.5 (5.8 to 26.6) coughs/hour. There was no significant relationship between CF24 
and age, gender, forced expiratory volume in 1 second (FEV1), body mass index 
(BMI) or duration of cough. There was no significant difference in cough frequency 
before and after meals (median cough frequency 14.0 coughs/hr vs. 12.5 coughs/hr, 
p=0.43). There was also no significant difference in cough frequency between the 
first and second hour after awakening (p=0.65). Cough frequency during awake-
hours was significantly greater than that during sleep; median CFday 13.2 vs. CFnight 
4.2 coughs/hr; difference between medians 8.9; 95% confidence interval of 
difference 6.8 to 12.6; p<0.001 (Figure 5-1). CF24 was more strongly related to CFday 
(ρ=0.98, p<0.001) than CFnight (ρ=0.62, p<0.001). Cough frequency during the 
arbitrary day-time period between 0800 to 2200 and night-time period between 
2200 to 0800 related well to actual CFday and CFnight (ρ=0.99; p<0.001 and ρ=0.78; 
p<0.001 respectively). Cough frequency (CF24) was moderately related to health 
related quality of life and cough VAS (Table 5-2). 
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Figure 5-1 Diurnal variation in cough frequency in patients with chronic cough  
 
Data presented as median (interquartile range) 
Table 5-2 Relationship between short and long duration cough recordings, 
cough-specific quality of life and cough VAS 
Cough frequency  
method 
CF24 QOL (LCQ) VAS 
ρ ICC ρ ρ 
CF1 0.77 0.63 -0.31 0.34 
CF2 0.85 0.73 -0.35 0.37 
CF3 0.88 0.79 -0.41 0.37 
CF4 0.90 0.82 -0.48 0.49 
CF5 0.92 0.84 -0.48 0.49 
CF6 0.93 0.85 -0.48 0.48 
CF24 - - -0.50 0.44 
Spearman's ρ and intraclass correlation coefficients. All p-values are <0.01. CF1-CF6: 
cough frequency obtained from first hour of recording to first 6 hours of recording; 
CF24: 24-hour cough frequency; ICC: intraclass correlation coefficient; LCQ: Leicester 





There was a strong and significant correlation between all short duration cough 
frequency recordings and CF24 (Table 5-2). The relationship between subjective 
cough assessment scores (cough VAS and LCQ) and cough frequency determined 
from recordings of ≥4 hours duration was comparable to that of CF24. Cough 
frequency from 4-hour recordings (CF4) was selected for further analysis since it was 
the shortest recording duration that retained this good relationship with CF24 and 
subjective cough assessment scores. CF4 was significantly higher than CF24; median 
cough frequency 16.6 (7.3-36.8) coughs/hr v 11.5 (5.8-26.6) coughs/hr; difference 
between medians 3.5 coughs/hr; 95% confidence interval of difference 1.5 to 7.4; 
p<0.001. There was good agreement between CF4 and CF24 (Figure 5-2 and Table 
5-2). Cough frequency obtained from 4-hour recordings was strongly related to 
CFday regardless of the time of day they were commenced (Table 5-3). One patient 
with idiopathic chronic cough had an extremely high 24-hour cough count (2977 
coughs). This was verified manually. The correlation between CF4 and CF24 was 
repeated without this patient and the relationship was unchanged. 





Table 5-3 Relationship between 4-hour cough frequency obtained from different 
times of day and awake cough frequency 
4-hour recording period 
(time of day) 
Correlation between cough frequency obtained 
from 4-hour and day-time recordings 
8:00 AM to 12:00 PM 0.88 
9:00 AM to 1:00 PM 0.88 
10:00 AM to 14:00 PM 0.89 
11:00 AM to 15:00 PM 0.90 
12:00 PM to 16:00 PM 0.92 
13:00 PM to 17:00 PM 0.94 
14:00 PM to 18:00 PM 0.91 
15:00 PM to 19:00 PM 0.91 
16:00 PM to 20:00 PM 0.88 
17:00 PM to 21:00 PM 0.88 
18:00 PM to 22:00 PM 0.93 
Correlation coefficients (Spearman ρ). All p-values <0.001. 
In the subgroup of patients undergoing assessment of responsiveness, 6 reported a 
good response, 4 partial response and 10 reported no response following a trial of 
therapy. There were significant differences in the change in cough frequency 
between the 3 response categories for short recordings CF2-CF6 (p=0.01-0.04); for 
CF1, p=0.27. CF4 compared favourably with longer daytime recordings as an 
outcome measure for the assessment of response to therapeutic trials (Figure 5-3). 




Figure 5-3 Changes in cough VAS, LCQ and cough frequency following 
therapeutic trials 
 
Data presented as median percent change from baseline. LCQ: Leicester Cough 
Questionnaire; VAS: cough visual analogue scale; CF4: 4-hour cough frequency; 
CF24: 24-hour cough frequency 
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Difference in CF 
(coughs/hr) 
P-value Effect size 
(95% CI) 
1-hour 29.0 (6.8, 56.0) -5.5 (-22.8, 8.3) 0.39 0.28 (-0.36 to 0.91) 
2-hour 34.8 (11.8, 67.0) -12.5 (-38.1, -3.5) 0.04 0.48 (-0.19 to 1.13) 
3-hour 34.3 (10.9, 68.6) -16.0 (-42.3, -9.3) 0.04 0.52 (-0.16 to 1.17) 
4-hour 32.6 (11.3, 64.9) -14.8 (-39.7, -5.3) 0.04 0.52 (-0.16 to 1.17) 
5-hour 35.0 (12.1, 67.5) -14.0 (-43.9, -7.1) 0.04 0.59 (-0.10 to 1.25) 
6-hour 34.4 (12.4, 70.4) -13.8 (-43.7, -8.1) 0.03 0.59 (-0.10 to 1.25 
     
24-hour 28.5 (11.5, 44.3) -9.0 (-25.8, 1.3) 0.07 0.64 (-0.06 to 1.31) 
Responsiveness of short duration cough frequency measures in patients with chronic cough undergoing trials of therapy (inhaled or nasal 






This is the first study to investigate cough frequency measurement with short cough 
monitor recordings in patients with chronic cough. There was good agreement 
between 4-hour and 24-hour cough recordings. Both 4-hour and 24-hour cough 
frequencies were associated with subjective measures of cough severity. 4-hour 
recordings were responsive, suggesting they could be used to assess the efficacy of 
therapeutic trials. 
Cough monitors are usually set to record for 24 hours. I hypothesised that short 
daytime recordings could reflect longer recordings since the majority of coughs 
occur during the day [119, 173]. The findings of this study have shown that cough 
counts from 4-hour recordings are strongly correlated to 24-hour recordings and 
have a similar relationship with subjective parameters. The time of day for starting 
the monitoring did not affect the performance of short duration recordings. This is 
most likely due to the stability of cough counts during daytime [146]. There was also 
no significant impact of meal times and awakening on cough frequency. 
Cough frequency from 4-hour recordings was greater than that from 24-hour 
recordings. This was due to the low frequency of cough during nighttime in 24-hour 
recordings. Other investigators have also reported that nighttime cough frequencies 
are lower than daytime [120, 146]. A good correlation and agreement was found 
between 4-hour and 24-hour cough frequencies despite the impact of diurnal 
variation on 24-hour cough frequencies. The wide range of CF4 suggests that this 
measure may be able to discriminate patients with low and high cough frequencies. 
Furthermore, in a small group of patients undergoing trials of therapy, CF4 was 
responsive to change, suggesting it may be useful in the assessment of patients 
undergoing therapeutic trials. 
The shortest recording reflective of 24-hour cough frequency was determined by 
predefined criteria - agreement with CF24, association with subjective cough 
outcome parameters and responsiveness. Longer recordings, such as CF6, had 
better agreement and responsiveness than CF4 but this difference was considered 
marginal. The advantage of the considerably shorter CF4 recording may outweigh 
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the minor improvements in agreement and responsiveness with longer recordings. 
Recordings less than 4 hours had a weaker relationship with cough severity and 
health related quality of life, although this may not limit the use of shorter cough 
recordings in the assessment of cough frequency. Cough recordings as short as CF2 
were responsive and should be evaluated further. 
There was no significant relationship between cough frequency and sex, consistent 
with another study [72]. This may seem surprising since females are more likely to 
seek medical attention for cough, have a more heightened cough reflex and report 
a greater impairment in cough specific quality of life [48, 273, 279]. Faruqi et al and 
Kelsall et al however, have reported higher cough frequency in female patients with 
cough [146, 279]. The reason for inconsistent findings regarding the relationship 
between cough frequency and gender is unclear. It is possible that the lack of 
gender difference in cough frequency in this study may be due to differences in the 
performance of the cough detection software between genders; this needs further 
investigation. The findings of this study raise the possibility that the differences in 
quality of life and the need to seek medical attention may be related to factors 
other than cough frequency such as cough intensity or the presence of adverse 
cough related symptoms such as urinary incontinence. It is not known if other 
cough sound characteristics such as bandwidth and energy could yield diagnostic 
information; this needs further investigation. As reported previously, there was a 
moderate relationship between cough frequency and self-reported cough symptom 
severity and health related quality of life [120, 146, 198]. This supports the 
possibility that cough severity may be influenced by unaccounted factors such as 
cough intensity, urge to cough, personality traits and the presence of adverse 
symptoms related to cough [137, 280]. Little is known about cough intensity since it 
is difficult to measure and the gold standard has not been established. Cough sound 
recorders may be an alternative to physiological measurement of cough intensity 
and deserve further study. The lack of a strong relationship between subjective 
cough severity and objective measures of cough frequency suggests that a 
combination of assessment tools ought to be used to assess cough comprehensively 
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[146, 147]. The optimal combination of cough severity measures needs to be 
determined. 
There are some limitations to this study. Short daytime cough recordings do not 
capture cough during sleep; this can only be done by overnight or 24-hour 
recordings. Longer recordings may be necessary to evaluate drugs that are 
metabolised slowly. Studies that use short recordings will need a larger sample size 
since CF4 is more variable than CF24. The agreement between CF4 and CF24 was good 
when the whole study group was analysed but there was disagreement in some 
individual patients. The reason for this is unclear but the effects of diurnal variation, 
variable sleep duration and acclimatisation to the cough recorder during longer 
recordings are possible. The assessment of responsiveness of cough frequency 
monitoring was limited by the small number of patients studied and this may have 
been responsible for the wide confidence intervals for the effect sizes. Larger 
studies are needed to confirm the responsiveness of short and long duration 
recordings and the factors that influence them. The study was underpowered to 
detect differences in cough frequency between categories of chronic cough. The 
prevalence of idiopathic chronic cough was high in this study (29%), which may 
reflect increasing numbers of tertiary referrals but is consistent with the experience 
of other clinics [80]. The prevalence of GERD associated cough in the study was low. 
A low prevalence of GERD associated cough has also been reported by other 
investigators and may reflect differences in the evaluation of GERD [32, 36]. The 
purpose of this study however, was to evaluate sound based cough frequency 
assessment irrespective of diagnostic labelling. Cough severity is likely to be 
influenced by other factors in addition to the frequency of coughs, such as the 
intensity; this was not evaluated and emphasises the pressing need to develop non-
invasive tools that can assess cough intensity. It is possible that inaccuracies in the 
LCM automated cough detection could have affected the findings of this study. The 
LCM, however, has been validated against manually counted cough recordings and 
independently by another specialist cough clinic [169, 173]. The repeatability and 
responsiveness of the LCM supports its clinical validity [198].  Furthermore, the LCM 
has been evaluated in a randomised controlled trial setting, demonstrating its 
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potential for the evaluation of antitussive drugs [176]. Finally, short and 24-hour 
cough frequencies were obtained from the same recording. It is possible that 
patients would have behaved differently if they underwent 4-hour rather than 24-
hour monitoring. Prospective studies with 4-hour cough frequency monitoring are 
therefore needed to confirm the findings of this study.   
5.7 Conclusion 
In conclusion, this study demonstrated that objective cough frequency monitoring 
can be used in the clinic setting to validate the presence of cough and may be useful 
in assessing the response to trials of therapy. The findings suggest that shorter 4-
hour recordings may be sufficient to assess cough frequency. Shorter recordings are 
potentially more convenient for patients, require less time for analysis and are 




6 The intensity of voluntary, induced and spontaneous 
cough 
6.1 Abstract 
Rationale: The intensity or strength of cough is an important determinant of cough 
severity. Few studies have investigated the intensity of cough in patients with 
chronic cough. 
Objectives: To investigate the intensity of voluntary, induced and spontaneous 
cough in patients with chronic cough with physiological measures. 
Methods: Patients with chronic cough and healthy subjects underwent physiological 
assessment of the intensity of maximum voluntary, capsaicin induced and 
spontaneous cough. Assessments included cough gastric (Pga) and oesophageal 
pressure (Poes), peak cough flow rate (PCFR) and compression phase duration (CPD). 
Expiratory muscle strength (twitch gastric pressure, Twitch T10 Pga) and activation of 
abdominal muscles by electromyography (EMGabdo) were also assessed. Patients 
with cough also rated the intensity of cough using a visual analogue scale (VAS).  
Results: Most spontaneous and induced coughs occurred within bouts in contrast to 
voluntary coughs that were all single events. Poes, Pga and PCFR during maximum 
voluntary cough was significantly greater in patients with chronic cough compared 
with controls when taking into account the preceding inspired volume (p=0.003 to 
0.042). There was no significant difference in Twitch T10 Pga  or EMGabdo between 
patients and controls but CPD was increased in female patients with cough 
compared to healthy controls (mean ± SD CPD 0.50 ± 0.22 vs. 0.28 ± 0.17 seconds; 
p=0.007). The mean ± SD Poes during spontaneous cough was comparable to 
induced cough (128 ± 28 vs. 122 ± 37 cmH2O, p=0.686) but less than maximum 
voluntary cough (170 ± 46 cmH2O, p=0.020). Mean ± SD PCFR:PEFRpred during 
induced, spontaneous and maximum voluntary cough were 36, 82 and 143 
respectively (ANOVA, p<0.001). Median within-subject correlation coefficients 
between cough intensity VAS and Poes, Pga, PCFR and EMGabdo were ρ=0.86 to 0.9.  
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Conclusions: The intensity of voluntary cough is increased in patients with chronic 
cough compared with healthy controls. Physiological measures of cough intensity 
were strongly correlated with subjective perception of cough intensity in most 
subjects. The mechanism for the increase in cough intensity in patients is unclear; 
no difference in expiratory muscle strength was found between patients and 
controls. Further studies should evaluate the compressive phase of cough in more 
detail. Cough peak flow rate, pressure and gastric pressure are important and 
relevant measures of cough intensity in patients with chronic cough. 
6.2 Introduction 
Chronic cough is a common condition associated with significant physical and 
psychological morbidity [11]. Recent studies have reported a weak relationship 
between health-related quality of life and cough frequency [198]. This had led to 
the suggestion that cough intensity may be important in some patients [52, 137]. 
Few studies have investigated the intensity of cough and, in particular, there is a 
paucity of studies that have assessed it objectively.  
6.3 Aims 
The aim of this study was to investigate the physiological characteristics and 
intensity of voluntary, induced (reflex) and spontaneous cough in patients with 
chronic cough and healthy subjects.  
6.4 Methods 
6.4.1 Subjects  
Consecutive patients referred for investigation of a chronic cough were recruited 
from a respiratory outpatient clinic. All had cough for greater than 8 weeks and 
were symptomatic at the time of recruitment. The cause of cough was established 
following investigation and trials of treatment according to a standardised protocol 
[36]. Exclusion criteria were upper respiratory tract infection within the past 4 
weeks, current smokers or history of smoking within the past 1 year, history of 
neuromuscular disorders and connective tissue disease. Healthy control volunteers 
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were recruited through local advertising. Exclusion criteria in addition to those 
listed above were a history of respiratory disease and abnormal lung function 
(FEV1:FVC <80%). All subjects gave informed consent and the study had received 
ethical approval (East London and the City Research Ethics Committee 10/H0703/6) 
6.4.2 Physiological measures 
6.4.2.1 Cough oesophageal and gastric pressure 
Oesophageal pressure (Poes) and gastric pressure (Pga) were measured in accordance 
with American Thoracic Society/ European Respiratory Society recommendations 
[231]. Balloon catheters (Cooper Surgical, Berlin, Germany) were inserted nasally, 
attached to individual pressure transducers (MP45; Validyne, Northridge, CA, USA) 
and amplified (CD-280 amplifier; Validyne). Cough Poes was defined as the maximum 
pressure during coughs and Pga the trough-to-peak pressure during coughs (Figure 
1).  
6.4.2.2 Cough flow rate and inspiratory volume 
Respiratory flow was measured at the mouth using a Fleisch type 
pneumotachograph (P.K. Morgan Ltd, Kent, UK) attached to a full-face mask (Hans 
Rudolph Inc, Kansas City, USA). The pneumotachograph was calibrated prior to each 
study by 2-point calibration using a rotameter. Peak cough flow rate (PCFR), the 
maximum expiratory flow achieved during cough, was recorded and expressed as a 
percentage of predicted peak expiratory flow rate (PEFRpred), to correct for age, sex 
and height. Inspiratory volume (IV) and cough compressive phase duration (CPD) 
were calculated from the respiratory flow signal during coughs. On-screen cursors 
were placed automatically by a customised software script to ensure 
standardisation. The accuracy of all cursor positions were verified manually prior to 
calculation. 
6.4.2.3 Abdominal electromyography (EMGabdo) measurement 
EMG was recorded from the right rectus abdominis muscle using 55 mm diameter 
Ag-AgCl electrodes (Kendall liquid gel electrodes, Tyco healthcare, Hampshire, UK). 
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Prior to electrode attachment, the skin was thoroughly prepared using an abrasion 
gel (Nuprep abrasive skin gel, Weaver & Co, USA) [229]. The active electrode was 
placed 5 cm from the midline, just below the level of the umbilicus, and the 
reference electrode placed 5 cm laterally [133]. The earth electrode was placed 
over the anterior superior iliac spine. EMG signals were amplified and digitally 
filtered between 10 Hz and 2,000 Hz (1902 signal conditioner, Cambridge Electronic 
Design, Cambridge, UK). Peak abdominal EMG activity (EMGabdo) was taken as the 
absolute peak of the root-mean-squared EMG trace (50 ms windows) for any given 
cough [211, 214]. For group analyses, EMG data was normalised by expressing 
EMGabdo for each cough as a fraction of the largest EMGabdo observed during 
maximum voluntary cough and following non-volitional lower thoracic nerve root 
magnetic stimulation at 100% stimulator output (see below) [220].  
6.4.3 Respiratory Muscle Strength 
Non-volitional assessment of expiratory (abdominal) muscle strength was assessed 
by measuring gastric pressure during lower thoracic nerve root magnetic 
stimulations (twitch gastric pressure, Twitch T10 Pga) [111, 226, 255]. Stimulations 
were delivered using a double energy stimulator (Magstim Co Ltd, Dyfed, Wales) at 
maximum output and a 90 mm circular coil. Twitch T10 Pga was determined from the 
average response to five stimulations. In order to minimise potentiation, subjects 
were rested for 20 minutes prior to magnetic stimulation whilst refraining from 
talking or coughing [217]. All stimulations were performed with the subject relaxed 
and at end-expiration [111]. The optimal coil position for delivering stimulations 
was defined as the position at which the largest Pga response was evoked following 
stimulations at the 9th, 10th and 11th thoracic vertebrae [258]. Supramaximality of 
the magnetic stimulation was assessed by delivering stimulations of different power 
and demonstrating a plateau effect in the evoked abdominal compound muscle 
action potential (CMAP) amplitude with increasing magnetic power (see section 
3.8.2) [217, 259]. Supramaximality was defined as the absence of a significant 




6.4.4 Lung function 
Spirometry and peak expiratory flow rate were measured in accordance with 
international guidelines [242, 243]. 
6.4.5 Protocol 
All subjects participated in voluntary and induced cough studies. A subgroup of 9 
consecutive patients with chronic cough also underwent study of spontaneous 
cough. Poes, Pga, EMGabdo and flow were measured during each study. 
6.4.5.1 Spontaneous Cough  
Patients with cough were monitored continuously for a minimum of 10 minutes or 
until >10 coughs were recorded. Subjects were asked not to suppress cough but to 
cough freely if the urge arose. 
6.4.5.2 Maximum Voluntary Cough 
Maximum voluntary cough (MVC) was studied before induced cough to avoid any 
effect of capsaicin. Subjects were asked to perform >10 maximum coughs until 
cough Poes reached a plateau and was repeatable. Sufficient time was allowed 
between cough events to avoid fatigue and to ensure the return of lung volume to 
functional residual capacity before the subsequent effort. The MVC was the largest 
value observed during the protocol.  
6.4.5.3 Induced cough 
Reflex cough was evoked using nebulised sterile solutions of capsaicin (Sigma-
Aldrich, Missouri, USA) delivered via a side port into the connecting tubing of the 
face mask (ultrasonic nebuliser, Devilbiss Healthcare, UK). Nebulisation was 
undertaken for 1 minute each with saline control, followed by doubling 
concentrations of capsaicin (0.49-1000 µM) until subjects coughed 5 times or more 
(C5). A final nebulisation of capsaicin, one doubling concentration greater than C5 
was administered. There was a 1 minute interval between nebulisations. Nebulised 
saline was randomly interspersed during the protocol to minimise anticipation of 
dosing by subjects. Subjects were asked to avoid cough suppression. An additional 
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concentration of capsaicin, greater than that causing 5 coughs (supra-C5), was 
administered to ensure subjects were close to their maximum induced cough 
response. Superior repeatability has been demonstrated with supra-threshold 
stimuli in the assessment of the cough frequency response [215].   
6.4.6 Subjective assessment of cough intensity during voluntary cough 
To investigate the relationship between subjective perception and physiological 
measures of cough intensity, a randomly selected subgroup of 8 patients with 
chronic cough were asked to rate the intensity of 10 voluntary coughs on 0-100 mm 
visual analogue scales (VAS), whilst Poes, Pga, PCFR and EMGabdo were recorded for 
each cough. Subjects were asked to cough at different intensities of their choice and 
were blinded to the physiological measures of each cough. 
6.4.7 Analysis 
SPSS version 19 (IBM) and Prism version 5 (GraphPad) were used for statistical 
analysis. Appropriate parametric or non-parametric tests were used depending on 
distribution of data. Cough bouts were defined as continuous periods of coughing 
where individual events were <2 seconds apart (Figure 6-1) [281]. Cough events 
were categorised into cough (immediately preceded by inspiration) or expiratory 
reflex (with no preceding inspiration; ER) following interrogation of the flow signal. 
Although cough and ER sound similar, they differ in physiological characteristics 
[107]. Previous studies have reported an association between lung volume and 
intensity of cough [125, 218]. Therefore, Poes, Pga, PCFR and EMGabdo were adjusted 
for inspired volume (IV) preceding each cough. 
All physiological data were sampled at a frequency of 5,000 Hz, time synchronised, 
converted from analogue to digital format (Micro 1401 mk II; Cambridge Electronic 
Design, Cambridge, UK) and analysed on a computer with Spike 2 version 6 software 





Figure 6-1 The physiology of capsaicin induced cough 
 
Trace showing a number of expulsive events during capsaicin challenge testing 
(capsaicin concentration 1.95 µM) in a healthy male subject. Poes: oesophageal 
pressure; Pga: gastric pressure: EMG: abdominal electromyographic activity; bout: 
series of expulsive events with <2 second intervals between events; cough: expulsive 
event with preceding inspiration; ER: expiratory reflex (expulsive event without 
preceding inspiration); Exp: expiration; Insp: inspiration. 
6.5 Results 
6.5.1 Subject characteristics 
28 patients with cough and 21 healthy controls were recruited. Baseline 
characteristics are shown in Table 6-1. The groups were matched for age, gender 
and lung function. The principle causes of cough in patients were: asthma (21%), 
gastro-oesophageal reflux disease (14%), rhinitis (4%), idiopathic (43%), post-
infectious (7%), eosinophilic bronchitis (4%), obstructive sleep apnoea (4%) and 
bronchiectasis (4%). 21% of patients had multiple causes of cough.  
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Table 6-1 Baseline characteristics 
Data presented as mean ± standard deviation or median (interquartile range). BMI: body mass index; FEV1: forced expiratory volume in 1 
second; FVC: forced vital capacity; LCQ: Leicester Cough Questionnaire (range 3-21; higher score reflects better health status).  











Age (years) 57 ± 14 54 ± 19 0.632 57 ± 18 50 ± 23 0.385 
BMI (kg/m2) 28.5± 7.2 23.8 ± 1.2 0.051 27.6 ± 4.3 25.8 ± 3 0.287 
FEV1 (% predicted) 100 ± 20 106 ± 22 0.452 94 ± 16 101 ± 15 0.280 
FVC (% predicted) 113 ± 19 117 ± 26 0.684 97 ± 21 107 ± 19 0.269 
FEV1/FVC (%) 75 ± 9 78 ± 6 0.352 77 ± 6 76 ± 8 0.939 
Cough duration (months) 36 (26-83) - - 50 (20-85) - - 
LCQ score 11.2 (7.8-14.4) 20.9 (20.5-21.0) <0.001 13.4 (10.1-16.4) 21.0 (20.8-21.0) <0.001 
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6.5.2 Cough characteristics 
In patients with chronic cough and in controls, all maximum voluntary coughs (MVC) 
were single events; no bouts were observed during voluntary coughs. All cough 
events were preceded by inspiration; there were no expiratory reflexes (ER). In 
contrast to MVC, most events during capsaicin induced cough and spontaneous 
cough occurred within bouts, and most of these events were ERs (Table 6-2). The 
very first event during capsaicin induced cough challenges in patients with chronic 
cough was an ER in 63% of challenges (Table 6-3). In contrast, an ER was the first 
event in 27% of spontaneous cough bouts (Table 6-3). There was no significant 
difference in the prevalence of first event ER between gender (p=0.78 and 1.00 for 
C5 and supra-C5 respectively) and cough vs. control groups (p=0.12 and 0.69 for C5 
and supra-C5 respectively).  
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Table 6-2 The characteristics of induced and spontaneous cough 
 Females Males 
 Cough Controls Cough Controls 
Induced cough (C5)     
Number of events  18 (8-26) 9 (6-16) 16 (10-28) 8 (6-10) 
Events occurring in bouts (%) 100 (86-100) 100 (88-100) 100 (100-100) 100 (89-100) 
ER (% of all events) 69 (57-75) 73 (67-82) 75 (60-79) 71 (63-80) 
     
Induced cough (supra-C5)     
Number of events  15 (13-25) 16 (10-21) 15 (8-25) 16 (10-26) 
Events occurring in bouts (%) 100 (94-100) 98 (88-100) 100 (94-100) 100 (100-100) 
ER (% of all events) 69 (59-78) 78 (67-85) 75 (71-79) 70 (63-80) 
     
Spontaneous cough     
Number of events  45 (29-137) - 19 (13-84) - 
Events occurring in bouts (%) 96 (92-100) - 91 (81-100) - 
ER (% of all events) 62 (46-69) - 74 (37-81) - 
Data presented as mean ± standard deviation or median (interquartile range). 
Cough events were categorised as those preceded by inspiration and those without 
inspiration (expiratory reflex, ER). A bout is a series of 2 or more consecutive events, 
each separated by <2 seconds. Spontaneous cough was assessed for average 30 
minutes. C5: concentration capsaicin causing ≥ 5 cough events. Supra-C5: 
concentration of capsaicin one doubling dose higher than C5.  
148 
 
Table 6-3 A comparison of the intensity of voluntary, induced and spontaneous 
cough in patients with chronic cough 
 
MVC IC SC  
MVC vs. IC 
P-value 
MVC vs. SC 
 
IC vs. SC 
Poes (cmH2O) 170±46 122±37 128±28 0.250 0.020
* 0.686 
Pga (cmH2O) 207±60 140±76 141±43 0.156 0.030
* 0.938 
PCFR:PEFRpred 143±38 36±15 82±32 <0.001
* <0.001* 0.007* 
EMGabdo 0.11±0.11 0.06±0.04 0.07±0.07 0.078 0.008
* 0.641 
ER (% of events) 0 63 27    
Subjects are subgroup of patients with chronic cough who underwent study of 
spontaneous cough. Data presented as mean ± standard deviation or %. MVC: 
Maximum voluntary cough, IC: Induced cough - first cough or ER evoked by supra-C5 
capsaicin concentration, SC: first spontaneous cough or expiratory reflex in a bout; 
Poes: oesophageal pressure, Pga: gastric pressure; PCFR:PEFRpred: peak cough flow 
rate normalised to predicted peak expiratory flow rate; EMGabdo: abdominal 
electromyographic activity; *: p<0.05. 
6.5.3 Cough intensity during maximum voluntary cough 
During maximum voluntary cough, Poes, Pga and PCFR:PEFRpred were significantly 
greater in female patients compared to female controls (Figure 6-2 and Table 6-4). 
There was no significant difference in EMGabdo. There were no differences in any 
cough intensity measure between male patients and controls. However, male 
patients with cough took lower inspired volumes of air prior to coughing (Table 6-4). 
When adjusted for inspired volume, Poes, Pga and PCFR:PEFRpred were significantly 
greater in patients with cough compared to controls for both females and males 
(Table 6-4).  
There was no significant difference in expiratory muscle strength as assessed by 
Twitch T10 Pga between patients and controls (Table 6-5). Abdominal muscle 
compound muscle action potential (CMAP) amplitude during twitch magnetic 
stimulation at maximum power was similar between patients and controls (Table 
6-5). Maximal stimulation was confirmed by demonstration of a plateau in evoked 
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CMAP amplitude with increasing magnetic stimulator power output (Figure 6-3 and 
Appendix 7). 
Figure 6-2 The intensity of maximum voluntary cough 
  
Graphs on left show unadjusted values and graphs on right show values adjusted for 
inspired volume. Data presented as mean ± standard deviation. Poes: oesophageal 
pressure; Pga: gastric pressure; PCFR:PEFRpred: peak cough flow rate normalised to 
predicted peak expiratory flow rate; EMGabdo:Tw: abdominal electromyographic 
activity normalised to EMGabdo during twitch magnetic stimulation; IV: inspired 
volume of air prior to cough. 
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Table 6-4 The intensity of maximum voluntary cough 











Poes (cmH2O) 172 ± 46 130 ± 33 0.018
* 189 ± 44 180 ± 58 0.681 
Pga (cmH2O) 195 ± 37 152 ± 41 0.011
* 212 ± 56 212 ± 60 0.999 
PCFR (L/min) 584±129 451±151 0.022* 713±241 853±184 0.139 
PCFR:PEFRpred 161 ± 35 120 ± 47 0.017
* 138 ± 40 161 ± 26 0.250 
EMGabdo:Tw 0.12 ± 0.02 0.09 ± 0.01 0.441 0.11 ± 0.01 0.21 ± 0.04 0.152 
Inspired volume (L) 1.46 ± 0.44 1.78 ±0.49 0.093 1.62 ± 0.84 2.23 ± 0.60 0.030* 
       
Adjusted for IV       
Poes /IV 133 ± 66 79 ± 34 0.007
* 139 ± 60 82 ± 29 0.009* 
Pga/IV 150 ± 65 90 ± 35 0.012
* 167 ± 92 96 ± 32 0.015* 
PCFR:PEFRpred/IV 117 ± 34 75 ± 49 0.003
* 99 ± 40 72 ± 14 0.042* 
EMGabdo:Tw/IV 0.10 ± 0.09 0.06 ± 0.03 0.239 0.10 ± 0.11 0.10 ± 0.07 0.463 
Data presented as mean ± standard deviation. Maximum voluntary cough from 10 attempts. Poes: oesophageal pressure; Pga: gastric pressure; 
PCFR: peak cough flow rate; PCFR:PEFRpred peak cough flow rate normalised to predicted peak expiratory flow rate; EMGabdo:Tw: abdominal 
electromyographic activity normalised to EMGabdo during twitch magnetic stimulation; IV: inspired volume of air prior to cough; 
*: p<0.05.  
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Table 6-5 Respiratory muscle strength testing 
 Females  Males  
 Cough Controls P-value Cough Controls P-value 
Twitch T10 Pga (cmH2O) 21.9 (13.2-30.3) 23.0 (15.6-37.3) 0.36 28.5 (20.1-67.0) 21.6 (19.3-63.0) 0.75 
       
CMAP (mV) 1.10 ± 0.74 1.58 ± 1.22 0.65 2.60 ± 1.69 2.52 ± 2.55 0.54 
Data presented as median (IQR) or mean ± SD. Twitch T10 Pga: twitch gastric pressure; CMAP: abdominal compound muscle action potential. 
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Figure 6-3 Abdominal compound muscle action potential during magnetic 
stimulation 
  
Data presented as mean ± SEM abdominal compound muscle action potential 
(CMAP) amplitude. A plateau of the CMAP amplitude is seen with increasing 
magnetic stimulator power, with maximal stimulation being achieved at 90% of 
power output. Data provided in Appendix 7. 
Compressive phase duration (CPD) was significantly higher in female patients with 
cough compared to controls; mean ± SD CPD 0.50 ± 0.22 vs. 0.28 ± 0.17 seconds; 
mean difference 0.21 seconds; 95% CI of difference 0.05 to 0.36; p=0.007. There 
was no significant difference in CPD between male patients with cough and 
controls; mean ± SD CPD 0.35 ± 0.27 vs. 0.31 ± 0.18 seconds; p=1.00. BMI was not 
related to Poes, Pga, EMGabdo:Tw or PCFR; p=0.20 to 0.90.  
6.5.4 Cough intensity during capsaicin Induced cough 
To standardise induced coughs, only the first evoked event following inhalation of 
capsaicin and only subjects with a first event preceded by inspiration were included 
in this analysis (patients with cough n=10, controls n=11). Subjects were not 
subdivided by gender due to small numbers. Poes, Pga, and PCFR:PEFRpred were 
numerically greater in patients with cough compared to controls, but this did not 
reach statistical significance (Table 6-6). Taking account for inspired volume, there 
was a trend towards significance for greater Poes, Pga, and PCFR:PEFRpred in patients 
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with cough compared to controls (p=0.082, 0.054 and 0.084 respectively and 
p=0.282 for EMGabdo:Tw). In induced cough, CPD did not differ between groups 
(p=0.76).  







Poes (cm H2o) 136 ± 64 111 ± 43 0.312 
Pga (cm H2o) 143 ± 77 109 ± 39 0.224 
PCFR:PEFRpred 47 ± 19 36 ± 5 0.099 
EMGabdo:Tw 0.07 ± 0.04 0.08 ± 0.06 0.955 
Data presented as mean ± standard deviation. Data is for first evoked cough event 
(preceded by inspiration) following inhalation of capsaicin at supra-C5 concentration 
(one doubling concentration higher than that causing >5 coughs). Subjects were 
excluded from this analysis if their first event was an expiratory reflex. Poes: 
oesophageal pressure, Pga: gastric pressure, PCFR:PEFRpred: peak cough flow rate 
normalised to predicted peak expiratory flow rate; EMGabdo:Tw: abdominal 
electromyography normalised to EMGabdo during twitch magnetic stimulation. 
6.5.5 Cough intensity during spontaneous cough 
Baseline characteristics of the subgroup of patients undergoing spontaneous cough 
study are presented in Table 6-7. To standardise the analysis of spontaneous cough, 
single events and the first event of each bout were analysed. Due to small numbers, 
sub-analyses for gender or different cough types were not performed. All 
physiological measures of spontaneous cough were significantly lower (57-75%) 
than those of MVC, Table 2. PCFR:PEFRpred was significantly greater in spontaneous 
cough compared to induced cough, but Poes, Pga, and EMGabdo:Tw were comparable 
(Table 6-3). A greater number of induced cough events were ERs compared to 
spontaneous and MVC (Table 6-3). In spontaneous cough, mean ± SD PCFR:PEFRpred 
was significantly greater in coughs preceded by inspiration compared to ER; 94 ± 37 
vs. 48 ± 25; mean difference 51, 95% CI of difference 16 to 85; p=0.010.  
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Table 6-7 Spontaneous cough subgroup baseline characteristics 
Characteristic Value 
Age (years) 60 ± 13 
Male: Female 4:5 
BMI (kg/m2) 28.3 ± 5.5 
FEV1 (% predicted) 92 ± 24 
FVC (% predicted) 100 ± 27 
FEV1/FVC (%) 76 ± 10 
Data presented as mean ± SD or n. BMI: body mass index; FEV1: forced expiratory 
volume in 1 second; FVC: forced vital capacity; LCQ: Leicester Cough Questionnaire 
(range 3-21; higher score reflects better health status). 
6.5.6 Intensity of expiratory reflexes during spontaneous cough 
Poes, Pga and PCFR:PEFRpred were greater for coughs preceded by an inspiration than 
for expiratory reflexes during spontaneous cough (Table 6-8). The differences in Poes 
and cough flow were significant between female patients and healthy controls and 
there was a trend to significance for Pga. The differences in cough intensity between 
male patients and controls failed to reach statistical significance (Table 6-8). 
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Table 6-8 Intensity of expiratory reflexes and coughs during spontaneous cough 






 Cough ER p-value Cough ER p-value Cough ER p-value 
Poes 148 ± 45 94 ± 27 <0.01* 141 ± 17 99 ± 20 0.02* 156 ± 69 94 ± 27 0.11 
Pga 169 ± 63 90 ± 34 <0.01* 164 ± 54 97 ± 27 0.06 174 ± 79 81 ± 47 0.23 
PCFR 411 ± 136 182 ± 87 <0.01* 455 ± 86 218 ± 63 <0.01* 356 ± 179 182 ± 87 0.06 
PCFR:PEFRpred 102 ± 38 48 ± 25 <0.01* 126 ± 23 61 ± 18 <0.01* 73 ± 32 5 ± 25 0.06 
Data presented as mean ± SD. Comparisons made between coughs and expiratory reflexes that occurred as single events or as the first event of 
bouts. Mann-Whitney tests or t-tests, depending on distribution of data. Poes: oesophageal pressure; Pga: gastric pressure; PCFR: peak cough 





6.5.7 Subjective assessment of cough intensity 
There was an association between subjective ratings of intensity of voluntary cough 
and physiological measures within subjects (Table 6-9). The median correlation 
coefficients (r) were: Poes 0.84, Pga 0.86, PCFR 0.82 and EMGabdo 0.69 (all % of 
maximum measurement obtained for MVC). The relationship between subjective 
and objective assessments of cough intensity in a single patient is shown in Figure 
6-4. 
Table 6-9 The relationship between subjective rating and physiological measures 
of cough intensity during voluntary cough 
Subject Poes Pga PCFR EMGabdo 
1 0.72†† 0.75†† 0.41 0.62 
2 0.77† 0.86† 0.73†† 0.62 
3 0.90* - 0.77† 0.90* 
4 0.59 0.70†† 0.62 0.53 
5 0.96* 0.95* 0.96* - 
6 0.96* 0.96* 0.87* 0.90* 
7 0.70* 0.85* 0.58 0.70* 
8 0.94* 0.92* 0.88* 0.83† 
     
Median 0.84 0.86 0.82 0.69 
Data presented as Spearman correlation coefficients between cough visual analogue 
score and objective measures of cough intensity. * p<0.001; † p=0.001 to 0.01; †† 
p=0.01 to 0.05. Poes: oesophageal pressure; Pga: gastric pressure; PCFR: peak cough 
flow rate; EMGabdo: abdominal electromyographic activity. Subjects 3 and 5 have no 




Figure 6-4 An example of the relationship between subjective and objective 
assessments of cough intensity in a patient with chronic cough 
  
Graphs showing relationship between cough intensity visual analogue score and 
physiological cough intensity measures during voluntary cough in a patient with 
chronic cough. Spearman correlation coefficients. VAS: visual analogue scale; Poes: 
oesophageal pressure; Pga: gastric pressure; PCFR: peak cough flow rate; EMGabdo: 




Few studies have investigated the physiological characteristics of cough in patients 
with chronic cough. This study has shown that most induced and spontaneous 
efforts occur within bouts. The most common sequence within a bout was a cough 
effort followed by ERs. ER however occurred more frequently as the very first effort 
during induced cough than during spontaneous cough. For both females and males 
with cough, maximum voluntary cough intensity was greater than that in healthy 
controls when adjusted for inspired volume. There was no difference in activation 
of abdominal muscles as measured by EMGabdo or the contractile response to lower 
thoracic nerve root magnetic stimulation as measured by Twitch T10 Pga between 
patients and controls. The compressive phase duration was greater in female 
patients compared to healthy controls, although this difference was not seen in 
males. There was a strong correlation between subjective assessment of cough 
intensity and objective physiological measures of cough intensity.  
Expulsive efforts were categorised as cough or ER based on the presence or absence 
of an inspiratory phase preceding the expulsive phase. Spontaneous cough 
consisted largely of bouts which contained cough efforts followed by ERs. This was 
also true for induced cough with the exception of the very first effort of the first 
bout, where the proportion of ERs compared to coughs were greater than that of 
the first effort of the spontaneous bouts. The ER is thought to be a distinct airway 
reflex [123, 127]. The lack of a preceding inspiratory effort may be advantageous in 
some circumstances to avoid aspiration of laryngeal contents. Physiological cough 
intensity measures of ERs were significantly lower than those of cough efforts 
preceded by an inspiration. The differences between male patients and controls did 
not reach statistical significance but this is likely due to the small numbers studied. 
Cough flow and volume is dependent on the starting lung volume [125]. Since ERs 
occur without a preceding inspiration, they are more likely to occur at lower lung 
volume, and this may explain why the flow rate was significantly lower in induced 
compared to spontaneous cough [107]. It is important to note that there is a lack of 
consensus on the importance of the distinction between coughs and ERs. Whilst the 
lack of a preparatory inspiration in the ER represents a clear physiological 
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difference, the characteristic sound associated with the expulsive phase for both is 
similar and some investigators argue that both reflexes should be regarded equally 
as a cough [282].  Further evaluation of the clinical importance of the ER is needed. 
However, the potential differences between cough and ER should be accounted for 
in future studies of cough intensity. 
Cough intensity was significantly greater in patients with chronic cough compared 
with healthy controls. Cough intensity measures were adjusted for inspired volume, 
since this has previously been shown to be an important determinant of peak cough 
flow [125]. The control group voluntary cough intensity data in this study was 
comparable to that reported by other investigators, suggesting that the differences 
observed were due to increased cough intensity in patients with cough [207, 283]. 
Our data suggests patients with cough have an enhanced ability to generate 
thoracic and abdominal pressure and flow for any given inspired volume. The 
increase in cough intensity was not due to increased activation of abdominal 
muscles as measured by EMGabdo, or contractility as measured by Twitch T10 Pga. 
Other investigators have also reported an enhanced cough without evidence of an 
increase in muscle strength [284]. It is possible that cough pressures were increased 
by an improved coordination of the cough manoeuvre. The findings of this study 
raise the possibility that, in female subjects, the increased cough intensity may have 
been due to an increase in the compressive phase duration. The compressive phase 
consists of rising thoracic pressure against a closed glottis. A longer glottis closure 
time may allow more time for thoracic pressure to rise closer to its maximum. It is 
not clear why the compressive phase duration was increased in female patients, but 
one hypothesis would be a learning effect. Methodological limitations need careful 
consideration since glottis closure was assessed indirectly and furthermore, an 
increase in compressive phase duration was not seen in male subjects. Future 
studies should include assessments of laryngeal movement and function. Another 
possibility for the increase in voluntary cough intensity is that, in patients with 
cough, muscles other than those assessed by twitch T10 magnetic stimulation are 
activated. In capsaicin induced cough, pressures and flow were numerically greater 
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in patients with cough compared with healthy controls, but the differences did not 
reach statistical significance and larger studies are needed.  
Few studies have investigated the physiology of spontaneous cough in patients with 
chronic cough. Spontaneous cough intensity was shown to be between 57-75% of 
that seen in MVC. This is not surprising since persistent coughing at an intensity 
equivalent to 100% MVC is likely to be associated with symptoms such as syncope. 
Lasserson et al demonstrated differences in the patterns of muscle EMG activation 
between voluntary and induced cough [133].  The significant additional reserve in 
cough intensity during MVC may be due to voluntary recruitment and/or 
coordination of muscles that are capable of generating the high intra-abdominal 
pressures required for other functions such as vomiting or labour. EMGabdo, Pga and 
Poes in spontaneous cough were comparable to those for capsaicin induced cough. 
Cough flow, however, was significantly lower in induced cough, 40% of that in 
spontaneous cough. The disproportionately low peak cough flow relative to 
pressure may suggest a failure of transmission of intra-thoracic pressure into flow 
during capsaicin induced cough. Future studies should investigate potential 
mechanisms for this. The physiological differences between induced and 
spontaneous cough may be important for explaining the differences in the efficacy 
of some antitussive drugs between pre-clinical models and clinical trials of patients 
with spontaneous cough.   
The intensity of cough was well judged by most patients when asked to rate the 
intensity of voluntary cough. EMG, pressure and flow all correlated well with 
subjective ratings of cough intensity. The relationship between cough intensity VAS 
and pressure was marginally better than that with flow. Flow, however, is easier 
and more practical to measure because it is non-invasive. Flow may therefore be 
the objective measure of choice to assess cough intensity. The study of subjective 
ratings of cough intensity ought to be repeated in larger numbers and extended to 
spontaneous cough in patients with chronic cough. The mechanism by which the 
brain receives information relating to the perception of cough effort requires 
further investigation.  
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There were some limitations to this study. A relatively small number of patients 
were studied. The wide standard deviations seen in some measures, such as 
expiratory muscle strength and oesophageal pressure are likely to be due to the 
small sample size. It was not possible to analyse induced and spontaneous cough 
physiological data in each gender or disease category separately due to the 
numbers studied and it is possible that intensity could have differed according to 
the aetiology. However, the aim of this study was to investigate the intensity of 
cough in patients with an isolated chronic cough, irrespective of the underlying 
cause. The comparison between ER and cough was also limited by small numbers 
and needs clarification in larger studies. Patients with chronic cough had a slightly 
greater body mass index than healthy controls, which could have had an impact on 
the physiological parameters assessed, but further analysis did not demonstrate any 
relationship between BMI and PCFR, Pga or Poes. Male patients with cough took 
smaller inspired volumes than controls and it is possible that this resulted in failure 
to achieve true maximum voluntary cough. A further study standardising inspired 
volumes is warranted to clarify this. Single voluntary coughs were studied, but not 
bouts of voluntary coughs. Other investigators, however, have demonstrated that 
the intensity of cough is similar between single efforts and bouts [125]. 
Furthermore, the relationship between cough pressure and inspired volume and 
cough flow has been reported to be best for the first cough of a bout [125, 285]. 
Respiratory muscle strength was assessed with a non-volitional measure (Twitch T10 
Pga) to obviate the effect of motivation but future studies could also consider 
maximum expiratory pressure (PE,max). Finally, whilst it is possible that the gastric 
pressure response to magnetic stimulation was not supramaximal, Twitch T10 Pga is 
known to be a repeatable measure used by many other investigators and the 
control group Twitch T10 Pga data was consistent with previous reports [217].   
6.7 Conclusion 
In conclusion, the intensity of voluntary cough is increased in patients with chronic 
cough. The mechanism for this is unclear but is unlikely to be due to an increase in 
expiratory muscle strength. Further studies should evaluate the larynx, particularly 
the compressive phase of cough. Physiological measures of the intensity of 
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voluntary cough correlate well with patients' subjective perception of cough 
intensity. Peak cough flow rate, oesophageal pressure and gastric pressure are 
important and relevant measures of cough intensity in patients with chronic cough. 
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7 The relationship between physiological measures of 
cough intensity and sound 
7.1 Abstract 
Rationale: In patients with chronic cough, the intensity of cough is an important 
determinant of global cough severity. Cough sound has been proposed as a 
measure of the intensity of coughs but few studies have validated its use against 
physiological measures. 
Objectives: To investigate the relationship between cough sound and physiological 
measures of cough intensity in patients with chronic cough and healthy controls. 
Methods: 17 patients with chronic cough and 15 healthy controls underwent 
contemporaneous measurements of cough sound, peak cough flow rate and 
oesophageal pressure. Cough sound was analysed for three time windows: phase 1 
(P1), phases 1-3 (P1-3) and 0.5 second window from onset of phase 1 (P0.5). A range 
of sound parameters was calculated for each time window (power (PW), peak 
energy (Ep), mean energy (Em), rise time, duration, peak frequency, bandwidth and 
centroid frequency). The relationships between sound and physiological measures 
were compared for P1, P1-3 and P0.5. The relationship between sound and subjective 
cough intensity visual analogue score (VAS) was evaluated in a subgroup. 
Repeatability of cough sounds and the effect of microphone position were also 
assessed.  
Results: Sound power and energy correlated strongly with cough flow (median 
Spearman r 0.88, 0.87 and 0.89 for P1 sound PW, Ep and Em respectively) and 
oesophageal pressure (median Spearman r 0.89, 0.89 and 0.90 for P1 sound PW, Ep 
and Em respectively). There was little difference in strength of correlations between 
sound measures analysed from P1, P1-3 or P0.5. PW and energy were also strongly 
correlated with cough intensity VAS. PW, Ep and Em were highly repeatable (ICC 




Conclusions: Cough sound power and energy correlate strongly with physiological 
measures of cough intensity and subjective perception of cough intensity. Analyses 
from phase 1 (P1) or 0.5 second (P0.5) time windows yield similar results, but the 
latter may be preferential due to the potential for automated analysis. Power and 
energy are highly repeatable measures but the microphone position is important 
and should be standardised and kept constant.  
7.2 Introduction 
In patients with chronic cough, the intensity of cough is an important determinant 
of global cough severity [140]. The intensity of cough can be assessed objectively 
with peak cough flow rate or oesophageal and gastric pressure. Limitations of cough 
flow and pressure are that they are either invasive or impractical to measure in an 
ambulatory setting. Recent technological advances have permitted the 
measurement of cough sounds continuously in the patients' own environment for 
the assessment of cough frequency [173]. Cough sound has been proposed as a 
measure of the intensity of coughs [184]. However, few studies have validated 
cough sound as a measure of cough intensity.  
7.3 Aims 
The aim of this study was to investigate the relationship between sound and 
physiological measures of cough intensity in patients with chronic cough and in 
healthy controls.  
7.4 Methods 
7.4.1 Subjects 
Consecutive patients referred for investigation of a chronic cough were recruited 
from a respiratory outpatient clinic. All patients had cough for greater than 8 weeks 
and were symptomatic at the time of recruitment. The cause of cough was 
established following investigation and trials of treatment according to a 
standardised protocol [36]. Exclusion criteria were smokers or history of smoking 
within the past 1 year and upper respiratory tract infection within the previous 4 
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weeks. Healthy control subjects were recruited from local advertising. Exclusion 
criteria for control subjects in addition to those listed above included symptoms of 
cough, history of respiratory disease and abnormal lung function. Ethical approval 
was granted by the East London and the City Research Ethics Committee 
(10/H0703/6). All subjects gave informed consent.  
7.4.2 Physiological measures of cough intensity 
7.4.2.1 Cough flow rate  
Respiratory flow was measured at the mouth using a Fleisch type 
pneumotachograph (P.K. Morgan ltd, Kent, UK) attached to a full-face mask (Hans 
Rudolph Inc, Kansas City, USA). The pneumotachograph was calibrated prior to each 
study by 2-point calibration with a rotameter. Peak cough flow rate (PCFR) was 
measured as the peak expiratory excursion during cough and expressed as a 
percentage of predicted peak expiratory flow rate (PEFRPred) to adjust for age, 
gender and height. 
7.4.2.2 Cough oesophageal pressure 
Thoracic (oesophageal pressure, Poes) was measured in accordance with American 
Thoracic Society recommendations [231]. A balloon catheter (Cooper Surgical, 
Berlin, Germany) was inserted nasally and positioned within the lower oesophagus. 
The balloon catheter was attached to a pressure transducer (MP45; Validyne, 
Northridge, CA, USA) and signal amplifier (CD-280; Validyne). Cough Poes was 
defined as the peak pressure during coughs. 
7.4.3 Cough sound 
Cough sounds were recorded using a free-field microphone (MKE 2-5-C, Sennheiser, 
Wedermark, Germany) placed 20 cm inferior to the mouth and a pizo-electric 
contact microphone (3017, Philips Respironics, Surrey, UK) placed over the larynx. 
The positions of the microphones were standardised for all subjects. The recordings 
were sampled at a frequency of 8,000 Hz, amplified (free field microphone gain x10, 
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contact microphone gain x3) and digitally filtered between 20 Hz and 4,000 Hz 
(1902 signal conditioner, Cambridge Electronic Design, Cambridge, UK) [183].  
A cough sound can comprise of up to 3 phases; explosive (phase 1), intermediate 
(phase 2) and voiced (phase 3), Figure 7-1. They correspond to glottal opening, 
steady-state flow and interruption of airflow due to narrowing of the glottis 
respectively [115]. Phase 3 is not always present and in its absence the 
identification of the termination of phase 2 becomes difficult due to the gradual 
dissipation of the signal [187, 188]. Therefore, the explosive phase (phase 1, P1) was 
selected for primary analysis since it is the most consistently present and 
identifiable of all phases. The onset and end of P1 was manually marked using Spike 
software (Figure 7-1). The duration from the onset of phase 1 to the end of phase 3, 
if present, (P1-3) was also manually marked for analysis (Figure 7-1). Finally, cough 
sounds were analysed using a constant time duration, 0.5 seconds from onset of 
Phase 1 (P0.5), since the mean duration of an entire cough sound (all phases) has 
previously been reported to fall within this duration (Figure 7-1) [192, 286]. P0.5 was 
considered sufficiently brief to avoid overlap with adjacent coughs and would 
provide preliminary data for potential automated analysis of these measures.  
Figure 7-1 Phases of cough sound 
 
Phases of classic 3-phase cough sound signal. TP1: phase 1 time window; TP1-3: 
phases 1-3 time window; T0.5: 0.5 second time window. 
167 
 
A custom script (MATLAB®, The MathWorks, Massachusetts, USA) was used to 
calculate the following sound parameters from the cough signal in a standardised 
manner: Peak energy (Ep), Mean energy (Em), rise time (RT), duration (D), power 
(PW), peak frequency (Fp), centroid frequency (Fc) and bandwidth (BW). Ep, Em and 
RT were calculated from the root mean square (RMS) of the cough signal in its time 
domain (to convert all values into positive values) (Figure 7-2) [260]. Ep was defined 
as the maximum value of the root mean square cough signal; Em was defined as the 
average RMS value per time frame of the cough signal (at a sampling frequency of 
8,333 Hz, each time frame was approximately 3.84 ms in duration); and RT was 
defined as the duration of time taken for the RMS cough signal to rise from 10% to 
90% of the peak energy value. PW, BW, Fp and Fc were calculated from the 
frequency spectrum of the cough signal following Fast Fourier Transformation 
(Figure 7-3) [187, 194]. PW was defined as the area under the curve (AUC) of the 
power spectral density (PSD); BW was defined as the frequency range or band 
containing 95% of the total spectral power; Fp was defined as the frequency at 
which 95% of the cumulative total spectral power was reached; and Fc was defined 
as the frequency at which the mass of the entire PSD signal spectrum was centred, 
that is, at 50% of the cumulative power (Figure 7-3). 
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Figure 7-2 Cough sound intensity parameters - time domain  
 
Top trace depicting a typical cough sound signal in the time series domain and lower 
trace depicting the root mean square (RMS) derivative. 
Figure 7-3 Frequency spectrum domain 
 




7.4.4 Lung function 
Spirometry and peak expiratory flow rate were measured in accordance with 
international guidelines [242, 243]. 
7.4.5 Protocol 
7.4.5.1 Relationship between cough sound intensity and Poes and peak 
cough flow 
Subjects were instructed to perform at least 10 single maximum voluntary coughs 
(MVC) until cough Poes reached a plateau and was repeatable. Sufficient time was 
allowed between cough efforts to avoid fatigue and to ensure the return of lung 
volume to functional residual capacity. Subjects were then asked to perform at least 
10 voluntary coughs within each of the following quintiles of cough intensity: 0-
20%, 21-40%, 41-60%, 61-80% and 81-100% of maximum voluntary cough Poes. Real-
time visual feedback with graphical demonstration of the Poes trace on a computer 
screen was used to guide subjects. All coughs were recorded and analysed 
individually. 
7.4.5.2 Repeatability 
In order to assess the repeatability of cough sound measures, 10 healthy subjects (6 
female) performed 10 maximum voluntary coughs on 2 occasions, 1 week apart. 
Cough peak flow rate and cough sounds were recorded using the free-field 
microphone. The microphone position was standardised for all subjects as 
described previously. 
7.4.5.3 Microphone position 
The impact of position of the microphone on cough sound measures was 
investigated by simultaneously recording cough sounds in 8 healthy subjects. 4 
identical free-field microphones were placed in different positions relative to the 
mouth. The standard microphone position (centre) was located 20 cm inferior to 
the mouth. 3 additional microphones were positioned 5cm superior, inferior and 
lateral to the standard position (Figure 7-4). Subjects were asked to produce 10 
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voluntary coughs of similar intensity. The coefficients of variation of the cough 
sound measures were calculated for each subject in order to ensure repeatability of 
the series of coughs. A coefficient of variation less than 10% was considered 
acceptable. The mean values for the sound parameters from each microphone 
position were compared.  
Figure 7-4 Microphone position  
 
Figure depicting positions of microphone for investigation of effect on cough sound 
measures. Centre microphone positioned 20 cm inferiorly to mouth. T: top; C: centre; 
B: bottom; L: left.  
7.4.5.4 Relationship between cough sound and subjective assessment of 
cough intensity 
A subgroup of 8 subjects with chronic cough was instructed to produce at least 10 
single voluntary coughs of varying intensity in a random order. Subjects were 
blinded to all physiological and sound measures of cough. After each cough effort, 
subjects were asked to subjectively rate the intensity of the cough on a 100 mm VAS 
scale. VAS scores and cough intensity measures for all coughs were then compared 




Physiological and sound data for coughs were time synchronised, converted from 
analogue to digital format (Micro 1401 mk II; Cambridge Electronic Design, 
Cambridge, UK) and analysed with Spike 2 version 6 software (Cambridge Electronic 
Design, Cambridge, UK) on a computer. Statistical analysis was performed using 
SPSS version 19 (IBM) and Prism version 5 (GraphPad). Appropriate parametric or 
non-parametric tests were used depending on distribution of the data. Within-
subject correlations were calculated between cough sound parameters and 
physiological measures (PCFR:PEFRpred and Poes) using Spearman correlation 
coefficients. To demonstrate a correlation coefficient ρ=0.5 between cough sound 
and peak cough flow rate or Poes against a null hypothesis of ρ=0 with 80% power 
and 5% error, a sample size of 29 subjects was required. To assess repeatability, 
intra-class correlation coefficients (2-way average) were calculated for the cough 
sound parameters between visits 1 and 2. In order to study the impact of 
microphone position on cough sound intensity, an analysis of variance (ANOVA) was 
performed for cough sound parameters from each microphone position, and paired 
t-tests between the centre and other positions. All sound analyses were derived 
from the free-field microphone unless otherwise stated. 
7.5 Results 
17 patients with chronic cough and 15 healthy subjects were recruited. Baseline 
characteristics are given in Table 7-1. The causes of cough in patients were asthma 
(24%), gastro-oesophageal reflux disease (24%), eosinophilic bronchitis (6%), post-
infectious (6%), bronchiectasis (6%) and idiopathic (35%). 
1058 coughs from patients and 758 coughs from healthy subjects were recorded 
and analysed. The maximum peak cough flow, Poes and key sound measures during 
MVC are presented in Table 7-2. 
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Male (n, %) 6 (35) 7 (47) 0.720 
Age (years) 55 ± 16 47 ± 21 0.317 
BMI (kg.m-2) 28 ± 7 24 ± 1 0.101 
FEV1 (% predicted) 96 ± 17 100 ± 17 0.541 
FVC (% predicted) 107 ± 18 108 ± 20 0.855 
FEV1/FVC (%) 75 ± 7 78 ± 8 0.301 
Duration of cough (months) 34 (24-85) - - 
Data presented as mean ± SD, n (%) or median (IQR). BMI: body mass index; FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity. 
Table 7-2 Physiological and sound measures during maximum voluntary cough 
 Patients Controls P-value 
PCFR (L/min) 653 ± 200 674 ± 288 0.808 
PCFR:PEFRpred 1.50 ± 0.36 1.44 ± 0.46 0.674 
Poes (cmH2O) 184 ± 48 155 ± 52 0.115 
 
Free Field microphone 
   
PW  47.6 ± 1.7 49.6 ± 2.0 0.457 
PW coefficient of variation 14.9% 16.0%  
Ep  1.09 ± 0.74 1.30 ± 1.06 0.792 
Ep coefficient of variation 67.6% 81.6%  
    
Contact microphone    
PW   39.2 ± 7.4 42.9 ± 8.0 0.308 
PW coefficient of variation 18.8% 18.6%  
Ep  0.39 ± 0.26 0.57 ± 0.40 0.308 
Ep coefficient of variation 68.1% 70.6%  
Data presented as mean ± SD. Cough sound analysed from phase 1 (P1) of cough 
sound. PCFR: peak cough flow rate; PCFR:PEFRpred: peak cough flow rate normalised 
to predicted peak expiratory flow rate; Poes: oesophageal pressure; PW: power; Ep: 
peak energy.  
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7.5.1 Relationship between physiological and cough sound measures 
7.5.1.1 Flow 
The correlation coefficients between PCFR:PEFRpred and sound measures derived 
from P1, P1-3 and P0.5 are presented in Table 7-3. The sound parameters with the 
strongest correlations with PCFR:PEFRpred were power (PW), peak energy (Ep) and 
mean energy (Em) (Table 7-3). The median (interquartile range) within-subject 
correlation coefficient between sound PW and PCFR:PEFRpred was 0.88 (0.78-0.93), 
all individual subject p-values <0.001 (Table 7-3). These relationships remained 
strong when patients, controls and gender were analysed separately (Table 7-4 to 
Table 7-6). A representative example is shown in Figure 7-5. The correlations 
between sound power and energy and PCFR:PEFRpred were marginally superior with 









Sound analysis time window 
 
 
P1 P1-3 P0.5 
PW 0.88 (0.78-0.93) 0.82 (0.60-0.90) 0.88 (0.79-0.92) 
Ep 0.87 (0.78-0.92) 0.81 (0.56-0.90) 0.87 (0.79-0.91) 
Em 0.89 (0.78-0.92) 0.79 (0.38-0.89) 0.87 (0.79-0.92) 
RT 0.31 (0.02-0.48) 0.01 (-0.18-0.3) 0.23 (-0.05-0.42) 
D 0.29 (-0.11-0.59) 0.60 (0.23-0.82) -0.02 (-0.19-0.16) 
Fp 0.11 (-0.25-0.34) 0.35 (0.07-0.53) 0.17 (-0.06-0.45) 
BW -0.24 (-0.53-0.11) 0.05 (-0.16-0.35) -0.10 (-0.35-0.19) 
Fc 0.49 (0.25-0.71) 0.63 (0.26-0.79) 0.48 (0.19-0.78) 
 
b) Oesophageal pressure 
Sound parameter 
 
Sound analysis time window 
 
 
P1 P1-3 P0.5 
PW 0.89 (0.84-0.95) 0.85 (0.65-0.91 0.89 (0.81-0.94) 
Ep 0.89 (0.82-0.95) 0.85 (0.58-0.93) 0.89 (0.82-0.94) 
Em 0.90 (0.80-0.94) 0.80 (0.45-0.87) 0.88 (0.83-0.95) 
RT 0.35 (-0.04-0.45) 0.05 (-0.33-0.53) 0.23 (-0.13-0.5) 
D 0.23 (-0.11-0.54) 0.70 (0.47-0.84) 0.01 (-0.15-0.18) 
Fp 0.06 (-0.30-0.41) 0.36 (0.12-0.60) 0.26 (-0.11-0.46) 
BW -0.40 (-0.58-0.10) 0.06 (-0.13-0.39) -0.15 (-0.43-0.24) 
Fc 0.53 (0.22-0.76) 0.68 (0.48-0.82) 0.53 (0.25-0.80) 
Data presented as median (IQR) within-subject Spearman correlation coefficients for 
patients with chronic cough and healthy controls combined. Sound recorded with 
free-field microphone. The correlations were similar when patients and controls 
were analysed separately (Table 7-4 to Table 7-6). PW: power; Ep: peak energy; Em: 




Table 7-4 The relationship between P1 cough sound, flow and oesophageal pressure 
a) Flow 
P1 sound parameter All subjects Females Males Patients Controls 
PW 0.88 (0.78-0.93) 0.83 (0.78-0.92) 0.92 (0.87-0.95) 0.79 (0.76-0.92) 0.89 (0.85-0.95) 
Ep 0.87 (0.78-0.92) 0.84 (0.77-0.89) 0.91 (0.86-0.96) 0.82 (0.76-0.92) 0.89 (0.86-0.95) 
Em 0.89 (0.78-0.92) 0.85 (0.74-0.92) 0.91 (0.88-0.95) 0.79 (0.73-0.92) 0.89 (0.87-0.94) 
RT 0.31 (0.02-0.48) 0.29 (0.05-0.42) 0.33 (-0.02-0.48) 0.28 (-0.08-0.43) 0.41 (0.12-0.48) 
D 0.29 (-0.11-0.59) 0.15 (-0.21-0.60) 0.43 (-0.11-0.62) 0.47 (-0.08-0.69) 0.02 (-0.17-0.43) 
Fp 0.11 (-0.25-0.34) 0.18 (-0.24-0.34) 0.10 (-0.28-0.49) 0.03 (-0.22-0.32) 0.28 (-0.27-0.45) 
BW -0.24 (-0.53-0.11) -0.22 (-0.54-0.11) -0.41 (-0.57-0.09) -0.26 (-0.63-0.02) -0.16 (-0.53-0.11) 
Fc 0.49 (0.25-0.71) 0.47 (0.18-0.68) 0.61 (0.29-0.75) 0.47 (0.21-0.67) 0.62 (0.24-0.83) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1 cough sound and cough flow. Sound recorded 
with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: mean 




Table 7-4 The relationship between P1 cough sound from a free-field microphone, flow and oesophageal pressure 
b) Oesophageal pressure 
P1 sound parameter All subjects Females Males Patients Controls 
PW 0.89 (0.84-0.95) 0.87 (0.81-0.91) 0.94 (0.88-0.96) 0.88 (0.85-0.94) 0.91 (0.82-0.95) 
Ep 0.89 (0.82-0.95) 0.84 (0.81-0.91) 0.94 (0.88-0.96) 0.84 (0.81-0.94) 0.91 (0.86-0.95) 
Em 0.90 (0.80-0.94) 0.85 (0.77-0.92) 0.94 (0.87-0.95) 0.87 (0.78-0.94) 0.92 (0.85-0.94) 
RT 0.35 (-0.04-0.45) 0.35 (-0.02-0.42) 0.40 (-0.06-0.48) 0.35 (-0.14-0.45) 0.36 (0.07-0.46) 
D 0.23 (-0.11-0.54) 0.10 (-0.26-0.51) 0.37 (-0.07-0.61) 0.51 (-0.03-0.55) -0.05 (-0.26-0.42) 
Fp 0.06 (-0.30-0.41) 0.16 (-0.3-0.43) 0.00 (-0.31-0.53) 0.05 (-0.31-0.38) 0.08 (-0.29-0.47) 
BW -0.40 (-0.58-0.10) -0.43 (-0.59-0.10) -0.34 (-0.64-0.11) -0.34 (-0.70-0.10) -0.43 (-0.52-0.11) 
Fc 0.53 (0.22-0.76) 0.52 (0.20-0.80) 0.64 (0.26-0.76) 0.52 (0.24-0.78) 0.64 (0.22-0.76) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1 cough sound and oesophageal pressure. Sound 
recorded with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: 
mean energy; RT: rise time; D: duration; Fp: peak frequency; BW: bandwidth; Fc: centroid frequency. 
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Table 7-5 The relationship between P1-3 cough sound, flow and oesophageal pressure 
a) Flow 
P1-3 sound parameter All subjects Females Males Pts Controls 
PW 0.82 (0.60-0.90) 0.80 (0.56-0.90) 0.85 (0.63-0.94) 0.79 (0.59-0.89) 0.83 (0.65-0.95) 
Ep 0.81 (0.56-0.90) 0.79 (0.49-0.89) 0.84 (0.59-0.96) 0.77 (0.55-0.87) 0.89 (0.60-0.96) 
Em 0.79 (0.38-0.89) 0.79 (0.38-0.88) 0.80 (0.21-0.92) 0.73 (0.45-0.87) 0.80 (0.31-0.93) 
RT 0.01 (-0.18-0.3) -0.03 (-0.25-0.29) 0.16 (-0.18-0.60) -0.05 (-0.18-0.27) 0.27 (-0.21-0.56) 
D 0.60 (0.23-0.82) 0.59 (0.23-0.78) 0.64 (0.22-0.84) 0.58 (0.24-0.77) 0.66 (0.23-0.83) 
Fp 0.35 (0.07-0.53) 0.16 (-0.21-0.43) 0.39 (0.27-0.63) 0.34 (0.07-0.53) 0.38 (0.03-0.57) 
BW 0.05 (-0.16-0.35) -0.08 (-0.38-0.10) 0.30 (0.21-0.38) -0.03 (-0.21-0.28) 0.22 (-0.02-0.45) 
Fc 0.63 (0.26-0.79) 0.41 (0.07-0.79) 0.67 (0.52-0.78) 0.64 (0.35-0.79) 0.57 (0.11-0.77) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1-3 cough sound and cough flow. Sound recorded 
with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: mean 




Table 7-5 The relationship between P1-3 cough sound, flow and oesophageal pressure 
b) Oesophageal pressure 
P1-3 sound parameter All subjects Females Males Pts Controls 
PW 0.85 (0.65-0.91) 0.85 (0.65-0.89) 0.90 (0.63-0.96) 0.85 (0.59-0.89) 0.88 (0.67-0.95) 
Ep 0.85 (0.58-0.93) 0.82 (0.58-0.88) 0.93 (0.49-0.97) 0.82 (0.49-0.88) 0.90 (0.58-0.97) 
Em 0.80 (0.45-0.87) 0.78 (0.46-0.85) 0.84 (0.44-0.93) 0.79 (0.44-0.84) 0.84 (0.43-0.93) 
RT 0.05 (-0.33-0.53) -0.05 (-0.35-0.45) 0.20 (-0.21-0.65) -0.06 (-0.35-0.32) 0.38 (-0.20-0.70) 
D 0.70 (0.47-0.84) 0.72 (0.45-0.82) 0.70 (0.59-0.85) 0.64 (0.45-0.80) 0.76 (0.52-0.85) 
Fp 0.36 (0.12-0.60) 0.16 (-0.11-0.53) 0.43 (0.23-0.73) 0.31 (0.16-0.56) 0.39 (0.09-0.62) 
BW 0.06 (-0.13-0.39) -0.05 (-0.24-0.21) 0.32 (0.00-0.46) -0.06 (-0.30-0.28) 0.29 (-0.03-0.43) 
Fc 0.68 (0.48-0.82) 0.60 (0.23-0.77) 0.69 (0.60-0.87) 0.69 (0.31-0.79) 0.66 (0.60-0.86) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1-3 cough sound and oesophageal pressure. Sound 
recorded with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: 




Table 7-6 The relationship between P0.5 cough sound, flow and oesophageal pressure 
a) Flow 
P0.5 sound parameter All subjects Females Males Patients Controls 
PW 0.88 (0.79-0.92) 0.85 (0.77-0.90) 0.93 (0.83-0.96) 0.80 (0.77-0.91) 0.91 (0.85-0.96) 
Ep 0.87 (0.79-0.91) 0.81 (0.78-0.87) 0.91 (0.84-0.95) 0.81 (0.76-0.90) 0.89 (0.82-0.95) 
Em 0.87 (0.79-0.92) 0.85 (0.77-0.91) 0.92 (0.84-0.95) 0.84 (0.76-0.92) 0.91 (0.85-0.95) 
RT 0.23 (-0.05-0.42) 0.17 (-0.07-0.32) 0.25 (-0.05-0.51) 0.10 (-0.06-0.33) 0.27 (0.04-0.48) 
D N/A N/A N/A N/A N/A 
Fp 0.17 (-0.06-0.45) 0.27 (-0.25-0.45) 0.14 (-0.01-0.50) 0.13 (-0.05-0.40) 0.38 (-0.25-0.47) 
BW -0.10 (-0.35-0.19) -0.10 (-0.44-0.21) -0.19 (-0.32-0.12) -0.10 (-0.34-0.13) -0.03 (-0.46-0.26) 
Fc 0.48 (0.19-0.78) 0.36 (0.16-0.79) 0.51 (0.21-0.79) 0.36 (0.18-0.61) 0.65 (0.19-0.81) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P0.5 cough sound and cough flow. Sound recorded 
with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: mean 
energy; RT: rise time; D: duration; Fp: peak frequency; BW: bandwidth; Fc: centroid frequency. 
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Table 7-6 The relationship between P0.5 cough sound, flow and oesophageal pressure 
b) Oesophageal pressure 
P0.5 sound parameter All subjects Females Males Patients Controls 
PW 0.89 (0.81-0.94) 0.87 (0.76-0.89) 0.94 (0.92-0.96) 0.89 (0.79-0.92) 0.89 (0.83-0.96) 
Ep 0.89 (0.82-0.94) 0.84 (0.80-0.89) 0.94 (0.88-0.96) 0.88 (0.82-0.93) 0.89 (0.80-0.96) 
Em 0.88 (0.83-0.95) 0.85 (0.78-0.89) 0.95 (0.91-0.96) 0.89 (0.83-0.92) 0.88 (0.84-0.96) 
RT 0.23 (-0.13-0.50) 0.11 (-0.24-0.37) 0.25 (-0.11-0.56) 0.11 (-0.19-0.50) 0.25 (0.01-0.52) 
D N/A N/A N/A N/A N/A 
Fp 0.26 (-0.11-0.46) 0.32 (-0.14-0.47) 0.13 (-0.04-0.55) 0.23 (-0.10-0.42) 0.30 (-0.14-0.53) 
BW -0.15 (-0.43-0.24) -0.13 (-0.46-0.32) -0.19 (-0.39-0.12) -0.19 (-0.41-0.18) -0.03 (-0.48-0.32) 
Fc 0.53 (0.25-0.80) 0.50 (0.25-0.79) 0.65 (0.24-0.82) 0.50 (0.28-0.71) 0.61 (0.18-0.87) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P0.5 cough sound and oesophageal pressure. Sound 
recorded with free-field microphone. Peak cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: 
mean energy; RT: rise time; D: duration; Fp: peak frequency; BW: bandwidth; Fc: centroid frequency.  
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Table 7-7 The relationship between P1 cough sound from a contact microphone, flow and oesophageal pressure 
a) Flow 
P1 sound parameter All subjects Females Males Patients Controls 
PW 0.82 (0.71-0.91) 0.79 (0.68-0.89) 0.89 (0.78-0.93) 0.82 (0.74-0.91) 0.81 (0.68-0.89) 
Ep 0.83 (0.74-0.90) 0.80 (0.72-0.89) 0.89 (0.82-0.92) 0.82 (0.75-0.90) 0.84 (0.72-0.89) 
Em 0.81 (0.72-0.90) 0.75 (0.70-0.86) 0.89 (0.77-0.92) 0.81 (0.73-0.92) 0.81 (0.70-0.89) 
RT 0.20 (-0.06-0.35) 0.19 (-0.09-0.33) 0.21 (0.05-0.46) 0.15 (-0.09-0.43) 0.21 (0.14-0.33) 
D 0.29 (-0.11-0.59) 0.15 (-0.21-0.60) 0.43 (-0.11-0.62) 0.47 (-0.08-0.69) 0.02 (-0.17-0.43) 
Fp 0.20 (-0.19-0.62) 0.15 (-0.21-0.39) 0.57 (0.01-0.76) 0.17 (-0.17-0.52) 0.39 (-0.21-0.72) 
BW -0.09 (-0.46-0.33) -0.17 (-0.48-0.08) 0.03 (-0.24-0.41) -0.09 (-0.52-0.23) 0.01 (-0.42-0.33) 
Fc 0.68 (0.33-0.86) 0.49 (0.10-0.71) 0.86 (0.70-0.91) 0.62 (0.36-0.72) 0.81 (0.11-0.92) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1 cough sound and cough flow. Peak cough flow 
rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: mean energy; RT: rise time; D: duration; Fp: peak 
frequency; BW: bandwidth; Fc: centroid frequency. 
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Table 7-7 The relationship between P1 cough sound from a contact microphone, flow and oesophageal pressure 
b) Oesophageal pressure 
P1 sound parameter All subjects Females Males Patients Controls 
PW 0.86 (0.76-0.90) 0.83 (0.70-0.88) 0.90 (0.86-0.94) 0.88 (0.81-0.92) 0.83 (0.68-0.90) 
Ep 0.86 (0.79-0.90) 0.83 (0.75-0.89) 0.90 (0.87-0.93) 0.89 (0.82-0.92) 0.84 (0.75-0.90) 
Em 0.85 (0.77-0.90) 0.85 (0.72-0.88) 0.88 (0.83-0.93) 0.88 (0.85-0.93)† 0.80 (0.72-0.88) 
RT 0.21 (-0.07-0.42) 0.21 (-0.08-0.45) 0.28 (0.06-0.48) 0.22 (-0.12-0.48) 0.20 (0.03-0.45) 
D 0.23 (-0.11-0.54) 0.10 (-0.26-0.51) 0.37 (-0.07-0.61) 0.51 (-0.03-0.55) -0.05 (-0.26-0.42) 
Fp 0.21 (-0.19-0.73) 0.08 (-0.25-0.49) 0.68 (0.05-0.81) 0.18 (-0.17-0.55) 0.41 (-0.21-0.81) 
BW -0.13 (-0.45-0.36) -0.18 (-0.51-0.16) 0.06 (-0.24-0.55) -0.14 (-0.45-0.26) -0.10 (-0.45-0.49) 
Fc 0.71 (0.43-0.92) 0.58 (0.22-0.74) 0.91 (0.74-0.94) 0.64 (0.43-0.84) 0.88 (0.17-0.94) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients between P1 cough sound and oesophageal pressure. Peak 
cough flow rate normalised to predicted peak expiratory flow rate. PW: power; Ep: peak energy; Em: mean energy; RT: rise time; D: duration; 




Figure 7-5 Relationship between cough sound and cough oesophageal pressure 
and flow in an individual patient with chronic cough 
 
Patient is a representative example. Cough sound power calculated from P1 time 
window. Spearman correlation coefficients.  
7.5.1.2 Pressure  
The correlation coefficients between Poes and sound measures derived from P1, P1-3 
and P0.5 are presented in Table 7-3. The strongest relationships with Poes were found 
with PW, Ep and Em. The median (IQR) within-subject correlation coefficient 
between PW and Poes was 0.89 (0.84-0.95), all individual subject p-values <0.001 ( 
Table 7-3 and Figure 7-5). The correlations between sound measures and Poes were 
similar to those with flow (Table 7-3). The correlations were also similar when 
patients, controls and gender were analysed separately (Table 7-4 to Table 7-6). 
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7.5.2 Relationship between physiological and sound measures using a 
constant time-window (P0.5) 
The correlation coefficients between cough sound PW, Ep and Em evaluated from a 
0.5-second time-window (P0.5) and cough flow and pressure were strong for all 
subjects (median correlation coefficient between PW, Ep and Em and cough flow 
0.88, 0.87 and 0.87 respectively and between PW, Ep and Em and pressure 0.89, 
0.89 and 0.88 respectively). These correlations were comparable to those evaluated 
from cough sound phase 1 and phase 1-3 (Table 7-3). 
7.5.3 Clinical characteristics affecting cough sound 
PW was selected for further analysis since it had a marginally superior relationship 
with flow and pressure (Table 7-4). Cough sound measures from free-field 
microphones were used in preference to contact microphones because of their 
marginally stronger correlations with cough flow (Table 7-4 and Table 7-7). Sound 
PW during MVC was significantly higher in males compared with females (mean ± 
SD PW 52.7 ± 8.4 vs. 45.7 ± 5.2, difference between means 7.1, 95% CI 2.2-12.0, 
p=0.006) (Figure 7-6). PW during MVC was not associated with age (ρ=-0.26), weight 
(ρ=0.15), BMI (ρ=-0.06), or FVC (ρ=0.34), and only weakly associated with height 
(ρ=0.39, p=0.026) and FEV1 (ρ=0.39, p=0.026). Subgroup analyses for individual 
diagnostic categories of cough were not performed due to sample size limitations. 
Figure 7-6 Gender differences in cough flow and sound during maximum 
voluntary cough 
 
Data presented as mean ± SD. Cough sound power calculated from phase 1 time 
window (P1) from free-field microphone.    
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7.5.4 Repeatability of cough sound measures 
The intraclass correlation coefficients (ICC) for cough sound PW, Ep and Em derived 
from P1 on two occasions were good (ICC 0.93, 0.94 and 0.89 respectively, all p-
values <0.01; Figure 7-7 and Table 7-8). For P0.5, the repeatability of PW and Ep 
were good (ICC 0.93 and 0.94, p≤0.001) but was weaker for Em (ICC 0.74, p=0.030; 
Table 7-8). There were no significant differences in sound PW between visits 1 and 2 
for P1 (p=0.489) or P0.5 (p=0.408). 
Figure 7-7 Repeatability of cough sound power during maximum voluntary 
cough 
 
Bland-Altman plot of cough sound power during maximum voluntary cough on two 
separate occasions. Power taken from free-field microphone. PW: power; ICC: 
intraclass correlation coefficient.  
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Table 7-8 Repeatability of cough sound measures during maximum voluntary 
cough 
 ICC P-value 
Phase 1, P1   
PW 0.93 <0.001 
Ep 0.94 <0.001 
Em 0.89 0.002 
 
0.5-second time-window, P0.5 
  
PW 0.93 <0.001 
Ep 0.94 <0.001 
Em 0.74 0.030 
Data presented as intraclass correlation coefficients (ICC). Sound recorded with free-
field microphone. PW: power; Ep: peak energy; Em: mean energy. 
7.5.5 Effect of microphone position on cough sound measures  
For all subjects, the coefficient of variation of cough sound PW for the 10 coughs 
was less than 10%, suggesting that the series of coughs were of similar intensity. 
Mean cough sound PW was greatest in the standard centre position (Table 7-9). 
There was a significant difference in mean PW between the centre position and all 
other positions (ANOVA, p<0.001) and the difference was greatest between the 
centre position and the bottom position (Table 7-9 and Figure 7-8). 
Table 7-9 The impact of microphone position on cough sound power 
 Cough sound power P-value vs. Centre 
Centre 55.8 ± 4.3 - 
Top 53.3 ± 5.3 0.004 
Bottom 48.8 ± 5.6 <0.001 
Left 54.0 ± 4.9 0.002 
Right 53.1 ± 4.8 <0.001 
Data presented as mean ± SD and paired t-test p-values. Data is for P1 sound power 
recorded with free-field microphone. 
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Figure 7-8 Effect of microphone position on cough sound power 
 
Upper graph shows mean ± SD sound power for each microphone position. Lower 
graph demonstrates the matched values for each subject. PW: power; C: centre; T: 
top; B: bottom; L: left; R: right. 
7.5.6 Relationship between cough sound and subjective assessment of 
cough intensity 
The median correlation coefficients between cough sound measures and subjective 
cough intensity visual analogue score are presented in Table 7-10. Individual p-
values for P1 sound are given in Table 7-11. The correlations were strongest for PW, 
Ep and Em. The correlations for constant time duration P0.5 were similar to those for 
phase 1 (P1). The relationships between free-field microphone derived cough 
sounds were generally better than those from the contact microphone (Table 7-10). 
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Table 7-10 The relationship between cough sound measures and subjective cough 
intensity visual analogue score in patients with chronic cough 
a) Phase 1, P1 
P1 sound parameter Correlation with cough intensity VAS 
Free-field microphone Contact microphone 
PW 0.84 (0.69-0.96) 0.76 (0.4273-0.90) 
Ep 0.86 (0.64-0.93) 0.62 (0.53-0.88) 
Em 0.76 (0.58-0.97) 0.67 (0.45-0.91) 
RT 0.29 (-0.04-0.78) 0.31 (-0.24-0.69) 
D 0.47 (0.20-0.75) 0.47 (0.20-0.75) 
Fp 0.32 (0.24-0.71) 0.70 (0.11-0.88) 
BW 0.10 (-0.20-0.30) 0.06 (-0.33-0.80) 
Fc 0.44 (0.16-0.87) 0.71 (0.62-0.79) 
 
b) 0.5-second time-window, P0.5 
P0.5 sound parameter Correlation with cough intensity VAS 
Free-field microphone Contact microphone 
PW 0.88 (0.67-0.90) 0.83 (0.46-0.85) 
Ep 0.77 (0.61-0.88) 0.68 (0.52-0.88) 
Em 0.86 (0.65-0.90) 0.71 (0.31-0.91) 
RT 0.32 (-0.09-0.66) 0.44 (-0.02-0.71) 
D 0.17 (0.00-0.31) 0.17 (0.00-0.31) 
Fp 0.43 (0.21-0.65) 0.30 (0.00-0.64) 
BW 0.03 (-0.62-0.32) 0.12 (-0.24-0.39) 
Fc 0.34 (0.06-0.72) 0.66 (0.31-0.78) 
Data presented as median (IQR) within-subject Spearman's correlation coefficients 
between cough sound and cough intensity visual analogue score (VAS). Individual 
correlation coefficients for P1 sound are presented in Table 7-11. PW: power; Ep: 
peak energy; Em: mean energy; RT: rise time; D: duration; Fp: peak frequency; BW: 
bandwidth; Fc: centroid frequency. 
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Table 7-11 Individual correlation coefficients between cough sound and cough 
intensity visual analogue score 
P1 Subject 
Sound parameter 1 2 3 4 5 6 7 8 
PW 0.85* 0.67* 0.38 0.82* 0.99* 0.73* 0.89* 0.98* 
Ep 0.70* 0.62 0.43 0.77* 0.98* 0.84* 0.88* 0.95* 
Em 0.72* 0.54 0.41 0.73* 0.99* 0.80* 0.91* 0.99* 
RT 0.44 -0.09 0.12 0.78* 0.90* -0.3 0.77* 0.14 
D 0.78* 0.15 0.41 0.66* 0.36 0.12 0.81* 0.54 
Fp 0.25 0.33 0.83* 0.32 0.76* 0.24 0.55* -0.16 
BW -0.64* 0.31 0.22 -0.15 0.26 -0.03 0.31 -0.21 
Fc 0.15 0.24 0.90* 0.18 0.65* 0.81* 0.89* -0.56 
Data presented as individual Spearman correlation coefficients between cough 
sound and cough intensity visual analogue score (VAS). Sound recorded with free 
field microphone and measures derived from P1 time window. *: p<0.05. 
7.6 Discussion 
This study has shown that cough sound power, peak energy and mean energy 
correlate strongly with peak cough flow rate and oesophageal pressure during 
voluntary cough. There was little difference in the strength of correlation between 
physiological measures and sound measures analysed from the first phase of cough 
sound, all three phases or a 0.5-second constant time window. Sound power and 
energy were strongly associated with subjective cough intensity visual analogue 
scores. The performance of sound measures from the free field microphone was 
marginally superior to that of sound measures from the contact microphone.  
 
Cough sounds have been studied by a number of investigators, but few have 
evaluated their potential as a measure of cough intensity [194-196, 241]. Pavesi et 
al used sound power as a measure of cough effort in a randomised controlled trial 
of dextromethorphan in acute cough but they did not assess the validity of PW for 
this purpose [183, 184]. To my knowledge, few studies have validated cough sound 
measures against a physiological measure of cough intensity. 
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The sound parameters selected for evaluation were chosen based on previous 
studies and knowledge of their properties [189, 196, 260, 287]. The parameters 
were derived from the time domain and the frequency spectrum domain (following 
Fast Fourier Transformation, FFT) of the cough sound signal. FFT is a widely used 
method for assessing power spectral density [183, 184, 187].  In this study, sound 
power, peak energy and mean energy had the best correlations with cough flow 
and oesophageal pressure. The data suggests that sound power may be better than 
energy since there was less variation during maximum voluntary coughs. Thorpe et 
al also reported a relationship between total power and peak flow of first cough 
phase, but the correlation was weak (ρ=0.42) [187]. However, they performed a 
group analysis of 114 voluntary coughs from 12 asthmatic and 5 healthy children of 
different ages. In contrast, I assessed within-subject correlations between sound 
and flow for an average of 57 coughs per subject. The other sound parameters such 
as peak frequency and centroid frequency had weaker relationships with flow, but 
there was a wide variation in strength of the association between individual 
subjects.  
 
The sound parameters were calculated for three pre-defined time windows within 
the cough signal (Phase 1, Phases 1-3 and constant 0.5-second duration from onset 
of Phase 1). It was found that there was little difference between P1 and P1-3 in their 
relationship with flow and pressure. This may be because P1 contains the majority 
of the energy in cough sounds [260]. P1 has the advantage of being present in all 
cough sounds, whereas the third phase in missing in some coughs [187]. However, 
the required manual marking of the onset and offset of P1 is labour intensive and 
therefore less practical in future. For this reason, P0.5, a time window with duration 
of 0.5 seconds from the onset of Phase 1, was also evaluated. The onset of Phase 1 
is easier to detect and hence is more potentially amenable for automated marking. 
Previous studies have reported the duration of cough sounds to be within this range 
[192, 286]. Sound power and energy from P0.5 was found to have a good 




The correlations between cough sound power and energy and subjective cough 
intensity visual analogue score were strong for most subjects, demonstrating that 
these measures are concordant with perception of cough intensity. The likely 
reason for the strength of the relationship is that sound power and energy are 
closely correlated with cough flow and pressure, which in turn are strongly 
associated with subjective cough intensity (Section 6.5.7). Future studies should 
assess the relationship between cough sound and health related quality of life.  
 
The factors that influence the intensity of sound are poorly understood. Differences 
in energy and power were found between gender and weak relationships found 
between sound and height and lung function. Other factors such as ethnicity, 
smoking and environmental exposures may also be important and warrant further 
investigation. A better understanding will allow the definition of normal ranges and 
predicted values to facilitate direct between-subjects comparisons. An alternative 
method for allowing between-subject comparisons is normalisation of sound 
measures to the values observed for each subject's maximum voluntary cough 
(MVC), a method used with other physiological measures such as electromyography 
[133, 214].  
 
The findings in this study demonstrate that cough sound power and energy are 
highly repeatable. The use of automated scripts to calculate all sound parameters 
ensured standardisation of their calculation. Responsiveness was not evaluated in 
this study and this should be formally assessed in future studies. However, the 
ability of cough sound to discriminate differing levels of cough intensity would 
suggest that it has the potential to be a responsive measure. 
 
Little difference in performance was found between sound measures derived from 
the free-field microphone and those derived from the contact microphone for their 
correlations with cough flow rate and oesophageal pressure. The free-field 
microphone yielded only marginally superior results. However, the performance of 
the free-field microphone was superior with respect to the relationship with 
subjective perception of cough intensity. The coefficient of variation of sound 
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power and energy during repeated maximum voluntary coughs was also slightly 
better with free-field microphones. Free-field microphones are generally more 
convenient and less prone to limitations that could affect contact microphones, 
such as quality of skin contact due to factors such as sweating and displacement. 
 
The position of the microphone was found to have an important affect on sound 
power and energy, with a noted reduction with displacement of the microphone in 
all directions from the standardised central position. Other studies have confirmed 
that distance from mouth affects the intensity of cough sounds [183]. 
Standardisation of microphone position is therefore essential for any future 
qualitative studies of cough sound.  
 
A potential application for cough sound measures of cough intensity is in the 
assessment over prolonged periods in an ambulatory setting. This would allow the 
study of any diurnal effect on cough intensity, similar to that of cough frequency 
[170]. A future role exists for combining cough monitoring technology to quantify 
cough frequency and intensity contemporaneously, permitting a more complete 
objective measure of global cough severity. 
 
There are some limitations to this study. The study was restricted to voluntary 
cough since this permitted the evaluation of a range of different cough intensities in 
a systematic manner. This study should be extended to spontaneous and induced 
cough in future. Only isolated single coughs were studied; the findings need to be 
confirmed for coughs occurring within bouts. The study was limited to healthy 
volunteers and patients with excessive cough. Future studies in patients with weak 
cough are warranted to validate the findings in this population. This study was not 
powered to perform subgroup analyses on patients with chronic cough by aetiology 
of cough and therefore any potential differences would need further investigation. 
The facemask, which was used to house a pneumotachograph for the measurement 
of cough flow, could have introduced a filtering effect of cough sounds. However, 
any filtering effect would have been constant for each subject, and only within-
subject analyses were performed. Furthermore, the performance of sound 
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measures from the laryngeal contact microphone, which would not have been 
affected by the facemask, was similar to that of the free-field microphone. Use of 
novel technologies such as optoelectronic or structured light plethysmography, 
which do not require a pneumotachograph and have been shown to correlate well 
with conventional spirometry, may be able to confirm these findings [288, 289]. 
Finally, all studies were performed in a quiet room, free from ambient noise. This 
was important to establish whether a relationship between sound and flow or 
pressure truly exists. Future ambulatory studies will need to accommodate for the 
effect of ambient noises.  
7.7 Conclusion 
Cough sound power and energy correlate strongly with physiological measures of 
cough intensity and subjective perception of cough intensity. Analyses from phase 1 
(P1) or 0.5 second (P0.5) time windows yield similar results, but the latter may be 
preferential due to the potential for automated analysis. The use of free field 
microphones is recommended due to marginal superiority over contact 
microphones. The position of the microphone should be standardised and kept 
constant throughout the study period. Future studies should assess the 




8 Discussion and conclusions 
8.1 Summary of key findings 
The aim of this thesis was to evaluate objective measures of cough frequency and 
cough intensity in patients with acute and chronic cough. 
Few studies have characterised cough frequency objectively in acute cough. The 
work within this thesis has demonstrated that in otherwise healthy subjects with 
acute cough, objective 24-hour cough frequency was elevated at baseline and 
health related quality of life was significantly impaired, similar to that of patients 
with chronic cough. 24-hour cough frequency reduced significantly over the 8-day 
study period and the minimal clinically important difference at 4 days was 
quantified as a 54% reduction from baseline. Minimal important differences for 
cough severity VAS and LCQ were also defined as 17 mm and 2.0 LCQ score changes 
respectively, allowing comprehensive sample size calculations for future clinical 
trials. This data has been used to power a multi-centre randomised placebo-
controlled trial of a new antitussive drug (EudraCT number: 2013-002728-17).  
The standard cough frequency monitoring duration is 24 hours and data defining 
24-hour cough frequency in health and disease exists. It is a repeatable and 
responsive measure, but its analysis can be time consuming [146]. A shorter 
monitoring duration could be more convenient for patients and practical for 
investigators. It was hypothesised that shorter duration daytime cough frequency 
would be comparable to 24-hour cough frequency since most coughs occur in the 
daytime [119]. Shorter duration cough frequency of between 1 and 6 hours 
duration were all found to correlate strongly with 24-hour cough frequency. Those 
less than 4 hours in duration were limited by weak relationships with subjective 
measures of cough. 4-hour cough frequency bore a similar relationship with 
subjective cough severity and health related quality of life to that of 24-hour cough 
frequency and, importantly, was responsive to change, supporting its feasibility as a 
tool for assessing outcomes in chronic cough. A recent randomised controlled trial 
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of gabapentin for refractory cough has since cited this data to qualify the use of 
short duration cough frequency as an endpoint [88].  
The intensity of coughs is an important determinant of global cough severity for 
patients with chronic cough, but most studies examining cough intensity have been 
conducted in healthy subjects or in patients with weak cough during experimentally 
induced and voluntary cough [140]. Little is known about cough intensity in patients 
with chronic cough and few have described it during spontaneous or pathological 
cough. In chapter 6, voluntary, induced and spontaneous cough in patients with 
chronic cough and healthy controls were studied using physiological measures of 
cough intensity such as oesophageal pressure, gastric pressure and cough flow. 
Physiological measures of cough were closely correlated with cough intensity visual 
analogue score, suggesting that these objective indices are important to subjective 
perception of cough intensity. Patients with chronic cough were found to be 
capable of significantly stronger maximum voluntary coughs than matched controls. 
Induced cough intensity also appeared greater in patients, although this did not 
reach statistical significance. There was no difference in expiratory muscle strength 
and abdominal muscle electromyography between patients and controls, but 
compression phase duration was increased in female patients compared to 
controls, suggesting that laryngeal function may be important. Cough intensity was 
greatest during maximum voluntary cough, and was similar between induced and 
spontaneous cough. Voluntary coughs were invariably preceded by an inspiration, 
whereas induced or spontaneous coughs predominantly contained expiratory 
reflexes that were present within bouts. Since cough intensity may be lower for 
expiratory reflexes than coughs preceded by inspiration, this could have important 
implications when considering the use of experimental cough models to simulate 
effects on spontaneous cough.  
Cough sound has been suggested as a measure of cough intensity but it has not 
previously been validated against physiological measures of cough intensity [184]. 
The measurement of cough sound has the advantage of being non-invasive and 
ambulatory recording technology is already available. The results from chapter 7 
support the feasibility of cough sound as a non-invasive measure of cough intensity. 
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Cough sound power and energy were highly correlated with oesophageal pressure 
and peak cough flow rate during voluntary cough. The strength of correlations for 
sound analysis from a 0.5-second time-window were similar to those from phase 1 
or phases 1-3 time-windows, supporting the potential for future automated 
analysis. Sound power and energy were found to be highly repeatable and 
correlated with subjective cough intensity visual analogue score in most subjects. 
Further large-scale studies are now needed to define normal ranges and assess the 
responsiveness of these measures.  
The use of sound recordings for cough monitoring can raise issues regarding 
privacy, especially as all sounds including private conversations would be recorded. 
This is an important issue and some subjects may find the risk to confidentiality by 
this technology too intrusive. The confidentiality of subjects is preserved as much as 
possible with the Leicester Cough Monitor system since the analysis is mostly 
automated. During the manual validation stage, the investigator is only presented 
with a number of one-second audio segments that the computer program has 
extracted from the recording, having identified these segments as containing 
candidate cough sounds. It is not possible to detect conversations from within these 
short segments. It is also important to acknowledge that there is an ethical code of 
conduct stipulating that investigators will not listen to an audio recording in its 
entirety. Any subjects undergoing such monitoring require full informed consent 
highlighting the ethical obligations of the investigator. The use of cough sound 
monitoring in all of the studies within this thesis was granted full ethics committee 
approval based on these reassurances. During the work for this thesis, only one 
subject declined participation in cough monitoring studies because of 
confidentiality reasons.  
8.2 General limitations 
Some aspects of the studies would have been improved by recruitment of a larger 
sample size in order to permit subgroup analysis. Larger numbers would have 
increased confidence in the findings of responsiveness of short duration cough 
frequency and provided adequate statistical power to assess the effect of 
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anthropometry, viral aetiology and duration of illness at recruitment on acute 
cough patterns. A larger sample size would also have given extra support to the 
finding of a strong correlation between cough sound and subjective cough severity, 
which was limited to the study of only 8 subjects. 
Short duration and 24-hour cough frequencies were calculated from the same 24-
hour recording and it is possible that patients will behave differently if they undergo 
4-hour rather than 24-hour periods of monitoring. This should be addressed with 
prospective studies conducting short duration and 24-hour recordings separately. 
Cough intensity was not evaluated in tandem with cough frequency monitoring in 
the acute or chronic cough studies. Validated tools for assessing cough intensity in 
the ambulatory setting are not available but the promising role for cough sound as a 
non-invasive measure may facilitate this in future. 
Lung volumes prior to cough were not measured during cough intensity studies, 
although inspired and expired lung volumes were calculated for each cough 
manoeuvre. Cough sounds may have been affected by a filtering effect introduced 
by the use of a mask to house the pneumotachograph. New technologies such as 
optoelectronic plethysmography may be useful for quantifying lung volumes and 
may be useful in future studies comparing sound with flow since this negates the 
need for a mask, thereby avoiding the risk of introducing sound filtering effects. The 
compression phase duration of cough was derived from interrogation of the 
respiratory flow trace, a recognised method, but laryngeal activity was not directly 
assessed.  
Finally, the cough sound studies were performed in a quiet room free from ambient 
noise in order to establish the relationship between sound and physiological 
measures in the most optimal environment. Future ambulatory studies will need to 
accommodate for the effect of ambient noises. 
8.3 Areas for ongoing research  
A larger scale study in acute cough controlling for viral aetiology and duration of 
illness at recruitment would be of interest to investigate the factors that may 
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influence the rate of change in cough frequency. The responsiveness of short 
duration cough frequency should be assessed. This measure may be particularly 
suited to rapidly changing conditions, such as acute cough, and could be evaluated 
in this population.  
Further detailed study of the compression phase duration is warranted to evaluate 
its role in the mechanism for increased cough intensity in patients with chronic 
cough compared to healthy controls. These studies should include direct 
assessment of laryngeal function and activity, for example with direct video 
laryngoscopy or laryngeal EMG. Larger scale studies that are powered to compare 
the intensity of expiratory reflexes and coughs preceded by an inspiration in 
spontaneous cough are also needed. The potential for cough sound as a measure of 
cough intensity is another exciting area for further research. The work described 
within this thesis has demonstrated a strong relationship between cough sound and 
physiological cough intensity, but the study should now be extended to 
spontaneous cough to identify whether the relationships remain during non-
experimental cough. Furthermore, cough sound in subjects with weak cough should 
be prospectively studied to determine its potential for assessing ineffective cough. 
In addition, the responsiveness of sound power and energy should be evaluated to 
assess whether these measures may be useful in clinical practice.  
Lastly, there is now an opportunity to consider the development of a composite 
outcome score which combines objective cough frequency and cough intensity with 
subjective cough scores for a truly comprehensive measure of global cough severity 
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Appendix 1  Supporting data for validation of pressure volume characteristics of 
balloon catheter system 


































Data shown from single experiment performed under laboratory conditions. 
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Appendix 2  Supporting data for validation of linearity of mouth pressure 
transducer system 






















Data shown from single experiment performed under laboratory conditions. 
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Appendix 3  Supporting data for validation of linearity of oesophageal balloon 
catheter system 















































Data shown from single experiment performed under laboratory conditions. 
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Appendix 4  Supporting data for validation of linearity of gastric balloon 
catheter system 















































Data shown from single experiment performed under laboratory conditions. 
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Appendix 5  Supporting data for validation of linearity of pneumotachograph 
system 
















Data shown from single experiment performed under laboratory conditions. 
Appendix 6  Supporting data for validation of linearity of pneumotachograph 
system following capsaicin nebulisation 
















Data shown from single experiment performed under laboratory conditions. 
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Appendix 7  Supporting data for validation of supramaximality of lower thoracic 
nerve root magnetic stimulation 
Power output of magnetic stimulator (%) CMAP amplitude (mV) 
30 0.17 ± 0.06 
40 0.84 ± 0.41 
50 0.66 ± 0.17 
60 1.38 ± 0.34 
70 1.17 ± 0.31 
80 1.35 ± 0.28 
90 1.85 ± 0.31 
100 1.86 ± 0.29 
Data acquired from patients with chronic cough and healthy controls and presented 
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